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ABSTRACT

Tian Xie. Ph.D., Purdue University, May 2016. Improved Amorphous Solid Dispersion
Performance Using Binary Polymer Combinations. Major Professor: Lynne S. Taylor.
With increasing attrition rate of new molecular entities due to sub-optimum aqueous
solubility, formulation strategies that could improve the dissolution rate and apparent
solution concentration are of current interest. Amorphous solid dispersions are attractive
over other enabling technologies since they are supersaturating solid dosage forms.
However, crystallization may occur during storage as well as during dissolution of ASDs,
negating the solubility advantage. Unfortunately, choosing the optimum pharmaceutically
acceptable polymeric inhibitor for each of these crystallization pathways is largely
empirical. The best polymer for inhibiting solid state crystallization may be ineffective in
preventing crystallization during dissolution. Moreover, the release rate of the drug from
the ASDs depend on both the type and the amount of the polymer in the formulation.
Therefore, an important advance in solid dispersion formulation could be to incorporate
combinations of polymers to tailor release profiles, while providing optimized
crystallization inhibition. This will expand the application of solid dispersions based on a
rational formulation approach that includes both solid state and solution performance
characteristics, and provide greater confidence in the use of solid dispersion strategies.

1

CHAPTER 1. INTRODUCTION

1.1

Biopharmaceutics Classification System (BCS)

Bioavailability, by definition, is the fraction of an administered dose of unchanged drug
that reaches the systemic circulation. For orally administered drugs, adsorption in the
gastrointestinal (GI) lumen is a prerequisite for this purpose. According to the Fick’s first
law, the flux of drug (J) across the GI wall is given by:
𝐽 = 𝑃𝐶

1-1

Where P is the permeability coefficient of the gastrointestinal barrier to the drug and C is
the free drug concentration. Based upon such considerations, Amidon et al1 developed a
Biopharmaceutics Classification System (BCS) to predict the in vivo pharmacokinetic
performance of drugs from their permeability and solubility (Table 1-1). High/low
permeability is determined by the logP and ClogP parameters. These parameters are
measured by the partitioning of neutral/unchanged state of drug molecules between noctonal and water. Drugs with a logP value greater than that of metoprolol (LogP=1.72)
are classified as highly permeable and vice versa. Metoprolol is used as a reference
standard because it is known to be 95% absorbed from the GI. In terms of solubility, the
criterion for classification is the Dose number (Do), defined as the ratio of the required
dose in a glass of water (250ml) to saturation solubility in an aqueous environment. Drugs
with Do>1 are classified as low solubility drugs while for high solubility drugs, Do is <1.

2
It should be acknowledged that other factors important in determining drug absorption and
bioavailability such as food effects, absorptive transporters, efflux transporters, and routes
of elimination (renal/biliary) were not taken into account in the development of the BCS,
but were later addressed by Benet et al2. With the introduction of high throughput medicinal
chemistry, serious drug solubility problems have emerged. Thousands of new chemical
entities are screened for biological activity in the discovery stage using dimethyl sulfoxide
(DMSO) or polyethylene glycol (PEG) as the solvent to introduce the compound into the
aqueous assay medium. As a result, many candidate molecules with extremely low aqueous
solubility (BCS II or BCS IV) give positive results and are moved onto the development
stage. They are the so-called "brick dust" or "grease ball" compounds. The poor solubility
is usually a consequence of their high crystal lattice energy and/or hydrophobicity. It has
been estimated that over 40% of the drugs currently in the market have low solubility.
Around 80% to 90% of the drug candidates in the R&D pipeline fall into these categories
(Table 1-1)3. The unfavorable dissolution property leads to low bioavailability and high
drug attrition in late stage development.

1.2

Fundamentals of Dissolution

During the preformulation stage, an understanding of the dissolution of a drug candidate is
essential as it is considered a major factor influencing bioavailability. The dissolution of
crystalline solids can be considered in three stages4 (Figure 1-1): (1) Removal of a solute
molecule from its crystal lattice: energy is required to overcome the solute-solute attractive
forces in the solid state. (2) Creation of a cavity in the solvent: the energy required in this
step is considerably less than in step 1 and is often negligible. (3) Insertion of the solute

3
molecule into the cavity by convection and/or diffusion, forming solute-solvent
interactions
The mixing of molecules begins at the surface when the solids are placed in the solvent.
The thermodynamic driving force for this process is the free energy of mixing:
∆Gmix = ∆Hmix − T∆Smix

1-2

Where, ΔHmix is the enthalpy of mixing, T is the absolute temperature, and ΔSmix is the
entropy of mixing. ΔHmix is a factor dependent on intermolecular interactions. Dissolution
is favorable when the solute-solvent interaction is stronger than the total of solute-solute
and solvent-solvent interactions. The intermolecular forces (e.g. hydrogen bonds, Van der
Waals) vary with the molecular conformation in the solids. Hence, for the same compound,
the enthalpy term is different among different polymorphs or for the amorphous solid. The
entropy of mixing represents the driving force for an increase in the randomness or chaos
of the system, and always favors mixing. Spontaneous mixing occurs when the free energy
of mixing is negative.
The solution phase will be in equilibrium with the solid phase when the solution contains
the amount of solute as limited by its solubility (s), which is temperature dependent. This
parameter is usually measured at infinite time (e.g. 24hrs) when the equilibrium is reached.
Under certain circumstances, the concentration of drug monomers in the solvent could
exceed this limit. The system is said to be supersaturated. The degree of supersaturation, σ,
is defined as:
c
σ = ln ( ) = lnS
s

1-3
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Where, c is the concentration of solute in the supersaturated solution, often referred to as
apparent solubility, s is the equilibrium solubility, and S is the supersaturation ratio,
respectively. The apparent solubility is often not directly measured due to the possibility
of rapid phase conversion in solution. Instead, it is calculated from the following equation:
c=s×(

Jm
)
Js
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Where Jm is the intrinsic dissolution rate of the metastable form, and J s is the intrinsic
dissolution rate of the stable form.
The rate at which the drug dissolves from the solid state is referred to as the dissolution
rate. It can be described by the Noyes–Whitney equation:
dC AD(Cs − Ct )
=
dt
h

1-5

Where dC/dt is the dissolution rate, A is the specific surface area of the drug particle, D is
the diffusion coefficient of the compound, Cs is the solubility of the compound in the
dissolution medium, Ct is the drug concentration in bulk solution, and h is the diffusion
layer thickness. As can be inferred from this equation, the rate of dissolution of a low
solubility compound can be increased by manipulating the parameters in this equation. The
diffusion coefficient is dependent on the molecular weight of the compound and the
viscosity of the luminal contents6. The diffusion layer thickness is dependent on the
hydrodynamics in the GI tract. The physiological parameters are difficult to change from
a formulation perspective. However, the surface area may be increased by particle size
reduction (e.g. micronization).

However, micronized particles have propensity to

aggregate or agglomerate due to the high surface free energy, thereby negating the gains
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achieved by the milling procedure. Surface tension is reduced in the presence of surfactants;
solvent accessible particle surface area could be increased by improved wetting
characteristics. In addition, improved wetting might also decrease the boundary layer
thickness. Saturation solubility is dependent on both physiological parameters (e.g. pH,
buffer capacity, bile, and food components) and physicochemical parameters (e.g.
hydrophilicity, crystal structure and solubilisation). It could be increased by chemical
modification of the drug molecule such as prodrug, salt or cocrystal formation.
Alternatively, a high energy form (e.g. metastable polymorph, amorphous solid) may be
employed to obtain a high apparent solubility. Nano particles may enhance the dissolution
by both mechanisms: (1) increased surface area and (2) enhanced apparent solubility as a
function of the high curvature for particles below 200um in size7.
Evaluation of dissolution rate is extremely important for drug development, formulation,
and quality control. There are two widely used methods in the pharmaceutical industry to
compare the dissolution behavior of solids: powder dissolution and intrinsic dissolution.
They are inherently different in several aspects: geometry, solution conditions, and
hydrodynamics8. Dissolution data obtained from the two methods are analyzed in a
different manner, yet are often complementary for interpretation.
In powder dissolution, solid particles are dispersed in dissolution medium which is agitated
by a rotating paddle (USP II). In the absence of phase transformation, the dissolution
profile will exhibit a continuous increase in solution concentration of the drug until a
plateau is reached. The rate of dissolution is given by the Noyes-Whitney equation. When
excess solids are added to the dissolution medium, solution concentration increases with
time until the plateau concentration is observed which equals drug solubility. Such a
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dissolution condition is known as a non-sink condition. In this case, dissolution is retarded
by a concentration gradient. On the other hand, sink conditions are generated when the
drug that can be dissolved in a given volume of the dissolution medium (as determined by
its solubility) is at least 5-10 times greater than the amount of drug to be dissolved. The
concentration of drug in bulk solution is thus always maintained at low level (Cb<<Cs), so
that the solution concentration does not affect the dissolution rate of the dissolving solids.
To achieve this, a large volume of dissolution medium is required, or there must be a certain
mechanism to replenish the medium. In vivo, whether sink condition is met is contingent
on the composition and volume of luminal fluids as well as the permeability of the mucosa
to the drug molecule.
In the presence of a solution mediated phase transformation during powder dissolution
testing, the dissolution profile typically exhibits an initial peak concentration
(supersaturation) followed by a decrease until a plateau concentration is reached, which
equals the solubility of precipitated form. While powder dissolution testing maybe easy to
set up and operate, it suffers from several disadvantages8. First, the hydrodynamics in the
vessel are poorly characterized, varying throughout the vessel and being dependent on
paddle speed. Such a variability in hydrodynamics may change the boundary layer
thickness of the particles, and hence dissolution rate. Moreover, the surface area of particles
also changes with time during a powder dissolution test. Many drug compounds are highly
hydrophobic and particles tend to float and/or aggregate in the medium so that the solvent
accessible surface area is variable. Finally, solution concentration maybe not uniform
throughout the vessel.
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The dissolution rate per unit area is the mass flux J, which is referred to as “intrinsic
dissolution rate” in pharmaceutics. The quantity is given by:
J=

dm 1
dc 1
( )=V ( )
dt A
dt A

1-6

Where, j is the mass flux (mg cm-2 S-1), m is the mass (mg), V is the volume of the
dissolution medium, c is the concentration of dissolved drug in the medium (mg/ml), A is
the surface area of the sample (cm2), and t is time (s).
The rotating disk method (Wood’s Die) is used to measure the IDR, where the drug is
placed in a cavity and compressed. The geometry and exposed surface area of the drug are
known. In addition, the intrinsic tendency for the material to dissolve can be assessed
without formulation excipients. This apparatus also enables the drug to be exposed to lower
hydrodynamic variability. The velocity components of fluid flow in a rotating disk
apparatus are well defined and can be solved analytically8. Under normal operating rotation
speed, the fluid flow is considered in laminar flow regime. The intrinsic dissolution rate
from the compact is related to the solubility of the drug by:
2

1

1

J = 0.62D3 ν−6 ω2 Cs
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Where D is the diffusion coefficient, ν is the kinematic viscosity, and ω is the angular
viscosity of the die. In the absence of solution-mediated transformation, plotting the
cumulative amount dissolved versus time yields a straight line passing through origin. The
derivative (i.e. slope) of this line is the intrinsic dissolution rate. If the intrinsic dissolution
rate is plotted versus time, the data points will vary randomly about the mean. When
solution phase transformation occurs, the solubility of the drug at the surface of the
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compact will decrease with time due to the precipitation of a more stable form. A curvature
will be observed in the cumulative amount dissolved versus time plot. The intrinsic
dissolution rate will decrease with time until a plateau is reached, which indicates that the
phase transformation is complete.

1.3

Characteristics and Thermodynamics of Amorphous State

Solids can exist in either a crystalline or an amorphous state. The crystalline state is
characterized by an ordered lattice structure. The interactions (e.g. hydrogen bonds and
electrostatic repulsion) are repeated with regularity. On the other hand, amorphous
materials show no long-range three-dimensional molecular order. However, they are not
random at a molecular level. They possess local or short-range order over a few molecular
dimensions9. They may exhibit regions of residual crystallinity and different density
(Figure 1-2). Studies of indomethacin10, 11 revealed that “structural elements” might exist
in amorphous solids. Amorphous materials frequently share the same intermolecular bonds
as their crystalline counterpart, but differ in range of disorder. The amorphous state can be
treated as a precursor to the crystalline state12. In fact, the amorphous material has been
employed as a starting point for designing crystallization screening procedures for new
polymorphs of drug compounds.
Normally, when cooling a melt, there will be a transition from the liquid state to the
crystalline state below the melting temperature. A discontinuity in enthalpy and volume
exists and is indicative of a first order phase transition (Figure 1-3). Amorphous materials
can be prepared by cooling of a melt at a rate faster than the molecules are able to organize
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into the crystalline lattice below the melting point. This amorphous state is considered to
be equilibrium “supercooled liquid” because it is energetically and structurally similar to a
liquid. It is also commonly referred to as rubbery state due to its macroscopic properties,
in particular in the polymer literature. In this region, the average timescale of molecular
motion is typically less than 100s and the viscosity ranges from 10-3 to 1012 Pa·s. Upon
further supercooling, there is a change from the equilibrium supercooled liquid to a
“kinetically frozen” nonequilibrium state with a higher enthalpy and volume than would
have been expected for the supercooled liquid. The amorphous material becomes a brittle
glass with very high viscosity (>1012Pa·s). This process is called vitrification. The
temperature at the transition is the glass transition temperature (Tg), which is considered as
a fingerprint of amorphous materials. The glass transition is a thermal event influenced by
kinetic factors and therefore occurs over a range of temperatures. T g is thus dependent on
operating conditions (heating/cooling rates), thermal history and purity of the sample14.
In Figure 1-3, it can also be seen that there is a thermodynamic requirement for the
supercooled liquid to undergo the glass transition. Otherwise, the supercooled liquid would
attain an even lower enthalpy and volume than crystalline materials below a certain critical
temperature. This would be paradoxical. This virtual temperature is known as Kauzmann
temperature (Tk). It represents the lower limit for the glass transition and the point of zero
configurational entropy of the system15, 16.
The glass stability (GS) refers to the resistance of a glass to crystallize. However, this
property is often determined by measuring the crystallization tendency in the supercooled
region above Tg, which reflects the stability of the supercooled liquid rather than that of
the glass. Therefore, the term GS is often a misnomer17.
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The glass forming ability (GFA) is defined as the ease of a material to be vitrified from the
melt upon cooling. A common parameter to evaluate a material’s GFA is the critical
cooling rate (Rcrit), defined as the minimum cooling rate needed for vitrification. High Rcrit
values imply poor glass forming ability, whereas low Rcrit values indicate facile glass
formation. Another important parameter determining GFA is the fragility9. It refers to the
temperature dependence of a liquid to undergo physical changes above T g. It is related to
the structural relaxation kinetics and mechanisms of amorphous materials. The temperature
dependence is described by the Vogel-Tammann-Fulcher (VTF equation):
𝜏 = 𝜏0 exp(

𝐷𝑇0
)
𝑇 − 𝑇0
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Where, τ is the mean molecular relaxation time (or viscosity), T is the temperature, T 0 is
the zero mobility temperature, and τ0 is a constant. D is the strength parameter. The
temperature dependence of viscosity of amorphous materials above Tg, η, is described by
the Williams-Landel-Ferry (WLF) equation:
𝜂 = 𝜂𝑔 𝑒𝑥𝑝{𝐶1 (𝑇 − 𝑇𝑔 )|[𝐶2 + (𝑇 − 𝑇𝑔 )]}
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𝐶1 = 𝐷𝑇0 /(𝑇𝑔 − 𝑇0 )
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𝐶2 = 𝑇𝑔 − 𝑇0
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Where, ηg is the mean viscosity at Tg. From a plot of viscosity (logη) or relaxation times
(logτ) versus Tg/T for T>Tg, materials are classified into strong liquids if the plot appears
linear (quasi-Arrehenius), or fragile if a non-Arrehnius behavior is observed (Figure 1-4).
Strong liquids have large D values (>30), higher viscosity (i.e. lower mobility) at Tm, and
hence are more resistant to structural changes. Also, the change in heat capacity at Tg is
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relatively small. On the other hand, fragile liquids have lower D values (<10), lower
viscosity at Tm, and are thus prone to structural reorganization. Many pharmaceuticals are
found to be moderately fragile (D ranges from 7 to 15).
The quantity Tb/Tm (where Tb is the boiling temperature) is another well known predictor
of glass forming ability for a given compound. As a thumb of rule, if Tb/Tm is greater than
2, a glass can be formed at reasonable cooling rates, and vice versa. This is because a
compound with low melting temperature tends to have weaker intermolecular force in the
crystalline state whereas a high boiling point indicates stronger intermolecular forces in the
liquid state. The crystallization tendency is therefore expected to be low for a compound
with high Tb/Tm. Nevertheless, exceptions to this rule have been observed18.
The chemical reactivity is another important factor in determining the optimal storage
conditions and the shelf life for an amorphous drug product. The amorphous state of drug
molecules exists at a higher energy than their respective crystalline forms, which provides
sufficient free volume and molecular mobility for molecules to react as described by
Arrhenius kinetics9:
𝑘 = 𝐴′𝑒𝑥𝑝[− (

𝑉∗
𝐸𝑎
) − ( )]
𝑉𝑓
𝑘𝑇
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Where k is the rate constant, A’ a pre-exponential factor, Ea is the energy of activation, Vf
is the free volume, and V* is the critical free volume for the molecular motion required for
reactivity9. Indeed, when comparing the reaction rates of crystalline and amorphous forms
of a drug under otherwise identical conditions, we have seen that amorphous forms have
higher reaction rate than the crystalline forms in a number of systems.19 20
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1.4

Preparation of Amorphous Solids

Amorphous solids can be prepared in various circumstances and situations. The preparation
of an amorphous form is relatively easy for good glass formers but difficult for poor glass
formers. From a thermodynamic perspective, molecules that are poorly arranged and
contain many degrees of freedom are much more easily rendered amorphous. Kinetically,
a slow crystallization rate allows the material to become a “frozen liquid” or vitrify without
crystallization21. Amorphous materials might be deliberately prepared to utilize their
advantageous physicochemical or biological properties. They could also be inadvertently
induced by thermodynamic or mechanical stress in various unit operations, as shown in
Figure 1-5.
If amorphous conversion is required, there is merit in investigating the use of more than
one preparative technique since the susceptibility to amorphous conversion by mechanical
and thermal techniques is compound specific. Finally, local structure in the amorphous
phase is also a function of the preparation method and may affect the solid’s physicalchemical properties.

1.4.1

Grinding and Milling

The direct crystal to glass transformation by milling involves supplying energy to excite
an equilibrium crystal and “freeze” it in an energized metastable amorphous state. The
mechanical activation leads to disruption of the crystalline lattice and an amorphous state
is formed via a solid state transition. The effectiveness of ball milling is dependent on the
unit cell structure of the compound. Patterson et al studied the influence of ball milling on
dipyridamole, carbamazepine, glibenclamide, and indomethacin19. Ball milling resulted in
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predominantly amorphous products for all compounds except carbamazepine. Ball milling
of carbamazepine resulted in a polymorphic transition of the starting material to form III
while an alternative approach of quench cooling was successful in preparing amorphous
carbamazepine. The resistance to the shearing force imparted by the milling might be due
to the formation of an intracellular and intermolecular hydrogen bonded dimer which is
perpendicular to the other molecules in the unit cell (Figure 1-6).
Whilst milling avoids the high thermal stress of melting and quench cooling, the free excess
enthalpy induced by mechanical activation has been shown to accelerate chemical
degradation. Key process parameters that might affect the physical or chemical state of the
ground product include: (I) Type of milling apparatus; (II) Intensity; (III) Duration; (IV)
Temperature; (V) Use of excipient.

1.4.2

Vitrification

Vitrification, also known as quench cooling, is the most frequently used procedure of
converting a material into a glass-like amorphous solid that is free from any crystalline
structure, by cooling the molten phase below glass transition temperature. In melting, the
amorphous state is obtained via the liquid state. If the solidification process is fast enough
the molecules do not have time to rearrange themselves into a regular array and, thus, an
amorphous state is formed. The drawback of this approach is its potential for chemical
degradation during the melting step. Thermal degradation is compound dependent and only
limited steps can be taken to overcome this problem such as heating under an inert gas.
Cooling rate is critical in the preparation and is dependent on the spontaneous tendency of
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the compound to crystallize, which is partially determined by the conformational diversity
existing in the liquid phase20.

1.4.3

Lyophilization

Lyophilization, also known as freeze drying, works by freezing the material and then
reducing the surrounding pressure and adding enough heat to allow the frozen water in the
material to sublime directly from the solid phase to gas. In freeze drying, as well as in spray
drying, an amorphous phase is created through a solution state. Fast evaporation of the
solvent can lead to formation of amorphous particles. There are three stages in the complete
freeze-drying process: freezing, primary drying, and secondary drying. Amorphization is
more likely to occur when the freezing step is rapid and performed at liquid nitrogen
temperature to prevent nucleation. Another critical step is the secondary drying, since
crystallization is likely to occur in the presence of residual solvent when the temperature
is high enough.

1.4.4

Spray Drying

By exposure to a heated atmosphere, materials are rapidly dried from a concentrated
solution or a suspension. A liquid phase is first atomized to obtain a maximal surface area
in contact with the drying gas since drying occurs within seconds. Spray drying can alter
biopharmaceutically relevant drug properties. It differs from lyophillization in that spray
drying could produce uniform spherical particles of desired size. As a result, the powder
obtained usually has good flow properties. However, an amorphous solid obtained from
spray drying may be unstable and prone to crystallization. Savolainena et al22 examined
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molecular-level differences in the amorphous state of indomethacin prepared from both α
and γ polymorphs using various preparative techniques: milling, quench cooling of a melt,
slow cooling of a melt and spray drying. According to the X-ray powder diffraction (XRPD)
and polarized light microscopy (PLM) measurements, all samples except the spray dried
indomethacin were amorphous after preparation. Spray dried indomethacin had some
residual crystallinity.

1.5

Characterization of Amorphous Material

There are many methods to analyze amorphous and crystalline materials. Powder x-ray
diffraction (PXRD), differential scanning calorimetry (DSC), Fourier transform infrared
spectroscopy (FTIR), solid-state nuclear magnetic resonance (ssNMR) are some of the
most popular ones. The basic principles of these methods will not be discussed, however
information about how some of these methods can be applied will be provided, using an
example where DSC has been employed to study the molecular mobility and the relative
stability of the amorphous material. Another method discussed is the use of Raman
Microscopy to evaluate surface amorphization.
It has been observed that the Tg occurs in a temperature range that is about 2/3 of the
melting point in Kelvin. This observation can be used to estimate Tg from Tm or vice versa.
If both these values are known then one can estimate the deviation from this rule, which
reflects the temperature dependence of molecular motions in the region just above Tg. If
the Tg/Tm is significantly greater than 2/3, then the material is likely to have a greater than
average temperature dependence of its molecular mobility in the region of Tg and vice
versa. Conventional DSC can be used to construct a semi-quantitative diagram of the
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excess enthalpy versus temperature. Tm, Tg, ΔHf and Tg can be obtained from DSC
measurements. In addition, modulated DSC facilitates the measurement of heat capacities
(which, is a measure of molecular motions). Shamblin et al23 found that the ΔCpTg
increased significantly as the material was heated through its Tg (Figure 1-7). This is
significant in studying disorder created from different processes as they have shown for
freeze dried and quenched cooled sucrose.
Therefore the temperature dependence of key thermodynamic properties can be determined
for new materials. These plots will indicate whether the amorphous material has Tg above
or below the normal storage and processing temperature. Hence for materials where the
Tg is significantly above normal operating temperatures, there should be a reasonable
chance of being able to produce and retain a stable amorphous material. On the other hand,
materials which have Tg values below ambient temperature are often hard to produce and
maintain in an amorphous state23.
Sometimes the undesirable characteristics introduced by the amorphous phase are due to
modifications of interfacial properties24. Inhalation devices provide an important example
in which amorphous material at the surface of an active or excipient causes alteration of
adhesion and cohesion, thus changing performance24. In addition, it seems likely that
surface amorphous material may be less stable due to its exposure to moisture and the
atmosphere, further adding to the importance of detecting its presence.
Vibrational spectroscopy such as Raman Microscopy provides information on the depth of
amorphous material present through peak broadening /shifts in the spectra. In one study,
Raman spectra of crystalline and glassy, quench cooled sorbitol were analyzed (Figure 1-8).
The glassy state is characterized by broader peaks and loss of fine spectral structure24. In
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particular, the broadening of the peak at 878 cm-1 assigned to the C-C-O stretch showed an
increase in full-width at half maximum from 15 (crystalline) to 34 cm-1 (glassy) and so
provided an intensity-independent method of mapping for sorbitol degree of crystallinity.

1.6

Solubility Advantage of Amorphous Solids

The excess internal energy and volume of the amorphous state as opposed to the crystalline
state can lead to enhanced dissolution and bioavailability. According to Lipinski et al25, the
solubility (s) of a solid solute is a function of three basic quantities:
𝑠 = 𝑓(𝐶𝑟𝑦𝑠𝑡𝑎𝑙𝑃𝑎𝑐𝑘𝑖𝑛𝑔𝐸𝑛𝑒𝑟𝑔𝑦 + 𝐶𝑎𝑣𝑖𝑡𝑎𝑡𝑖𝑜𝑛𝐸𝑛𝑒𝑟𝑔𝑦
+ 𝑆𝑜𝑙𝑣𝑎𝑡𝑖𝑜𝑛𝐸𝑛𝑒𝑟𝑔𝑦)
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The first major huddle for solubilization of crystalline solid is the energy required to disrupt
molecular packing. On the other hand, amorphous solid exhibit no long range order packing,
and hence no such energy barrier. For this reason, amorphous solid often show higher
solubility than crystalline solid. For the same compound, the solubility ratio between
amorphous solid and crystalline solid (4-14) is much higher than that between the
crystalline polymorphs (2-3)26. Some well-known examples of amorphous to crystalline
solubility ratios are nefidipine (~6)27, ritonavir (~10)28, and tolbutamide (4-6)29.
Theoretically, the free energy difference (∆G) between the amorphous and crystalline
forms can be calculated by the Hoffman equation30:
∆𝐺 = ∆𝐻𝑓

(𝑇𝑚 − 𝑇)𝑇
𝑇𝑚2

1-14
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Where ∆Hf is the enthalpy of fusion, Tm is the melting temperature, and T is the
temperature of interest. The solubility advantage of the amorphous form can then be
estimated by the following equation:
𝜎𝑎𝑚𝑜𝑟𝑝ℎ
𝜎𝑐𝑟𝑦𝑠𝑡𝑎𝑙

∆𝐺

= 𝑒 𝑅𝑇
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Where 𝜎 𝑎𝑚𝑜𝑟𝑝ℎ /𝜎 𝑐𝑟𝑦𝑠𝑡𝑎𝑙 represents the ratio of amorphous solubility to crystalline
solubility. Hancock et al31 predicted that amorphous materials can be 10-1600 times as
soluble as their crystalline counterparts. Experimental determination of the solubility
advantage of amorphous solids is impeded due to the frequent rapid conversion to
crystalline state upon dissolution. Furthermore, it has been pointed out32 that this model
did not take into account either the effect of ionization of the drug or water sorption by the
amorphous material on the free energy difference. Once correction factors are incorporated
into the equation, a good agreement can be sometimes attained between the prediction and
measured ratios.
For indomethacin31, the solubility ratios predicted are listed in Table 1-2. The experimental
solubility of amorphous indomethacin is consistently higher than that of the crystalline γ
form at room temperature as shown in Figure 1-9. Maximum solubility is achieved at about
10 minutes, and this value is about 5 times the solubility of the γ form. The
desupersaturation is attributed to the partial recrystallization of indomethacin from the
metastable amorphous phase to a more stable crystalline phase.

The experimental

solubility ratio of amorphous versus the γ form is significantly lower than the theoretical
estimate, which is due to the rapid crystallization tendency of indomethacin when exposed
to the dissolution medium. Despite this discrepancy, the calculated value represents the
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theoretical thermodynamic driving force for supersaturation in solution, and may be used
to compare different drugs and amorphous systems.
Mullins and Macek33 found that for novobiocin free acid, the amorphous form was at least
10 times more soluble than the crystalline counterpart when excess solids (< 10µm) of
either form were shaken in 0.1N HCL at 25 °C. The in vivo studies (dose=12.5mg/kg)
showed that novobiocin could not be detected in plasma when the crystalline form was
administered. In contrast, the plasma level of novibiocin reached 40ug/ml after 1hr when
administered in amorphous form. However, the amorphous novobiocin in suspension was
observed to slowly crystallize and hence lost therapeutic effect. Several agents including
methylcellulose, polyvinylpyrrolidone and sodium alginate were found to be able to
provide adequate inhibition against crystallization over significant periods of time.
For injectable insulin, the duration of action is controlled by both the degree of crystallinity
and the particle size. The amorphous insulin zinc complex is used in Prompt Insulin
Suspension USP to provide immediate effects and have a short duration of action. The
Extended Insulin Zinc Suspension USP is made up of a crystalline zinc complex. It is
slowly absorbed and has a long duration of action. The Insulin Zinc Suspension USP
contains a mixture of three parts amorphous and seven parts crystalline form to provide an
intermediate duration of action. These formulations also differ in particle size. Large
particles are formulated in prompt insulin whereas extended insulin is made up of small
particles.
There are also advantages in using the amorphous form of a drug for toxicological studies,
even if the final form used in the product is crystalline. Higher blood levels are expected
from an amorphous compound. Therefore, toxicological data obtained using an amorphous
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compound represent the “worst case” scenario and should be predictive of clinical toxicity
independent of the solid form selected for the drug product.
Atorvastatin is a synthetic lipid-lowering agent. It is used as calcium salt to treat
hypercholesterolemia. It exhibits high intestinal permeability over the physiologically
relevant intestinal pH34, 35. Corsini et al36 reported that the absolute bioavailability of
Atorvastatin is as low as 12% after an oral dose of 40mg. The oral bioavailability is limited
by its low aqueous solubility. Kim et al37 prepared amorphous atorvastatin hemicalcium by
spray drying and supercritical anti-solvent process (SAS). They exhibit similar maximum
supersaturated concentrations (460~480µg/ml), followed by a gradual decrease until a
plateau is reached (~200µg/ml) due to solvent mediated phase transformation. In contrast,
the unprocessed crystalline particles reached its equilibrium solubility (only 140µg/ml)
rapidly. This is consistent with the intrinsic dissolution results where the spay-dried and
SAS processed drug exhibit similar intrinsic dissolution values (both initial phase and late
phase), much higher than that of unprocessed drug. This is because there is no particle size
effect in intrinsic dissolution testing. Assuming hydrodynamic conditions are identical, the
intrinsic dissolution rate is proportional to the solubility of each form. In the powder
dissolution test, enhanced dissolution rate is observed for all processed particles as
compared to unprocessed atorvastatin (Figure 1-10). In addition, the SAS processed
particles exhibited superior dissolution performance to that of spray-dried particles, which
was attributed to difference in their particle size, as summarized in Table 1-337.
In good agreement with the results from in vitro study, the rank order of the AUC under
the plasma concentration-time curve is: SAS processed particles >spray dried
particles>unprocessed particles (Figure 1-11). Therefore, the improvement of
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bioavailability by SAS process is a consequence of combined benefits of high energy
amorphous form and increased surface area.

1.7

Structural Relaxation and Crystallization from Amorphous Solids

Despite its higher dissolution rate and kinetic solubility, the amorphous state is inherently
unstable due to its excess internal energy. The energy excess can be either partially relieved
through the mechanism of irreversible structural relaxation or completely released by
converting

back

to

the

thermodynamically

stable

crystalline

counterpart

(i.e.devitrification)32. Molecular mobility is an important factor that determines the
physical stability of the amorphous material. It is often related to the viscosity of the system
by the Stokes-Einstein equation:
𝑘𝑇
𝑥2
𝐷=
;𝐷 =
6𝜋𝜂𝑎
2𝜏
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Where T is temperature, D is the translational diffusion coefficient at that temperature, k is
the Boltzmann constant, η is viscosity, a is the hydrodynamic radius of the diffusing species,
x is the so called “jump distance” and τ is the diffusion correlation time. As temperature
decreases, the viscosity increases. This results in a smaller D, which means a slower
molecular diffusion. The time for molecules to diffuse a certain path length, x, increases.
Any physical changes, be it crystallization or structural relaxation, requires molecules to
go through a few diffusional jumps of those path lengths32. Hence a slower molecular
motion leads to better physical stability and vice versa. Figure 1-12 illustrates different
types of physical changes undergone by amorphous materials on annealing. Molecules may
diffuse in the material to arrange themselves to a less chaotic amorphous state (Glass 2)
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over a long period of time. This state has a lower volume, lower entropy and enthalpy than
the original amorphous state (Glass 1), and hence is more stable and relatively more
difficult to crystallize. Alternatively, molecules may move throughout the entire system
and rearrange into a highly ordered crystalline lattice structure. It is also possible for
molecules to have different substates and level of mobility (Figure 1-2), which depends on
how they were configured initially during preparation. This may result in a localized
crystallization from regions where molecules are highly mobile.
Devitrification consists of two sequential steps: (1) stable nuclei are formed after certain
lag time, (2) these nuclei grow into crystals. Despite the difficulties of achieving
homogeneous nucleation in large volumes of a sample, the Classical Nucleation Theory
remains the first estimation of nucleation kinetics. The thermodynamic driving force for
nucleation is the free energy difference of the liquid phase and the crystalline phase:
𝑇𝑚

𝑇𝑚

𝑇

𝑇

𝜕∆𝜇(𝑇)
𝛥µ(𝑇) = ∫ [
] 𝑑𝑇 = − ∫ ∆𝑆(𝑇)𝑑𝑇
𝜕𝑇
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Where Δµ is the difference in the chemical potential between the crystalline and the liquid
phase, ΔS(T) is the difference in the molar entropies between the crystal and the
supercooled melt and the T is the temperature in Kelvin. The clusters may aggregate or
decay until a stable nucleus of critical radius (rc) is formed:
𝑟𝑐 =

2𝛾𝑇 ∗
∆𝐻𝑓 ∆𝑇
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Where, T ∗ is the solid/liquid equilibrium temperature in Kelvin, γ is the interfacial tension
at the nucleus-liquid interface. ΔT (=T*-T) is the degree of supercooling, and ΔHf is the
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latent heat of fusion. The critical overall excess free energy (including both the surface and
bulk contribution) needed to form a stable nucleus is:
4
∆𝐺𝑐𝑟 = 𝜋𝛾𝑟𝑐2
3
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The rate of nucleation is:
𝐽 = 𝐴𝑒𝑥𝑝(

−16πγ3
∆𝐺 ′
−
)
3KT ∗ ∆𝐻𝑓2 𝑇𝑟 (∆𝑇𝑟 )2 𝑘𝑇
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Where, J is often denoted as Iss, the nucleation rate at steady state. A is the frequency factor
independent of temperature, 𝑇𝑟 = (𝑇⁄𝑇 ∗ ),∆Tr = (∆T⁄T ∗ ) = 1 − Tr . ΔG’ is the kinetic
barrier for nucleation. It is the activation free energy for molecules to diffuse in the matrix,
and is related to the viscosity of the system.
Nucleation is thermodynamically favorable at low temperatures (i.e. higher degree of
supercooling) while kinetically favored at higher temperature due to greater molecular
mobility (lower viscosity). The shape of the curve for nucleation rate (I0) clearly
demonstrates this balancing effect of temperature (Figure 1-14)
A limitation of CNT is its assumption of constant nucleation rate for spontaneous
nucleation. New models have been developed to account for the time dependent nature of
nucleation rate as shown in Figure 1-13. There is a lag time before a steady state
distribution of clusters of critical size jc is reached. During that lag time, the nucleation rate
for the formation of clusters of critical size jc is time dependent, and is always slower than
the steady state nucleation rate that is time independent. Nevertheless, there will be an
inevitable decrease of nucleation rate at a certain time after steady state is reached. It occurs
when most of the system has become nucleated. This applies to not only the nucleation
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kinetics of glasses during storage, but also to that of a supersaturated solution. More
specifically, as nucleation proceeds in a supersaturated solution, the degree of
supersaturation decreases, which in turn results in a decrease in nucleation rate.
Once the nucleation barrier is surmounted, the nuclei so formed grow into macroscopic
crystals. Whereas the presence of nuclei cannot be easily detected experimentally, the
growth kinetics can be readily determined based on observations from a microscope. The
growth rate of a crystal, U, is described in the following equation11:
𝑈=

𝐶𝑇𝑤
∆𝐺𝑣
[1 − exp(−
)]
𝜂
𝑘𝑇
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Where C is a constant, T is the temperature in Kelvin, and η is the viscosity, which indicates
molecular mobility. ΔGv is the free energy difference between the amorphous and the
crystalline phase, w is a constant that describes the growth mechanism, and k is Boltzmann
constant. For a typical glass former38, the temperature dependence of nucleation (I0), crystal
growth (G), non-steady state lag time for nucleation (τ) is shown in Figure 1-14. Equation
1-20 and 1-21 suggest different temperature dependencies of nucleation and growth.
Thermodynamically, nucleation is favorable at lower temperature (i.e. high degree of
supercooling), whereas crystal growth is favorable at higher temperature (i.e. low degree
of supercooling). Significant crystallization can only occur in a temperature zone located
between Tg and Tm where the two processes overlap.
For many amorphous materials, significant crystallization is observed above Tg. However,
it has also been shown that crystallization can occur below Tg39,

40

. It has been

recommended that a storage temperature of at least 50°C below Tg is used for amorphous
drugs to minimize risks of phase conversion. Determining Tg is advisable for designing a
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crystallization protocol as well as for preventing the occurrence of phase transformation.
For binary mixtures, the Tg of the mixture (Tg,mix) can be estimated by the Gordon Taylor
equation41:
𝑇𝑔,𝑚𝑖𝑥 =

𝑤1 𝑇𝑔,1 + 𝑘𝑤2 𝑇𝑔,2
𝑤1 + 𝑘𝑤2
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Where w is the weight fraction, and the constant k can be calculated by the Simha-Boyer
rule42:
𝑘=

𝜌1 𝑇𝑔,1
𝜌2 𝑇𝑔,2
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Where, ρ stands for the density of individual component. The Gordon Taylor equation
assumes no specific interactions between the two components. Deviation from prediction
often indicates non-ideal mixing that results from complex formation43. The CouchmanKarasz model is equivalent to Gordon-Taylor equation, where k is replaced by:
𝑘=

∆𝐶𝑝2
∆𝐶𝑝1

1-24

where ΔCpi is the change in heat capacity at glass transition events for pure component i.
Therefore, equation 1-22 becomes:
𝑇𝑔,𝑚𝑖𝑥 =

𝑤1 ∆𝐶𝑝1 𝑇𝑔1 + 𝑤2 ∆𝐶𝑝2 𝑇𝑔2
𝑤1 ∆𝐶𝑝1 + 𝑤2 ∆𝐶𝑝2
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Baird et al17 observed the presence or absence of crystallization during cooling and
reheating for 51 organic molecules from undercooled melt state. These compounds were
classified into several categories with the rank order of crystallization tendency:
IA>IB>II>III. Specifically, class IA compounds crystallize at both a moderate cooling rate
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by DSC and a rapid cooling rate by immersion in liquid N2. Class IB compounds can
crystallize on moderate cooling, but can also be kinetically frozen in the amorphous state
(at least partially) by rapid cooling. It has been hypothesized that a higher cooling rate
would result in a larger degree of undercooling before crystallization is observed, and the
Rcrit can be estimated by the Barandiaran and Colmenero (BC)44 and Cabral45 methods. It
turns out that this model works for some of the class I compounds (r2>0.7). However, for
some other class I molecules tested, the degree of super-cooling did not show such
dependency on their range of cooling rate (from 5 °C /min to 20°C /min) applied by DSC.
This was attributed to the stochastic nature of nucleation process and the inevitable
occurrence of heterogeneous nucleation. Class II compounds do not crystallize upon
cooling to below Tg, but were able to crystallize when subsequently reheated to above Tg.
Class III compounds fail to crystallize either on cooling to below Tg or on reheating to Tm
at 10°C /min. No Rcrit could be estimated for Class II or III compounds since they do not
crystallize on cooling. Not unexpectedly, all of the class II and III compounds are
moderately fragile or fragile liquids (D ranges from 1 to 11). The fact that class I
compounds have a higher tendency to crystallize upon cooling from the undercooled melt
state indicates its lower GFA than class II and III compounds. Glass stability was evaluated
by observing the crystallization of the amorphous samples of several selected molecules of
each class stored below their Tgs. The cross-polarized light optical images of those samples
indicate class I has the lowest GS, class III has the highest GS, and the GS of class II falls
in between. The GS also correlated well with the stability of samples when reheated above
Tg. Moreover, there seems to be a positive relationship between the GS and GFA. For class
II and class III molecules, it is thought that their nucleation zone and growth zone are more
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separated46, whereas there is a large overlap of the two zones for class I molecules (Figure
1-15)
This explains why only class I molecules crystallize on moderate cooling. The fact that
class IB and class II molecules are able to crystallize upon reheating whereas class III
molecules are not can be explained as following. The nucleation process is inherently a
much faster process than crystal growth. If the cooling rate is higher than the Rcrit, but lower
than the minimum cooling rate required to inhibit the formation of nuclei (RNcrit) , the nuclei
will be quenched in the “glassy” material during cooling and only able to grow when
reheated to the growth zone where there is sufficient molecular mobility. Whereas it is not
easy to detect the formation of nuclei experimentally, the overall crystallization upon
reheating can be analyzed without difficulty. Finally, the magnitude of the nucleation and
growth zone and the extent of their overlap might be cooling rate dependent. Class IA
compounds have a higher Rcrit than Class IB compounds. The cooling rate achievable by
DSC is slower than the Rcrit and RNcrit of both class IA and class IB. However, cooling by
liquid N2 is slower than the Rcrit and RNcrit for class IA, but larger than Rcrit and less than
RNcrit for class IB.
In order to investigate the relationship between the physicochemical properties of the
compounds with the observed crystallization tendency of each class, a principal component
analysis (PCA) was performed. They found that larger and more flexible molecules tend
to be in class III, whereas smaller and more rigid molecules tend to be in class I. During
cooling from the undercooled melt state, it is relatively difficult and therefore takes more
time for class III molecules to find the right conformer out of all the conformers in the
amorphous matrix and arrange them into the ordered crystalline lattice structure. Hence,
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those molecules can be easily trapped in the glassy state. The structural difference of
different classes is also reflected in the measured thermodynamic parameters. Class III
molecules on average tend to have a lower melting temperature which means lower energy
is needed for disrupting the crystal lattice. They also have a lower heat of fusion and
entropy of fusion implying lower energy difference between the crystalline and the
amorphous state and thus a lower thermodynamic driving force for crystallization.
Trasi et al46 showed how to experimentally determine the nucleation zone of a class II
compound, acetaminophen. In that study, samples were heated to just above the melting
temperature of the drug and subsequently cooled to different temperatures. The upper limit
of the nucleation zone was taken as the highest temperature to which the sample was cooled
when recrystallization was observed upon reheating. It was expected that the number of
quenched nuclei in the amorphous sample will affect the recrystallization temperature.
Hence the temperature, cooling below which, no significant change in peak
recrystallization temperature was observed, was considered as the lower limit of the
nucleation zone (Figure 1-16). The relative height of the nucleation zone was determined
by visually counting the number of crystal growth spots in a specified volume of the sample.
The nucleation zone of acetaminophen was 50-60°C, and the recrystallization exotherm
was not observed until the temperature reaches around 80°C in the reheating step. Hence
for acetaminophen, the nucleation zone and growth zone appear to be well separated.

1.8

Amorphous Solid Dispersions

Amorphous materials can be single chemical entities (e.g. an API or an excipient) or
molecular-level binary mixtures (e.g., drug-polymer solid dispersions), as illustrated in
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Figure 1-17. As compared to single component amorphous drugs, solid dispersions may
exhibit optimum stability and dissolution profiles.
Polymers are often incorporated into the amorphous matrix to stabilize amorphous drugs.
They have been extensively used in amorphous formulations. Several well known
examples are cellulosic polymers such as hydroxypropyl methylcellulose (HPMC), and
water

soluble

synthetic

polymers

such

as

polyethylene

glycol

(PEG)

and

polyvinylpyrrolidone (PVP). Selecting the optimal polymer is vital for the success of a
solid dispersion strategy. Janssens et al6 summarized several important criteria for carrier
selection, given in Table 1-4. A list of commercially available solid dispersions and the
polymers used is given in Table 1-5.
Currently, the methods for manufacturing solid dispersions can be generally divided into
two categories:
1. Hot melt extrusion
A twin-screw extruder is typically used for hot melt extrusion (Figure 1-18)6. A physical
mixture of drug and carrier is melted together, homogenized and then extruded and shaped
into pellets, granules and sheets. Conventional tablets can be produced after further
processing these intermediates. Hot melt extrusion method offers considerable advantages
over the solvent based methods. First, processing in the absence of solvents and water is
beneficial for both economic and ecologic reasons. Second, realization of a continuous
process reduces the number of unit operations and the production time. Better content
uniformity can be obtained by further processing granules of different size ranges. There
are also several disadvantages associated with this method. The miscibility of the API and
the carrier in the molten state is a prerequisite to the manufacture of amorphous solid
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dispersions by hot melt extrusion. In addition, the flowability of the polymer is essential to
processing. Another important limitation is that it cannot be applied heat-labile drugs
owing to the elevated temperature involved.
2. Solvent method
The drug and the carrier are dissolved in a common solvent, which are then removed by
spray drying or freeze drying, resulting in a solid dispersion. A prerequisite for the
application of this method is that both components are sufficiently soluble in the solvent.
Polymers that cannot be utilized in hot melt extrusion due to their high melting point (e.g.
PVP) can now be considered in the solvent based methods. The typical temperature range
of solvent evaporation is 23-65°C48, 49. The complete removal of organic solvent is critical
due to the toxicity concerns.

1.9

Crystallization Inhibition by Polymers during Storage

The amorphous drug may undergo irreversible crystallization during storage, and thereby
negating its solubility advantages over the crystalline form. However, presenting the
compound as a molecular dispersion by addition of a polymeric carrier may significantly
postpone this process. Several mechanisms have been proposed to be responsible for
crystallization inhibition by polymers, and no consensus has been reached thus far.
Amorphous polymers have high Tgs relative to small molecule drugs, and therefore are
considered as anti-plasticizers. The molecular mobility of the mixture is decreased, as
reflected in an increase of the Tg of the mixture, and thereby crystallization is delayed.
Yoshioka et al43 found that amorphous indomethacin (Tg=50°C) crystallizes rapidly at
temperatures above 30°C. In contrast, when indomethacin is dispersed with a low level of
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PVP (5%) and stored at up to 50 °C, an induction period of more than 20 days is required
for crystallization to initiate. The contribution of any anti-plasticizing effect is minimal, as
reflected by only a 5°C increase in Tg. There might be other mechanism(s) responsible for
crystallization inhibition. This postulation was further supported by a case50 of reduced
tendency of the amorphous drug in the solid dispersion to crystallize where the Tg of the
dispersion is lower than that of the drug alone. In this study, the COO-Na+ group of the
drug was found to form an ion-dipole interaction with the cyclic amide group of PVP.
Taylor et al10 investigated the intermolecular interactions between PVP and indomethacin
using vibrational spectroscopy. The γ form of indomethacin consists of cyclic dimers due
to the formation of hydrogen bonding between carboxylic acid groups. In α form, however,
the carboxylic acid groups hydrogen bond to form a chain structure. The amorphous form
mainly consists of cyclic dimers and a small fraction free groups. In the solid dispersions,
the amide carbonyl group of PVP could hydrogen bond with the acid group of
indomethacin (Figure 1-19). Therefore, dimer formation in indomethacin, a prerequisite
for nucleation, is effectively blocked. In contrast, in a physical mixture of amorphous
indomethacin and PVP, no such interaction was found. Similarly, Gupta et al51 have shown
that hydrogen bonding interactions exists between celecoxib and PVP in solid dispersions
using computer simulation.
Miyazaki et al52 investigated the crystallization of amorphous acetaminophen (ACTA) and
solid dispersions of ACTA with PVP and with PAA.

In the non-isothermal DSC

experiments, ACTA does not crystallize when dispersed in 5% PAA whereas
crystallization occurs even in the presence of 10% PVP. In the isothermal studies, samples
were stored at 40°C. In the dry state, it takes more time for 10% of ACTA to crystallize
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(t90) when ACTA is dispersed in either polymer than pure amorphous ACTA. The t 90
increases as the mass fraction of polymer increases. At the same mass fraction, PAA is
more effective in raising t90 than PVP. The enthalpy relaxation time is also prolonged due
to the presence of polymer: 247hr for ACTA/PAA (9:1), 84hr for ACTA/PVP (9:1), and
47hr for ACTA, indicating the effect of polymer on reducing molecular mobility. The fact
that ACTA crystallizes faster in PVP than PAA with a similar Tg suggests that in addition
to decreasing molecular ability, polymers may interact with ACTA. The interaction
between the carbonyl group of PVP and the hydroxyl group of ACTA is weaker than the
interaction between the carboxyl group of PAA and the hydroxyl group of ACTA.
However, in the case of ketoconazole dispersed in PVP-K2553, FT-IR and C13 NMR
results indicated no interaction between the drug and polymer. The crystallization
inhibition was solely attributed to anti-plasticizing effect of the polymer.
Konno et al54 measured the nucleation rate of amorphous felodipine dispersed in PVP,
HPMC, and HPMCAS, respectively. In this study, water was rigorously excluded from the
system during sample preparation as well as storage. Thermal analysis suggests that the T g
of PVP dispersions increases as the polymer fractions increases, close to what is predicted
by the Gordon Taylor equation. In contrast, there were negative deviations from predictions
of this equation for HPMC and HPMCAS dispersions, which implies that the polymerdrug interaction is weaker than the sum of the drug-drug interaction and polymer-polymer
interaction in HPMC and HPMCAS dispersions. Spectroscopic analysis proves that the
rank order of hydrogen bond strength between the polymer and drug were stronger in PVP
dispersions than in HPMC and HPMCAS dispersions. There was essentially no change of
Tg for the HPMC or HPMAS dispersions at the polymer compositions employed for the
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nucleation rate experiments (0 to 25% w/w). However, the abilities of all three polymers
to inhibit nucleation were similar, which indicates that an anti-plasticizing effect is not the
only factor that comes into play.
Instead, the change in nucleation rate was attributed to the ability of polymers to raise the
kinetic barrier to nucleation (ΔG’ in equation 1-20). Polymers may act as diluents to slow
the diffusion of drug molecules, which is evidenced by a decrease in nucleation rate as the
polymer fraction in the solid dispersions is increased. However, the disproportional change
(1.5 orders of reduction in nucleation rate at only 3% as compared to 2.5 orders of reduction
at 25%) indicates that the diluent effect is not the only mechanism (Figure 1-20). In addition,
they suggested that polymers are excluded as felodipine crystallizes and thus accumulates
to form a layer surrounding the growing crystal. Drug concentration in this layer is low,
and hence an increase in Tg occurs. A reduction in molecular mobility results in slower
mass transport of drug molecules to the crystal. Finally, the presence of such a polymer
rich layer may also raise the energy required to form new surface.
Trasi et al46 studied the relative impact of selected polymers on nucleation versus crystal
growth of the supercooled melt of acetaminophen. At the composition (10%) of polymer
used in the study, all polymers had little effect on raising Tg. However, these polymers had
differing levels of impact on crystal growth (Figure 1-21). Therefore an anti-plasticizing
effect, again, is not required for growth inhibition and does not correlate with growth rate
data. Interestingly, the most effective polymer in reducing the nucleation rate, HPMCAS,
was found to be the worst growth inhibitor. On the other hand, the best crystal growth
inhibitor PAA significantly increased the nucleation rate. However, PAA was the most
effective polymer in lowering the temperature where nucleation occurred (Figure 1-22).
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These results demonstrate that polymers may stabilize amorphous drugs by selectively
inhibiting nucleation or growth or both. A better understanding and differentiation might
potentially facilitate the development of a more robust amorphous formulation.
Moisture is ubiquitous and water is always the third component in any solid dispersions.
Crystalline solids adsorb water by a surface adsorption mechanism55. Amorphous solids
are more hygroscopic than their crystalline counterparts due to their disordered structure
and free volume. In addition to surface adsorption, water may penetrate into the bulk of
amorphous materials. The Tg of water is as low as 136K. When absorbed by amorphous
solids, water acts as a strong plasticizer, effectively lowering the Tg of the system. For
example, it has been shown that 1% water lowers the Tg of indomethacin by 10 °C 56. A
reduction in Tg increases the molecular mobility and free volume, and hence destabilizes
amorphous materials57. Polymers used in solid dispersions are typically much more
hydrophilic in nature than the API. They tend to have more polar groups to interact with
water (i.e. hydrogen bonding). In solid dispersions, the amount of water sorbed by the
system is mainly dependent on polymer chemistry/hygroscopicity. Therefore, it is of
interest to investigate when a solid dispersion is exposed to moisture, the competing effect
of polymers as anti-plasticizers to inhibit crystallization and the plasticizing effect due to
the ability of polymers in the dispersion to sorb water. It was found that even though
amorphous felodipine is not very hygroscopic, a small amount of sorbed water still caused
significant increase in nucleation rate58. When dispersed in polymeric carriers,
hygroscopicity of the system increased and the Tg decreased as expected. Despite the
increased moisture uptake, a reduction in nucleation is still observed as compared to drug
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alone. Nevertheless, the ability of the polymers to inhibit nucleation is weaker in the
presence of moisture than at dry conditions.

1.10 Crystallization from Solution: Theory
Crystallization in solution is a complex process involving several steps. First, a
supersaturated solution is formed and the system is in a non-equilibrium state. Then solute
molecules diffuse through bulk solution, collide with each other to form clusters, which is
accompanied with a concentration (density) fluctuation. These clusters increase their size
by addition of one monomer at a time. This eventually leads to the formation of nuclei,
defined as the minimum amount of new phase that could exist independently inside a large
volume of the old phase. Indeed, nucleation is a decisive step that determines the structure
and size distribution of the crystals.
From a thermodynamic point of view, the free energy of the initial solution phase exceeds
the sum of the free energy of crystalline phase and final solution phase. In terms of
nucleation, the free energy change required for the formation of clusters is:
∆G = ∆Gv + ∆Gs
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Where ΔGv is the volume free energy change associated with phase transformation. It
represents the spontaneous tendency for desupersaturation. It is a negative quantity and
reduces the free energy of the system. ΔGs is the free energy change due to the formation
of a solid/liquid interface. It is a positive quantity and increases the free energy of the
system. The growth of the clusters depends on the competition between ΔGv which favors
growth, and ΔGs which favors dissolution. This can be understood by the diagram shown
below.
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Initially, as clusters of small radii are formed, the surface contribution dominates. This
causes an increase in the total free energy change. Hence the smallest clusters usually
dissolve. There exists a critical cluster radius where the total free energy change goes
through a maximum (activation energy, ∆G∗ ):
∆G∗ = πυ2 γ3ns /3(k b Tln(S))

2
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Where ν is the frequency of molecular transport at the nucleus/liquid interface, which is
inversely related to viscosity η, γ is the interfacial energy per unit area between the medium
and the nucleating cluster, kb is the Boltzmann constant, and T is the absolute temperature.
The mechanism of nucleation59 can be divided into two categories: homogeneous
nucleation and surface induced nucleation (Figure 1-24). Homogeneous nucleation occurs
in the interior of a uniform substance. It rarely takes place in large volume (>100µl) due to
the presence of impurities in solution. Surface catalyzed nucleation, instead, is more
frequently encountered. It can be further divided into two subcategories: Nucleation
facilitated by the seed crystals of the solute is known as secondary nucleation. Or nuclei
may preferentially form at surface of the containers or random impurities because of
improved wetting. This mechanism is referred to as heterogeneous nucleation.
Despite being more practically important, heterogeneous nucleation is much more difficult
to model. For both homogeneous and heterogeneous nucleation, the volume free energy
change is:
𝑐
∆𝐺𝑣 = −𝛼𝑙 3 𝑣 −1 𝑘𝐵 𝑇𝑙𝑛 ( )
𝑠
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Where α is the volume-shape factor, l is the characteristic length, v is the molecular volume
of the crystallizing solute, KB is the Boltzmann constant, T is temperature, c is solute
concentration, and s is solubility. The equation above indicates higher supersaturation
decreases the free energy barrier for nucleation.
For homogeneous nucleation:
∆𝐺𝑠 = 𝛽𝑙 2 𝛾12
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Where β is the area shape factor and γ is the interfacial energy per unit area between the
crystallization medium, 1, and the nucleating cluster, 2. This equation suggests that the free
energy barrier for homogenous nucleation can be reduced when the interfacial energy
decreases.
For heterogeneous nucleation,
∆𝐺𝑠 = 𝛾12 𝐴12 + (𝛾23 − 𝛾13 )𝐴23
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Where A is the surface area of the interfaces, and subscript 3 represents the substrate. The
first term in the equation is the same as that of homogeneous nucleation. The second term
says that the surface free energy change can be reduced if the interfacial energy between
the nucleating cluster and substrate is less than that between the substrate and the medium.
This will in turn diminish the total free energy barrier and facilitate nucleation.
Nevertheless, the critical radius remains unchanged (Figure 1-25).
Heterogeneous nucleation mechanism may have profound impact on the dissolution of
metastable forms due to the reduced energy barrier for nucleation. Preparation of a high
energy amorphous form with higher solubility is aimed at achieving faster dissolution and
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higher concentration in solution, achievement of this may not be successful in the presence
of substantial surface catalyzed nucleation
The nucleation rate for homogeneous nucleation of spherical molecular assemblies is given
by the following equation59:
J = N0 υexp(

3
−16πυ2 γ12

c 2
3(k B T)3 (ln (s))

)
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Where J is the number of nuclei formed per unit time per unit volume, N0 is the number of
molecules of the crystallizing phase in a unit volume, and ν is the frequency of atomic or
molecular transport at the nucleus-liquid interface. This equation suggests that the
nucleation rate is increased when supersaturation increases or the interfacial energy
decreases. Some excipients in the formulation (e.g., polymers, surfactants) might alter the
nucleation rate by changing the viscosity of the solution and the rate of molecular transport6.
For non-surface active compounds, increasing solubility will decrease nucleation rate.
However,

adding

surfactants

at

a

concentration

above

the critical

micelle

concentration (CMC) may solubilize surface active drugs, causing them to partition into
the micellar phase. The overall solubility of the drug is increased.

However, the

supersaturation is relieved since the solubility of drug in water phase remains unchanged.
On the other hand, surfactants may lower the interfacial energy between the nucleating
clusters and the medium. Therefore, the influence of surfactants on nucleation rate is
dependent on the competition of their relative contribution on supersaturation and wetting.
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Nucleation rate is inversely proportional to the induction time, tind, of nucleation, which is
the time elapsed from when a supersaturated solution is created to the appearance of a solid
phase59:
t ind = t r + t n + t g
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Where tr is the relaxation time required to reach a quasi steady state distribution of
molecular clusters, tn is the time necessary for the formation of a stable nucleus, and tg is
the time needed for the nucleus to grow to an experimentally detectable size. Figure 1-26
illustrates how the induction time varies with supersaturation.
The growth stage occurs immediately after nucleation. It involves two steps: where growth
units diffuse from the bulk solution to the crystal/solution interface and are then integrated
into the ordered crystal lattice, accompanied by desolvation. The increase in crystal radius,
r, is calculated using the following equation6:
dr
D
= [DνNA /(r + )] (C − Ceq )
dt
k+
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Where D is the diffusion coefficient of the compound, k+ is the surface integration factor,
NA is Avogadro’s constant, and (C-Ceq) is the concentration difference between the bulk
solution and the boundary liquid layer between the growing crystal and the bulk solution.
Careful inspection of this equation reveals that crystal growth is controlled by the rate of
diffusion if r>>D/k+, and by the rate of surface integration if r<<D/k+. Similar to nucleation,
the presence of certain excipients may alter the viscosity, and thereby change D and ν. The
surface integration factor can be modified by adding excipients that are able to adsorb on
to the surface of crystal61.
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The surface-integration controlled growth can be subdivided into continuous growth and
layer growth mechanisms. Continuous growth occurs on relatively rough surfaces whereas
the layer growth occurs on relatively smooth surfaces. The layers (also referred to as steps)
can be formed by two different mechanisms: 2-D nucleation which takes place at high
supersaturation and screw dislocation which dominates at intermediate and low
supersaturation (Figure 1-27).
Volmer postulated that layers are formed when solute molecules adsorb onto an existing
crystallizing surface (Figure 1-28)60. The surface consists of terraces which are flat and
steps which are raised partial layers. The steps contain kink sites where molecules can
make more bonds with neighboring molecules than on terraces or flat step edges. On the
other hand, molecules detach from kinks more easily than from either complete step edges
or terraces. Therefore, the rate of addition of molecules to a crystal is proportional to the
kink density. Consequently, crystal growth rates can be altered through either roughening
steps or blocking kink sites. The flux of molecules detaching from the surface is dependent
on the bond strength of a molecule to its neighbors, which is a function of temperature
rather than solute concentration. The flux of molecules attaching to the crystallizing surface
is proportional to the concentration (or activity). Therefore, assuming all other factors are
equal, crystals of higher solubility compound will grow faster than a sparingly soluble
compound, even at equivalent supersaturation. Hence, crystal growth rates may also be
modified by shifting the solubility62. The entire layer is formed once the pre-existing steps
grow out to the edge of the crystal, leaving a featureless terrace. To enable further growth,
a new source of steps must be generated. This is accomplished through the formation of
two dimensional islands of molecules, which may then spread out. For these islands to
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form, a free energy barrier has to be overcome. The overall excess free energy for 2-D
nucleation59 consists of a surface component and a volume component, as given by the
following equation:
∆G = aγ + vΔGv
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Where, a and v are the surface area and volume of the nucleus, respectively. γ is the surface
tension.
Assuming a circular disc nucleus, where r is the radius and h is the height:
∆G = 2πrhγ + πr 2 h∆Gv
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The critical nucleus (rc) can be found by taking the derivative:
d∆G
= 2πhγ + 2πrh∆Gv = 0
dr

rc = −
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γ
∆Gv
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πhγ2 v
kTlnS
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The critical free energy is given by:
∆Gcrit =

And the 2-D nucleation rate is：
πhγ2 v
J = B ∙ exp[− 2 2 ]
k T lnS

1-39
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Figure 1-29 shows examples of crystal surfaces that do grow by 2-D nucleation mechanism
at sufficiently high supersaturations. However, the critical size is large at low
supersaturation, and hence the odds of obtaining the islands are prohibitively small.
Frank63 suggested that crystals are imperfect, containing edge dislocations and/or screw
dislocations upon which permanent sources of steps are generated (Figure 1-30). This
mechanism accounts for the crystal growth observed at low supersaturations. In this case,
interesting spiral arrangements of steps are generated by dislocation growth sources. This
feature is often referred to as growth hillocks (Figure 1-31). The equilibrium shape (i.e.
spiral staircase, pyramids, cubic spirals etc) is the one that possess minimum total surface
free energy and the radius of the curvature is dependent upon the critical radius.
The growth hillocks can be modified by impurities through four mechanisms (Figure 1-32).
Growth inhibition by impurities for each mechanism exhibits a different dependence of
step kinetics on impurity concentration, supersaturation and temperature64, 65.
1) Step pinning: Adsorption of impurities may block the attachment of molecules to
the step edges. In this case, steps can only proceed by growing around the blocked
sites.
2) Incorporation: Impurities maybe captured and incorporated into the kinks and
become part of the growing crystals.
3) Kink blocking: Kink density is temporarily reduced66 due to the adsorption of
impurities to kinks for very short residence time. In this case, step advancement is
not permanently stopped at the kink site, just kink propagation.
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4) Surfactants: The adsorption of impurities could lower the interfacial energy of the
step edge, and thereby modify the shape of the growth hillocks and the resulting
crystals.
For 2-D nucleation, the effect of impurities on crystal growth in a supersaturated solution
by the step pinning mechanism can be quantified by the Kubota and Mullin model65.
Assuming a constant step height for each layer, the relationship between the growth rate of
a single step V and that of the crystal face containing a step V is given by:
V
G
=
V0 G0
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Where, the numerator is the growth rate in the presence of impurities and the denominator
is the growth rate in the absence of impurities.
If steady state adsorption is assumed, (i.e., the adsorption equilibrium is reached
instantaneously, and the surface coverage of active sites by an impurity is independent of
time), then
𝑉
= 1 − 𝛼𝜃𝑒𝑞
𝑉0
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Where, θeq is the equilibrium surface coverage of active sites by an impurity. Assuming the
Langmuir adsorption isotherm, then
𝜃𝑒𝑞 =

𝐾𝑐
1 + 𝐾𝑐
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Where K is the Langmuir constant, c is the impurity concentration, and α is the impurity
effectiveness factor. Combining equation 1-41 and 1-42 gives:
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𝑉
𝛼𝐾𝑐
=1−
𝑉0
1 + 𝐾𝑐
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This equation is shown in Figure 1-33 where the dimensionless relative step velocity
(V/V0) is plotted against the dimensionless impurity concentration with the effectiveness
factor as a parameter.
It can be seen that the ability of an impurity to inhibit step growth decreases as the
effectiveness factor decreases. If this value is less than unity, the step advancement will
not be completely arrested, even at high impurity concentration. Instead, plateau regions
are observed where relative step velocity is independent of dimensionless impurity
concentration when the impurity concentration is high.
The impurity effectiveness factor α is given by:
𝛼=

𝛾𝑎
𝑘𝑇𝜎𝐿

1-44

Where L is the separation of sites available for impurity adsorption, γ is the surface tension,
a is the surface area occupied by one crystallizing molecule and k is the Boltzmann constant,
T is the temperature, and σ is the degree of supersaturation. This equation implies that for
any given temperature, the effectiveness of the impurity on growth rate inhibition decreases
as the degree of supersaturation increases.
Combining equation 1-40, 1-43 and 1-44 gives:
𝐺
𝜎𝑐
= 1 − (forσc < 𝜎)
𝐺0
𝜎

1-45

Where, σc is the critical supersaturation, defined as the supersaturation below which G=0
(dead zone):
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G
𝛾𝑎
𝐾𝑐
=0=1−(
)(
)
G0
𝑘𝑇𝜎𝑐 𝐿 1 + 𝐾𝑐

𝜎𝑐 =

𝛾𝑎𝐾𝑐
𝑘𝑇𝐿(1 + 𝐾𝑐)
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Equation 1-47 can be rewritten in the form of
1
C1
= + C2
σc
c
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Where C1=kTL/γaK, and C2=kTL/γa. This equation indicates a linear relationship exists
between the reciprocal of the critical supersaturation 1/σc and the reciprocal of impurity
concentration 1/c
If a second order growth law is applied:
G0 = kσ2
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G0
σ 2
=
(
)
kσ2c
σc
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By normalizing with kσc2, we obtain:

Combining equation 1-45and 1-49 gives:
G
σ
σ
= ( ) [( ) − 1]
2
kσc
σc
σc
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This equation is shown in Figure 1-34, where crystal growth inhibition by the impurity is
apparent. There also exists a supersaturation range (0<σ<σc), where the crystal does not
grow in the presence of impurity.
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1.11 Crystallization during Dissolution of Amorphous Solids
Amorphous solids have drawn much research interest today due to their capability of
increasing bioavailability by enhancing the solubility/dissolution characteristics of poorly
water soluble compounds. However, amorphous solids are inherently unstable and tend to
convert to less soluble crystalline forms, which negates such benefits. To fully take
advantage of amorphous materials, it is not enough just to ensure that drug remains
amorphous during the entire period of storage, preventing crystallization during dissolution
of amorphous solids is equally important67. While a plethora of investigations have been
conducted on the physical stability of amorphous solids during storage, there is a lack of
fundamental understanding around the underlying factors influencing phase transformation
during dissolution of amorphous pharmaceuticals.
A supersaturated solution has higher chemical potential (µ) as compared to saturated
solution (µeq). The difference in chemical potential is the thermodynamic driving force for
crystallization.
𝑎
𝛾𝐶
∆𝜇 = 𝜇 − 𝜇𝑒𝑞 = 𝑅𝑇𝑙𝑛 ( ) = 𝑅𝑇 (
)
𝑎𝑒𝑞
𝛾𝑒𝑞 𝐶𝑒𝑞

1-52

Where a is the activity of the solute in supersaturated state, and aeq is the activity of the
solute in saturated state, and γ is the activity coefficient. Assuming the activity coefficient
is independent of concentration, then
∆𝜇 = 𝑅𝑇𝑙𝑛 (

𝐶
) = 𝑅𝑇𝑙𝑛𝑆
𝐶𝑒𝑞
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Therefore, the higher the degree of supersaturation, the larger thermodynamic driving force
for crystallization of solute from solution. However, as mentioned previously, even if
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supersaturation is achieved, the activation energy barrier for nucleation has to be
surmounted. Otherwise, nucleation is suppressed, at least during a certain time frame.
There are several domains in the concentration versus temperature diagram as shown in
Figure 1-35. Solutions with concentrations lower than the solubility curve are considered
undersaturated (Δµ<0), and no crystallization will be observed. In the metastable region, it
is difficult for spontaneous nucleation to occur. However, crystals may grow rapidly if
added to the solution. In the labile zone, nucleation is spontaneous followed by rapid crystal
growth.
Solubilization formulation strategies aim at reducing the degree of supersaturation by
decreasing the free drug concentration in the aqueous phase (e.g. self emulsifying drug
delivery systems, surfactants above CMC, cyclodextrins). Hence, the distance between the
system and the saturation curve in the diagram is reduced and the thermodynamic driving
force for crystallization (Δµ) decreases. In contrast, during the dissolution of amorphous
solids, the presence of polymers sustains supersaturated concentrations of the solute and in
the meantime prolongs the time for the nucleating clusters to grow to the critical radius.
The high concentration of drug in the lumen results in enhanced flux acrossed the GI wall.
In this scenario, Δµ does not change significantly, at least during that time frame. Therefore,
this approach can be conceptually considered as increasing the metastable zone width68.
Raghavan et al69 studied the influence of selected polymers on the crystallization during
dissolution of amorphous hydrocotisone acetate (HA). Crystallization was spontaneous
for solutions at all levels of supersaturation investigated in the absence of polymers,
indicating that these concentrations were in the labile zone. Nucleation time was inversely
related to the degree of supersaturation at all the polymer concentrations studied.
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Nucleation time was prolonged in the presence of polymers and the effect was more
pronounced as the polymer content increased. In the absence of polymers, spontaneous
nucleation indicated that nucleation is not diffusion controlled. Polymers may associate
with HA to form hydrogen bonds in solution. Such bonds have to be broken before HA
molecules can diffuse and collide to form a nuclei of critical size. Cellulosic polymers have
more functional groups to hydrogen bond with HA than PVP or PEG, and hence a longer
nuleation time is expected. Unfortunately, only the nucleation times in the presence of
HPMC were shown in their paper. Crystals grown in the presence of any of the polymers
were smaller than crystals grown without polymer. They suggested that once nuclei are
formed, there will be competitions between HA growth units and polymers for growth sites
on the crystal surface. Due to size and structure considerations, polymers will be excluded
as the HA growth units are incorported into the crystal lattice. However, the excluded
polymer molecules do not leave immediately. Instead, they may adsorb and accumulate on
the boundary region between the crystal surface and solution due to their ability to form
hydrogen bond with HA molecules (Figure 1-36).
This layer provides a mechanical barrier to retard the diffusion of HA molecules from
solution to the crystal surface. In addition to growth inhibition, cellulosic polymers were
able to modify the crystal habit of HA: from a well-faceted polar prismatic morphology to
a boomerang morphology with very rough surfaces and edges. In contrast, PVP and PEG
do not have such effect. A change in crystal morphology suggests that cellulose polymers
may preferrentially adsorb on the surface where HA molecules have more functional
groups for hydrogen bonding. The growth of these faces are delayed. The fact that the
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morphology of HA crystal is less affected by PVP and PEG is perhaps because these
polymers do not have as many functional groups per monomer unit as cellulose polymers.
When introduced to the aqueous medium, amorphous solids have a tendency to convert to
a thermodynamically stable, less soluble crystalline state directly from the amorphous
matrix. Water is absorbed by the amorphous material upon exposure and causes a
substantial reduction of Tg at the surface of the solids. This will increase molecular mobility,
and may lead to crystallization at the surface of the solid. If the solid to solid conversion is
extremely rapid, then the concentration-time profile of the amorphous solids will mimic
that of the crystalline form because it is essentially the transformed crystalline material that
is dissolving. If the solid state transition is relatively slow as compared to the dissolution
of the amorphous material, a supersaturated solution will be attained. Once the solution
concentration exceeds the metastable zone, the solute will crystallize spontaneously,
whereby the nucleation and growth rate are propotional to the degree of supersaturation
(Figure 1-37). Eventually, the solution will attain thermodynamic equilibrium as the solute
is depleted. Based on the above considerations, Alonzo et al67 hypothesized that the level
of supersaturation achieved during dissolution of amorphous materials depends on the
kinetics of solid state crystallization as well as solution crystallization. Polymers may
reduce crystallization tendency of either or both routes. They compared the dissolution
behavior of amorphous felodipine and indomethacin in the presence/absence of
predissolved PVP, HPMC and HPMCAS. At 25°C, dissolution of amorphous felodipine
resulted in a small extent of supersaturation, followed by desupersaturation due to solution
crystallization. At 37°C, however, the dissolution profile of amorphous felodipine looked
very similar to that of the crystalline solid. A slurry experiment with Raman analysis
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showed that powdered felodipine commenced crystallization immediately upon contact
with the medium and proceeded rapidly at 37°C. The phase transformation kinetics were
relatively slower at 25°C. All three polymers were able to delay solid state crystallization
of amorphous felodipine, and therefore higher levels of maximum supersaturation were
observed at 37°C. It was suggested that the polymers interact with the surface of the
amorphous drug and thereby inhibit surface crystallization. HPMC and HPMCAS were
able to effectively inhibit crystallization from solution and maintain the supersaturation.
PVP, however, was a poor inhibitor of solution crystallization. In the case of indomethacin,
high maximum supersaturations were observed at both temperatures because the solid state
crystallization of indomethacin was much slower as compared to felodipine. In the absence
of polymers, desupersaturation occurred at both temperatures. Hence, for indomethacin,
solution crystallization was the predominant mechanism of negating the solubility
advantage of amorphous solids. Similar to the felodipine case, polymeric additives were
able to stabilize the supersaturation by inhibiting solution crystallization. At 25°C, the
presence of PVP and HPMC yielded a similar maximum concentration consistent with the
value estimated using the Hoffman equation. Interestingly, at 37°C, the same maximum
concentration was achieved in the presence of PVP, followed by significant
desupersaturation. A lower maximum concentration was achieved in the presence of
HPMC. However, no desupersaturation was observed. To conclude, the kinetics of both
crystallization pathways determine the overall shape of concentration-time profiles for
amorphous solids. The maximum solution concentration observed will be close to the
estimated amorphous solubility only when both the metastable amorphous solid and the
supersaturated solution are stabilized against crystallization. Assessment of the ability of
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different polymers in inhibiting each route could lead to rational design of amorphous
formulation. Multiple polymers can be incorporated into a single formulation, with one
optimized for solid state crystallization inhibition and the other for solution crystallization
inhibition.
With respect to solution crystallization, a follow up study70 was conducted to quantify the
relative impact of pre-dissolved HPMC on nucleation versus growth kinetics of felodipine
from supersaturated solution. Growth inhibition by the polymer was quantified by
measuring the desupersaturation rate in the presence of seed crystals. At low levels of initial
supersaturation (S≤6), the presence of HPMC at all concentrations investigated (from
0.2ug/ml to 3.5ug/ml) resulted in measurable reduction of the desupersaturation rate and
consequently the growth rate. At high levels of initial supersaturation (S≥8), HPMC present
at the lowest concentration (0.2ug/ml) was not able to decrease desupersaturation and
growth rate. As supersaturation increased, the rate of growth increased no matter whether
HPMC was present or not, indicating there is a certain limit of growth inhibition that
HPMC can provide at a given S. In other words, HPMC became less effective in inhibiting
crystal growth as initial supersaturation was increased. At a given S, as polymer
concentration increases, more polymer molecules are available to be adsorbed onto the
surface of the crystal, and hence have a more profound impact on growth rate. However,
there is a limit of surface area on the crystal that can be covered by the polymer. The
adsorption isotherm suggested that maximum coverage was attained when polymer was
present at 1ug/ml. This was consistent with the finding that there was no further increase
in the extent of growth rate inhibition by increasing polymer concentration beyond 1ug/ml.
In the absence of HPMC, the growth of crystals was controlled by both diffusion and
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integration. The presence of HPMC reduced the rate at which the growth units were
incorporated into the lattice while not affecting the diffusion of growth units from bulk
solution into the incorporated site. Nucleation inhibition by HPMC was quantified from
measurement of the desupersaturation rate in seedless solution. At an S of 10 (high level
of supersaturation), the presence of HPMC at 1ug/ml resulted in an approximately 1000
fold reduction in nucleation rate. In contrast, there was only a 2 fold reduction in growth
rate at the same S and HPMC concentration.
Figure 1-38 clearly shows that the pre-dissolved HPMC has a much more significant effect
on nucleation than on crystal growth70. Hence for felodipine, preventing nucleation from
solution and minimizing residual crystallinity in the formulation are extremely important
for maintaining supersaturation.

1.12 Drug-Polymer Solubility and Miscibility
In small molecule solutions, the chemical potential of the solute in the solid phase equals
the chemical potential of the solute in the liquid phase when the solution concentration
reaches the equilibrium solubility at a given temperature. This concept can be extended to
crystalline drug-polymer mixtures, where the composition of drug in the polymer at
equilibrium is the solubility. In other words, it refers to the ability of a polymer to play the
role of solvent to dissolve a crystalline API. On the other hand, miscibility refers to the
property of liquids to mix in all proportions, forming a homogeneous solution. For polymer
blends, miscibility can be well characterized since the amorphous polymer components are
stable. In binary solid dispersions, the liquid components to be mixed are the amorphous
drug and the amorphous polymer, respectively. In this case, complexity around the
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miscibility arises because as compared to polymers, small molecule drugs have greater
tendency to crystallize due to the relative ease of molecular rearrangement in the
amorphous matrix and subsequently form an ordered lattice structure. Eventually,
equilibrium will be attained with respect to crystalline drug in the amorphous polymer. The
mixture composition at this equilibrium would be the solubility of the crystalline drug in
the polymer. Therefore, the term miscibility is meaningful only if the drug can maintain
the supercooled liquid state in the dispersion within the experimental timeframe well above
or close to Tg. Below or close to Tg, however, the material become too viscous (>1012 Pa·S)
for the system to reach equilibrium, which involves the kinetics of physical aging as well
as phase separation. Hence miscibility is only “apparent” in this case.
Achieving and maintaining molecular level mixing is important for two reasons. First,
regardless of the specific mechanism, the ability a polymer to inhibit crystallization relies
on the ability of the polymer to interact with the API and thereby change its local
environment. In a well mixed binary system, only a single amorphous phase exists. If the
two components are immiscible, regions with different API-to-polymer ratio will be
present in the system. It can be understood intuitively that crystallization will initiate from
the drug rich phase where the availability and thus the influence of polymer is minimal.
Second, if the drug is intimately mixed with the polymer at the molecular level, the
chemical potential of the API in the dispersion will be lower as compared to the pure
amorphous API. The lower chemical potential infers a reduced thermodynamic driving
force for crystallization as well. That is why crystallization inhibition was not observed in
the physical mixtures of indomethacin-PVP and sucrose-PVP71,
macroscopic mixing were achieved.
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, where only
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Feng et al73 proposed a hypothetical working diagram defined by drug loading in polymer
and temperature as shown in Figure 1-39. This diagram consists of six different domains
(labeled I-VI) that are separated by three curves: crystalline drug-polymer solubility,
amorphous drug-polymer miscibility, and Tg of a solid dispersion system. The goal is to
find a domain in which the solid dispersion is physically stable while maximizing the drug
loading in polymer to reduce the pill burden for patients.
As described by the Gordon-Taylor equation, the Tg of a binary solid dispersion decreases
as the drug loading increases. This curve represents a kinetic boundary, to the left of which
an amorphous solid become a highly viscous glass, and hence has very low molecular
mobility. Below Tg, the system is kinetically stabilized against phase separation and/or
crystallization, if any. For simplicity, the miscibility can be considered as the “solubility”
of an amorphous API in a polymer, since drug to polymer ratio is usually much less than
unity in a typical solid dispersion formulation. It follows that the amorphous drug-polymer
miscibility curve must be higher than the crystalline drug-polymer curve due to the higher
chemical potential of amorphous state as compared to the crystalline state. Below the
crystalline curve, there is no risk of destabilization of the system. If drug loading is above
the crystalline-drug solubility curve, the polymer solvent is supersaturated with respect to
crystalline drug. There is a potential risk of crystallization of the API from a
thermodynamic perspective. However, if the amorphous drug is relatively stable without
crystallization, the miscibility curve represents the boundary for destabilization of the
system. Above that curve, the free energy of mixing will become positive, resulting in
spontaneous phase separation. Crystallization would preferentially initiate in the drug-rich
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region. The thermodynamic nature and destabilization driving force for solid dispersion in
different domains73 are summarized in Table 1-6
Determination of domain III is of interest because in this region the solid dispersion is
stabilized both kinetically (limited molecular mobility below Tg) and thermodynamically
(below miscibility). In the meantime, a higher drug loading in polymer is achieved as
compared to domain I and II. If an even higher drug loading is required (above miscibility),
it is recommended to work in domain V to kinetically stabilize the system. Domain VI
should be avoided at any time based on similar arguments.
Thermodynamically, whether the formation of a homogeneous single phase mixture is
successful is governed by the Gibbs free energy of mixing of the system:
∆𝐺𝑚𝑖𝑥 = ∆𝐻𝑚𝑖𝑥− 𝑇∆𝑆𝑚𝑖𝑥
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Where, ΔGmix is the free energy of mixing, ΔHmix is the enthalpy of mixing, T is
temperature, and ΔSmix is the entropy of mixing. Mixing of the two components is
thermodynamically favorable if ΔGmix is negative. When ΔGmix is positive, mixing is
considered unfavorable.
The entropy of mixing is defined as the increase in the total entropy of a system, when
different and chemically non-reacting components are mixed by removing partition(s)
between the system's initially separate volumes. Assuming ideality, the entropy of mixing
for two components is given by:
∆𝑆𝑚𝑖𝑥 = −𝑛𝑅(𝑋𝑢 𝑙𝑛𝑋𝑢 + 𝑋𝑣 𝑙𝑛𝑋𝑣 )
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𝑋𝑢 = 1 − 𝑋𝑣
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In this equation, n is the total number of moles. Xis are the mole fractions of component i,
which are less than unity, and thus the natural logarithm is always negative. Upon removal
of the partition, nXi moles of component i will explore the combined volume which is not
initially accessible to it, resulting in an increase in ΔSmix by nRXilnXi. Mixing as ideal
solutions is always spontaneous, and there is no heat transfer involved or work is done.
The enthalpy of mixing is the heat taken up or released during mixing of the chemically
non-reacting pure components. It is given by:
∆𝐻𝑚𝑖𝑥 = (𝐻𝑢𝑢 + 𝐻𝑣𝑣 ) − 𝐻𝑢𝑣
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Where Huu, Hvv are the enthalpies of the pure components and Huv is the enthalpy of the
mixture. ΔHmix depends upon the interactions between the molecules, which may include
van der Waals force, hydrogen bonding interactions, charge transfer complexation, and
ionic interactions. The energy change during mixing can be regarded as being made of
three parts, the endothermic breaking of interactions within the two pure components, and
the exothermic formation of attractions between them. An ideal mixture is one in which
the interactions in the mixture are the same as for the two pure components. Hence the
process is athermal (i.e. ΔHmix=0). If the adhesive interactions are weaker than the sum of
cohesive interactions, ΔHmix will be positive (endothermic mixing), resulting in an increase
in ΔGmix, and vice versa.
From the discussion above, it follows that mixing is always entropically favored. A certain
level of unfavorable enthalpy interactions could be tolerated while molecular level mixing
is still achieved74. Therefore, a quantitative assessment of both enthalpic and entropic
contributions to the mixing free energy is advisable to enable an unequivocal prediction of
the miscibility.

57
Originally developed for polymer-solvent systems, the Flory-Huggins lattice theory was
adapted by Marsac et al74 to estimate the free energy of mixing for drug-polymer system
by assuming that the drug behaves similarly to a solvent:
ΔGmix
= ndrug lnΦdrug + npolymer lnΦpolymer + ndrug Φpolymer χ
RT
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Where ndrug is the number of moles of drug, npolymer is the number of moles of polymer,
Φdrug is the volume fraction of the drug, Φpolymer is the volume fraction of polymer. The
first two terms in the equation accounts for the entropy of mixing, which is similar to
equation 1-55. However, the mole fractions are replaced by the volume fractions. This is
attributed to the reduced ΔSmix for large molecular weight materials caused by the reduced
number of possible configurations of the two components in a binary mixture. χ is the
Florry-Huggins interaction parameter which accounts for the enthalpy of mixing, which is
a measure of the relative strength of cohesive and adhesive interactions. Positive interaction
parameter indicates stronger cohesive interactions than adhesive interactions in the system
and mixing is enthalpically unfavorable whereas a system with a negative interaction
parameter is characterized by extensive adhesive interactions and hence favorable mixing.
For a typical small molecule API (MW between 200 to 600)-polymer (MW between 10,000
to 1,500,000) system, the contribution of entropy term to the free energy of mixing was
determined to be relative constant by simulation (assuming χ=0). Whether a system is
miscible or not is essentially determined by the sign and magnitude of χ. Negative
interaction parameters were obtained by the melting point depression method for both
felodipine-PVP and nifedipine-PVP mixtures, and hence miscibility was predicted. A
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limitation to the melting point depression approach is that the χ estimated is only applicable
within a small temperature range close to melting point and at low polymer weight fractions.
Finally, a model was developed74 based on Flory-Huggins theory to predict the solubility
of a crystalline drug in a glassy polymer:
𝑙𝑛𝛾𝑑𝑟𝑢𝑔 𝑥𝑑𝑟𝑢𝑔 = −

∆𝐻𝑓𝑢𝑠
𝑇
1 𝑇
[1 − ] −
∫ ∆𝐶 𝑐𝑜𝑛𝑓𝑖𝑔 𝑑𝑇
𝑅𝑇
𝑇𝑚
𝑅𝑇 𝑇𝑚 𝑝

1 𝑇 ∆𝐶𝑝 𝑐𝑜𝑛𝑓𝑖𝑔
+ ∫
𝑑𝑇
𝑅 𝑇𝑚
𝑇
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where, xdrug is the mole fraction, ΔHfus is the enthalpy of fusion, Tm is the melting
temperature of the drug, and ΔCpconfig is the configurational heat capacity. γdrug is the
activity coefficient, which reflects non-ideality, and is given by:
2
𝑙𝑛𝛾𝑑𝑟𝑢𝑔 = ln (Φdrug ⁄𝑥𝑑𝑟𝑢𝑔 ) + (1 − 1⁄𝑚)Φpolymer + χΦpolymer
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Where, m is the ratio of the volume of the polymer to the molecular volume of the drug.
The solubility of nifedipine in PVP was determined to be very low (6~7%). This would
require at least 90% of polymer present in the formulation to ensure that the drug does not
crystallize due to supersaturation. In this case, the system is considered to be
thermodynamically stabilized. However, if a high drug loading is required, stabilization of
the amorphous nifedipine would mainly rely on the ability of polymer to retard the kinetics
of crystallization as discussed previously. By comparing felodipine and nifedipine, the
authors pointed out that the solubility of an API in a polymer increases as the melting point
and the heat of fusion increases and/or with a more negative enthalpy of mixing.
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For a binary amorphous mixture, the compositional dependence of ΔGmix can be described
by the following equation, which is originally developed for liquid mixtures75:
𝛥𝐺𝑚𝑖𝑥 = 𝑥𝐴 (𝜇𝐴 − 𝜇𝐴∗ ) + 𝑥𝐵 (𝜇𝐵 − 𝜇𝐵∗ )
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Figure 1-40 is the plot of free energy as a function of composition for binary systems with
different types of miscibility behavior76. If the two components are completely miscible at
any composition, a concave shaped curve with only one energy minimum will be observed.
Normally, immiscibility only occurs when the ΔGmix is positive, which is characterized by
a convex shaped curve over the complete range of compositions. However, some binary
systems may exhibit partial miscibility, that is, only a certain amount of one component
can be mixed with the other to form a homogeneous phase at a given temperature and
pressure. Above that concentration, however, the component in excess will phase separate,
even though the ΔGmix is negative with respect to the unmixed components. This is
illustrated in the red curve in Figure 1-40 and more details are given in Figure 1-41. It can
be seen that ΔGmix is negative at all compositions. Nevertheless, two minima are observed
at composition xAB and xBA, resulting in a miscibility gap. At these compositions, ΔGmix is
lower as compared to that of any compositions in between them. They are called binodal
points, at which the chemical potential of each component is equal in both phases. Any
composition below xAB or above xBA is stable and does not phase separate. The inflection
points between the binodal points and the point of maximum ΔGmix are known as spinodal
points (x*AB and x*BA). Mathematically, the spinodal points can be found by setting the
second derivative of ΔGmix with respect to concentration equal to zero. Between xAB and
x*AB and xBA and x*BA is the metastable region, where phase separation can occur after
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overcoming an energy barrier. The spinodal points envelope the unstable region, where
phase separation occurs spontaneously. This process is also referred to as spinodal
decomposition where a new phase is initiated without any thermodynamic barrier. The
resulting two liquid phases have equal chemical potential. Partial immiscibility is a
function of temperature. The degree of immiscibility decreases as temperature increases in
some systems. The temperature at which complete miscibility is observed is known as
upper consolute temperature (UCT).
If immiscibility occurs, different phases with varying composition of the components will
be present in the system. Such difference will be reflected in the measured physical
properties. DSC is the standard method to characterize the number of phases present in
amorphous mixtures. For a miscible system, a single Tg is expected. Conversely, the
presence of multiple Tgs is indicative of a phase separated system. Despite its
straightforwardness and hence popularity, the DSC method has several inherent limitations
in evaluating miscibility. First, if the Tgs of individual components are very similar,
identification of multiple Tgs in a phase separated system can be difficult. Second, a
minimum domain size (10-50nm for polymeric blends) 77 containing more than one phase
is required for Tg events to be detected. Third, the heat capacity change in glass transition
maybe too broad or weak to allow unambiguous identification. Fourth, multiple Tgs have
been reported for miscible polymer blends recently78. Last but not least, when a sample is
heated, there might be a shift in the miscibility behavior of the system due to the increase
in

temperature.

Techniques

such

as

atomic

force

microscopy

(AFM)

and

scanning/transmission electron microscopy (SEM/TEM) are able to achieve nanoscale
resolution. However, they cannot characterize the chemical compositions of different
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phases in the system. On the other hand, mid-infrared (MID-IR) and Raman mapping could
interrogate the chemical information, but suffer from limited spatial resolution as imposed
by the diffraction limit of light. Nanoscale mid-IR is a promising technique to bridge this
gap in that it provides the chemical information from mid-IR analysis with high spatial
resolution (submicrometer) thanks to the implementation of an AFM probe.
Eerdenbrugh et al79 explored this technique to evaluate the miscibility of felodipine and
PAA dispersions. The chemical structures of both components are shown in Figure 1-42.
Standard topolographical AFM imaging indicates miscibility at 25:75 (w/w) drug to
polymer ratio. The formation of discrete domains in a continuous phase was observed in a
50:50 (w/w) ratio dispersion. Further increasing the drug content to 75:25 (w/w) resulted
in apparent phase separation. The discrete domains began to dominate the image with the
compensating reduction of the continuous phase. Nevertheless, it was hard to determine
the chemical content in each domain. Therefore, a 50:50 (w/w) sample was then subject to
nanoscale mid-IR spectroscopy for this purpose. Reference nanoscale mid-IR spectra of
pure amorphous PAA, amorphous felodipine, and crystalline felodipine are shown in
Figure 1-43. It can be seen that both PAA and felodipine show a strong response at around
1700cm-1. As compared to pure PAA, the pure amorphous or crystalline felodipine has a
characteristic peak at approximately 1500cm-1, which was assigned to N-H bending
coupled with CH2 vibrations. Localized nanoscale mid-IR spectra are shown in Figure 1-44.
It can be seen that the spectra corresponding to discrete domains (marked in red) is
dominated by the peaks at 1700cm-1, and the peak at 1500cm-1 was much weaker. In the
spectra corresponding to the continuous phase (green marked), the peaks at 1500cm-1 were
stronger than at 1700cm-1. Such results verified the occurrence of phase separation, with
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the discrete domains being richer in drug while the continuous phase was richer in polymer.
The presence of felodipine in the continuous phase and polymer in the discrete phase is
inferred by the spectral contribution of their characteristic peaks. The system is hence
considered partially miscible at 50 (w/w) drug loading, in agreement with a previous
study76. Moreover, by comparing the localized spectra of the mixture with those of pure
crystalline and amorphous felodipine, it can be deduced that felodipine did not crystallize
during the experimental timeframe. This is consistent with the fact that felodipine is a slow
crystallizing compound17.
Marsac et al80 assessed the impact of environmental stresses on the miscibility of
amorphous dispersions of felodipine and PVP. Briefly, at room temperature, the drug-drug
cohesive hydrogen bonding is associated with an NH peak centered at 3341cm-1, whereas
the drug-polymer adhesive hydrogen bonding is related to an NH peak at 3290-1. The drugdrug interaction is gradually weakening for pure amorphous felodipine on heating, as
reflected by an increase in the corresponding NH peak position. Similar trend was observed
in the solid dispersions as well. Moreover, the drug-polymer interaction is also weakening,
but persisted up to the melting temperature of the drug, indicating that the miscibility of
the solid dispersions is retained. From Figure 1-45, we can see that the effect of temperature
on the intermolecular interactions is reversible80. Another interesting observation is that
the slope of peak positions versus temperature changes near the Tg of each system.
Upon exposure to moisture for short periods of time (2-24hr), the drug-polymer hydrogen
bonding is disrupted while the number of drug-drug interaction is increasingly numerous
and the resulting IR spectra increasingly resemble that of the pure amorphous drug80
(Figure 1-46). This change is most exaggerated at above 75% RH due to a dramatic increase

63
in water uptake when the relative humidity exceeds 75%. This is indicative of moisture
induced phase separation to a drug-rich amorphous phase and a polymer rich amorphous
phase, and is later confirmed by the DSC, AFM and TEM (transmission election
microscopy) results. Moreover, the spectroscopic change persisted after drying over
phosphorous pentoxide at room temperature for 1 week, suggesting that the moisture
induced immiscibility is irreversible. Similar spectroscopic change was observed for solid
dispersions of felodipine and PVP prepared with water added to the solvent during
production as compared to those prepared from the dry solvent. The moisture/liquid water
induced phase separation was explained by the asymmetry of interactions of the two
components with the water, which is reflected by the large difference in the Flory-Huggins
parameter of water with PVP (χ12=0.5) and water with felodipine (χ13=3.3). This is known
as the Δχ effect (where Δχ= |χ12-χ13|)81, 82. In addition, molecular mobility is also increased
due to water sorption, which enables faster diffusion of molecules to form drug-rich and
polymer-rich domains. As water is subsequently removed by heating at 125 °C, however,
remixing of felodipine and PVP gradually proceeded and completed within approximately
24 hrs80 (Figure 1-47). The occurrence of remixing at high temperature (well above the Tg
of felodipine and that of the corresponding one phase solid dispersion) is dictated by the
thermodynamic driving force for mixing in the absence of moisture. However, the fact that
remixing was not observed after drying at room temperature is a consequence of the
prohibitively slow kinetics. This is because both meta-stable phases are in the glassy
regime (high viscosity and hence slow molecular diffusion) at room temperature. The
implication from this study is that the water content of solvents has to be rigorously
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controlled and the exposure of the solid dispersions to high relative humidity needs to be
avoided so as to prevent water induced phase separation.

1.13 Drug Release Mechanisms from Solid Dispersions
To facilitate the design of a solid dispersion with optimal dissolution performance, a
fundamental appreciation of the underpinning mechanisms and complexities associated
with the release process is required. These factors may include the method of preparation,
weight fraction of the carrier used, the solubility/dissolution rate difference between the
drug and the carrier, crystallization tendency of the drug during dissolution, etc.
There are two types of release behavior of drug from solid dispersions reported in the
literatures. A carrier-controlled dissolution mechanism was proposed by Corrigan et al83,
84

who found that the dissolution rate of the drug in the polymeric carrier is equal to that of

the polymer alone. Support for this hypothesis was provided by Dubois and Ford85 who
showed that the release rates of different drugs in a single polymer were similar, indicating
the release behavior is dependent on the properties of the polymer rather than the drug.
Contradictory results were found in a Sjokvist and Nystrom86 report that the dissolution
rate enhancement was dependent on the particle size of the griseofulvin released from the
dispersions. In these cases, a drug-controlled dissolution mechanism is manifested.
Higuchi et al87, 88 developed a mathematical model to describe the dissolution of binary
systems. According to the Noyes Whitney equation, the dissolution rates of the both
components are proportional to their respective product of solubilities (Cs) and diffusion
coefficient (D). After a short period of time, one component (for example, B) will dissolve
into the bulk phase from the surface of the solid mass if the following condition is met:
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NA DA CsA
>
NB DB CsB
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Where, NA and NB are the amounts of A and B in the binary mixture, respectively. As a
result, an interfacial layer rich in A is left behind, through which B has to diffuse before
releasing into the bulk solution (Figure 1-48).
In this case, the dissolution rate of A is given by:
𝐺𝐴 =

𝐷𝐴 𝐶𝐴
ℎ
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Where, h is the effective diffusion layer thickness. The dissolution rate of B is determined
by that of A, as shown in the equation below:
𝐺𝐵 =

𝑁𝐵
𝐺
𝑁𝐴 𝐴
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It follows that a drug controlled dissolution mechanism is expected at high drug loading
whereas drug release from the dispersion is regulated by the dissolution rate of the polymer
at low drug loading. The condition at which dominance changes is given by:
NA DA CsA
=
NB DB CsB
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If similar diffusion coefficients are assumed, the drug loading up to which carriercontrolled release is anticipated will be lower for low solubility drugs than for more soluble
drugs. Contradictorily, Dubois et al85 observed a more limited range of drug loadings that
exhibit carrier-controlled release for a more soluble drug phenacetin (up to 5%) than for a
much less soluble drug indomethacin (up to 10%). However, this may be accounted for by
the difference in distribution of two drugs in their respective dispersions or the difference
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in diffusion coefficients. Sjokvist and Craig89 reported that the aqueous solubilities
decreased logarithmically with the molecular weight of PABAs. A linear relationship exists
between the initial intrinsic dissolution rate of the dispersions and the aqueous solubility
of para-aminobenzoates (PABAs), indicating a drug-controlled dissolution mechanism. In
addition they found that the dissolution rate of PABAs from the dispersions was similar to
that of the drug alone, independent of composition when the concentration of drug in the
dispersion exceeds 20% (Figure 1-49). This is consistent with Higuchi’s model. On the
other hand, at low drug loadings, a carrier-controlled release is expected according to
Higuchi. However, a positive interrelationship is apparent between the initial intrinsic
dissolution rate and the solubilities of the PABAs at drug concentrations below 20%.
To reconcile such contradictions, Corrigan et al83 provided an explanation for the dual
observations of carrier–controlled and drug-controlled dissolution at low drug loadings
(Figure 1-50), where a concentrated carrier layer is formed at the dissolving surface
according to Higuchi. In the first scenario (a), that of the carrier-controlled mechanism,
the dissolution of drug particles in the carrier layer is rapid as compared to the drug
diffusion through this layer. As a result, the rate determining step of drug release into the
bulk phase becomes the release of the carrier. In the second scenario (b), the dissolution of
drug in the carrier layer is much slower than the diffusion rate, which allows the drug to be
released effectively intact into the bulk phase. In this case, the dissolution rate of drug
becomes dominated by the properties of the drug, such as particle size and/or physical form.
Nevertheless, an enhanced release as compared to conventional dosage forms is still
expected because the polymer carrier diffusion layer may provide the improved wetting
and decreased agglomeration as the drug diffuses through. Overall, factors that may play a

67
role in determining the dissolution mechanism include the solubility of the drug in the
polymer layer, the viscosity of the polymer, and the hydrodynamics of the medium.
Konno et al90 compared the effect of different polymers (PVP, HPMC, and HPMCAS) on
the dissolution rate of felodipine from solid dispersions. These dispersions were prepared
at different polymer to drug ratio. They found that supersaturation was achieved for the
majority of the dispersions prepared, with the exception of 10% to 50% w/w PVP
dispersion. At each given polymer to drug ratio, HPMCAS dispersions generated the
highest extent of supersaturation, while PVP turns out to be the least effective. This was
attributed to the different magnitude of polymers’ ability to inhibit solution crystallization,
as has been discussed previously. Moreover, the extent of supersaturation observed
increased as the polymer to drug ratio increased. This dependence was strongest in
HPMCAS dispersions whereas PVP dispersions only shown limited increase in solution
concentration as a function of polymer concentration. For the majority of the release
profiles, a plateau region was observed which roughly equals the maximum solution
concentrations achieved. 75% HPMCAS dispersion were able to achieve the highest
solution concentration of 14µg/ml, as compared to only 0.9µg/ml equilibrium crystalline
solubility. However, desupersaturation occurs at the late stage of the experimental
timeframe. This finding, again, exemplified the increased thermodynamic driving force for
crystallization at high supersaturation. Finally, it was found that crystalline felodipine
solubility did not change whether those polymers were present or absent in the dissolution
medium tested. Therefore, any supersaturation attained during dissolution of solid
dispersions could not be accounted for by solubilization effect of polymers, which have
been reported in several literatures91-93.
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Alonzo et al94 investigated the dissolution and precipitation behavior of HPMC and PVP
amorphous solid dispersions (ASDs). Felodipine and indomethacin were selected as model
compounds. They found that at moderate drug loading (50%), the maximum solution
concentrations generated were similar to the predicted amorphous solubility (5-6 µg/ml for
felodipine at 25°C) using the Hoffman equation, despite there being more drug in the
systems (Figure 1-51). In this case, the dissolution behavior of the ASDs was controlled
by a pure layer of amorphous drug, which was left behind after the polymer entered the
bulk solution. Therefore, the maximum solution concentration cannot exceed that of the
pure amorphous drug. At low drug loading (10%), however, the initial dissolution rates
were much faster than that of the 50% dispersions, resulting in very high apparent peak
concentrations. In this scenario, the drug loading was not sufficient to allow the formation
of a drug rich layer limiting dissolution. Instead, the dissolution rate of the drug was
controlled by the rapid dissolution of the polymer. Hence, very high supersaturation was
generated. Another interesting observation is that the solutions became uniformly cloudy
upon dissolution of the 90:10 ASDs whereas cloudiness was not observed during
dissolution of the 50:50 ASDs.
Shown in Figure 1-52 are the cross-polarized microscope images of the ASDs exposed to
phosphate buffer, which provides a qualitative assessment of the dissolution behavior. It
can be seen that the particles of the 50:50 HPMC-felodipine dispersion were able to
maintain their size and shape for at least 30 minutes whereas particles of the 90:10 HPMCfelodipine dispersion lost their integrity within 5 minutes of exposure.
Dynamic light scattering (DLS) experiments were performed to monitor the particle size
generated during the dissolution of ASDs. It can be seen from Figure 1-53 that particles of

69
submicron scale were detected during dissolution of 90:10 solid dispersions, which then
gradually increase in size. It is also apparent that PVP was less effective in inhibiting the
growth of the particles. The growth of particles from artificially supersaturated solution in
the absence of any polymer was much more rapid. At 7 minutes, the average particle
diameter was slightly below 1 micron. This size is enough for significant precipitation to
occur.

1.14

Research Overview

The overall goal of this research is to improve the physical stability and dissolution
performance of amorphous solid dispersions (ASDs) by using a combination of polymers,
whereby one polymer is included to inhibit crystallization during dissolution, whereas a
second polymer is used to achieve another key property such as rapid release or enhanced
storage stability. Before this strategy can be implemented, research is necessary to
determine factors such as miscibility in the ternary systems, as well as the optimum level
of the solution stabilizing polymer, since it is clear that an additional polymer cannot be
added at the expense of drug loading.
In this chapter, the thermodynamics with respect to the miscibility of amorphous materials
are discussed. The mechanisms of polymeric additives in inhibiting nucleation and growth
of drugs from both solid and solution phase are examined. The impact of polymers in
modifying drug release from ASDs are also discussed. In chapter 2, efforts were made to
probe the relative effectiveness of various polymers in inhibiting matrix crystallization of
ASDs of CEX upon exposure to aqueous medium versus crystallization from supersturated
solutions generated during dissolution of the ASDs. In chpater 3, the strength of
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intermolecular interaction and miscibilty of polymer blends and CEX with polymer(s) and
are investigated, directed towards obtaining a better mechanistic understanding on the
stability of the CEX ASDs during storage at different environmental conditions. Chapter 4
showcased an example where both the drug release rate and supersaturation behavior can
be optimized in a ternary ASD, so long as the relavant properties of polymeric carriers are
appreciated.
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Table 1-1 Biopharmaceutics classification system of drugs and recommended formulation
strategies

Table 1-2 Experimental Solubility Ratios for indomethacin

Table 1-3 Intrinsic Dissolution Rate and Solubility of Crystalline and Amorphous
Atorvastatin Calcium in Water at 37 °C.

Increase in IDR and solubility compared to the crystalline form is given as (_ times).
SASA: supercritical antisolvent amorphous from acetone. SDA: spray-dried amorphous
from acetone
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Table 1-4 Desired carrier properties for solid dispersion formulation

Table 1-5 Examples of commercially available solid dispersions

Table 1-6 Thermodynamic nature and destabilization driving force for solid dispersions in
zone I-VI Assuming all solid dispersions were homogeneously mixed initially.
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Figure 1-1 Three steps required for a solute to be displaced from solid state and to enter
solution5

Figure 1-2 Schematic Representation of the three types of continuity between 100%
crystalline and 100% amorphous solids13
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Figure 1-3 Schematic depiction of change in volume and enthalpy with temperature9.

Figure 1-4 Molecular mobility/viscosity of amorphous materials as a function of
normalized temperature above Tg.9
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Figure 1-5 Amorphous state produced in typical pharmaceutical unit operations.

Figure 1-6 On Left-Packing diagrams of carbamazepine form I (N2-O1 intermolecular
hydrogen bond length 2.929A°). On Right: Carbamazepine form III (N2-O1 intermolecular
hydrogen bond length 2.928 A°)19
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Figure 1-7 Heat Capacity Vs Temperature for Sucrose.

Figure 1-8 Raman Spectra: (a) crystalline sorbitol and (b) quench cooled glassy sorbitol.

Figure 1-9 Experimental aqueous solubility profiles for amorphous and crystalline
indomethacin ( ●) amorphous; ( ) γ-crystal; and ( ) α-crystal (A) at 5°C (B) at 25 °C (C)
at 45°C.31
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Figure 1-10 Powder dissolution profiles of unprocessed atorvastatin particles ( ), SAS
processed amorphous atorvastatin calcium precipitated from an acetone solution ( ), SAS
processed amorphous atorvastatin calcium precipitated from a tetrahydrofuran solution ( ),
spray-dried amorphous atorvastatin calcium from an acetone solution (○) and spray-dried
amorphous atorvastatin calcium from a tetrahydrofuran solution (□) (n = 3, mean±S.D.).37

Figure 1-11 Plasma concentration–time curves of unprocessed atorvastatin particles ( ),
SAS processed amorphous atorvastatin calcium precipitated from an acetone solution ( ),
SAS processed amorphous atorvastatin calcium precipitated from a tetrahydrofuran
solution ( ), spray-dried amorphous atorvastatin calcium from an acetone solution (○) and
spray-dried amorphous atorvastatin calcium from a tetrahydrofuran solution (□) (n = 5,
mean±S.D.). 37
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Figure 1-12 Enthalpy and specific volume change of amorphous materials during
annealing32

Figure 1-13 Time dependence of nucleation rate I (jc,t): (1) steady state nucleation; (2) nonsteady state nucleation rate32.
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Figure 1-14 Schematic of nucleation rate (I0),crystal growth rate(G), non-steady state lag
time for crystallization (τ), and viscosity (η) in a supercooled liquid. T0 is the VTF zero
mobility temperature, Tg is the glass transition temperature, and Tm is the melting
temperature. Shaded region is where the nucleation and growth overlap32

Figure 1-15 Schematic diagram of the temperature dependence of nucleation rate (J) and
growth rate (U)46.
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Figure 1-16 (a) A schematic of the expected DSC plot when the sample is cooled to
different regions of the nucleation temperature zone. (b) An actual example of a nucleation
zone experiment for APAP-PVPVA (10%w/w) showing that the recrystallization peak
temperature does not change when cooled below 30 °C.

Figure 1-17 Amorphous solid solution: solute molecules are dispersed molecularly but
irregularly in an amorphous solvent47
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Figure 1-18 Scheme of a hot melt extruder.

Figure 1-19 Species proposed to be present in indomethacin-PVP solid dispersions. a)
hydrogen bonded indomethacin-PVP species, b) non hydrogen bonded PVP and c)
indomethacin symmetric dimer10.
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Figure 1-20 Nucleation as a function of polymer concentration at 0% RH. Symbols
represent data for felodipine with HPMCAS ( ), PVP (●), and HPMC ( )54

Figure 1-21 Radial growth rate of the spherulite of APAP ( ) and in the presence of
HPMCAS ( ), E100 ( ), HPMC ( ), PVP ( ), PVPh ( ), PVPVA ( ), PAA 1800 ( ),
and PAA (450 K) ( )46
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Figure 1-22 A semi quantitative representation of the nucleation temperature zones and
relative nucleation rates of pure APAP (shaded region) and APAP in the presence of 10%
w/w polymer46.

Figure 1-23 Nucleation free energy change as a function of the clusters radius r.
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Figure 1-24 Mechanisms for crystal nucleation

Figure 1-25 Free energy barrier for homogeneous nucleation and heterogeneous nucleation
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Figure 1-26 The induction time for nucleation as a function of supersaturation60

Figure 1-27 Mechanisms for crystal growth.59
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Figure 1-28 Surface layer adsorption of solute molecules onto the growing crystal surface

Figure 1-29 AFM images showing examples of 2D nucleation at high supersaturation for
(a) calcite and (b) canavalin. N-locations where islands have nucleated on top of other
islands60
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Figure 1-30 Edge dislocation and screw dislocation

Figure 1-31 AFM images of dislocation hillocks on (a) calcite, (b) canavalin, (c) brushite
and (d) calcium oxalate monohydrate60

88

Figure 1-32 Four models for impurity interactions and their effect on step kinetics: (a) step
pinning, (b) incorporation. (c) kink blocking, and (d) surface action64.

Figure 1-33 Theoretical relationship between the relative step velocity and the
dimensionless impurity concentration Kc for different values of the impurity effectiveness
factor α65.
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Figure 1-34 Theoretical normalized face growth rate G/k σc2 as a function of normalized
relative supersaturation σ/σc for the second order growth law G0 = k σ2. The face growth
rate is suppressed over a wide range of relative supersaturation in this steady state impurity
action.65

Figure 1-35 Regions of solution stability
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Figure 1-36 Schematic diagram showing the mechanism of growth inhibition and habit
modiﬁcation of HA crystals by polymers69.

Figure 1-37 Schematic illustrating the competition between dissolution and crystallization
via the solid or solution state for amorphous systems67.
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Figure 1-38 Unseeded and seeded desupersaturation of felodipine (S of 10) in the presence
of 1ug/ml HPMC.

Figure 1-39 A hypothetical diagram consists of drug-polymer solubility, miscibility, and
glass transition temperatures of a solid dispersion system73.
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Figure 1-40 composition dependence of free energy of mixing (ΔGmix) for a binary
hypothetical mixture, showing complete immiscibility (green), partial immiscibility (red),
and complete miscibility behaviors (black)76.

Figure 1-41 Gibbs free energy function exhibiting liquid-liquid miscibility gap75.
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Figure 1-42 Chemical structure of felodipine (left) and PAA (right).

Figure 1-43 Reference mid-IR spectra (1200–1800 cm−1): Average local nanoscale mid-IR
spectra (n = 10, normalized and offset). From top to bottom: pure PAA, pure amorphous
felodipine, and pure crystalline felodipine79.
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Figure 1-44 Localized nanoscale mid-IR spectra of a 50:50 (w/w) felodipine–PAA system
obtained at discrete domains (1–4) and in the continuous phase (5–8): (a) topographical
image (1.5 ×2.5 µm2, color scale is 100 nm, the positions of the spectral measurements are
marked), (b) nanoscale mid-IR spectra (1200–1800 cm−1, spectra from bottom to top
corresponds to locations 1–8, normalized and offset), and (c) average spectra of both phases
(1–4 bottom, 5–8 top, n = 4, normalized and offset)79.

Figure 1-45 Peak position associated with drug-drug hydrogen bond interactions (closed
symbols) and drug-polymer hydrogen bond interactions (open symbols) for the amorphous
molecular level solid dispersions of felodipine with 37 wt% PVP as a function of increasing
temperature ( ) and decreasing temperature (●).
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Figure 1-46 Amorphous molecular level solid dispersions of felodipine and 46.4 wt% PVP
immediately after sample preparation and after storage at 75, 84, and 94% RH for 1 day.
Also shown for comparison are the amorphous and crystalline spectra of felodipine. PVP
does not exhibit any significant absorption in this region.

Figure 1-47 FT-IR spectra of NH stretching region of amorphous solid dispersion of
felodipine with 50% PVP. The sample was stored at 94% RH for approximately 4 h, then
dried using a dry air purge for an hour. Subsequently, the sample was heated to 125°C, and
the infrared spectra collected; they are (bottom to top): initial, and after 5, 10, 15, 20, 25,
30, 45, 60, 90, 120, 150, 240, 300, 360, 420, and 1500 min. The top-most spectrum (thicker
line) shows a solid dispersion sample at the same drug-to-polymer ratio that was never
exposed to moisture.
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Figure 1-48 Dissolution behavior of two-phase mixture of A and B. In case A, phase B
dissolves fast enough to leave a layer of pure A behind; in case B, the reverse is true; while
in case C, dissolution rates of A and B are proportional to their relative amounts in the
mixture83.

Figure 1-49 Relationship between initial intrinsic dissolution rate and concentration of
para-aminobenzoic acid (PABA) in PEG 4000 solid dispersions. (○) Methyl PABA; (●)
ethyl PABA; (□)propyl PABA; (■)butylPABA89.
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Figure 1-50 Schematic diagram showing the fate of drug particle during the dissolution
process. (a) Carrier-controlled dissolution, wherby the drug dissolves into the concentrated
carrier layer prior to release and (b) drug-controlled dissolution whereby the drug is
released effectively intact into the dissolution medium. Large spheres represent
undissolved drug particles, small spheres partially dissolved drug particles, shaded region
correspond to hydrated material.

Figure 1-51 Apparent dissolution profiles of 90:10 HPMC–felodipine (■), 50:50 HPMC–
felodipine (●), 90:10 PVP–felodipine (Δ), and 50:50 PVP–felodipine (◊) solid dispersions
at 25°C. Error bars represent 1 standard deviation (n = 3). Error bars for the 50:50 data are
smaller than the symbols94.
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Figure 1-52 Solid dispersion microscope images under cross-polarized light: 50:50
HPMC–felodipine (10× magnification) initial (a) and 30min after exposure (b), and 90:10
HPMC–felodipine (20× magnification) initial (c) and 5min (d) after exposure94

Figure 1-53 Average particle diameter generated by a 90:10 HPMC–felodipine solid
dispersion at 30 (■) and 50(●) µg/mL, a 90:10 PVP–felodipine solid dispersion at 40
µg/mL ( ), and an artificial supersaturation in the absence of polymer at 30µg/mL ( Δ) at
25◦C. All concentrations refer to the nominal amount of felodipine in the system94.

99
1.15 References
1.
Amidon, G.; Lennernäs, H.; Shah, V.; Crison, J. A Theoretical Basis for a
Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product
Dissolution and in Vivo Bioavailability. Pharm Res-Dordr 1995, 12, (3), 413-420.
2.
Benet, L.; Broccatelli, F.; Oprea, T. BDDCS Applied to Over 900 Drugs. AAPS J
2011, 13, (4), 519-547.
3.
Thayer, A. M. FINDING SOLUTIONS. Chemical & Engineering News Archive
2010, 88, (22), 13-18.
4.
Florence, A. T.; Attwood, D., Physicochemical principles of pharmacy.
pharmaceutical press: 2011.
5.
Williams, H. D.; Trevaskis, N. L.; Charman, S. A.; Shanker, R. M.; Charman, W.
N.; Pouton, C. W.; Porter, C. J. H. Strategies to Address Low Drug Solubility in Discovery
and Development. Pharmacological Reviews 2013, 65, (1), 315-499.
6.
Janssens, S.; Van den Mooter, G. Review: physical chemistry of solid dispersions.
Journal of Pharmacy and Pharmacology 2009, 61, (12), 1571-1586.
7.
Matteucci, M. E.; Brettmann, B. K.; Rogers, T. L.; Elder, E. J.; Williams, R. O.;
Johnston, K. P. Design of Potent Amorphous Drug Nanoparticles for Rapid Generation of
Highly Supersaturated Media. Mol Pharmaceut 2007, 4, (5), 782-793.
8.
Greco, K.; Bogner, R. Solution-mediated phase transformation: Significance
during dissolution and implications for bioavailability. Journal of Pharmaceutical Sciences
2012, 101, (9), 2996-3018.
9.
Hancock, B. C.; Zografi, G. Characteristics and significance of the amorphous state
in pharmaceutical systems. Journal of Pharmaceutical Sciences 1997, 86, (1), 1-12.
10.
Taylor, L.; Zografi, G. Spectroscopic Characterization of Interactions Between
PVP and Indomethacin in Amorphous Molecular Dispersions. Pharm Res-Dordr 1997, 14,
(12), 1691-1698.
11.
Andronis, V.; Zografi, G. Crystal nucleation and growth of indomethacin
polymorphs from the amorphous state. Journal of Non-Crystalline Solids 2000, 271, (3),
236-248.
12.
Rodrı́guez-Spong, B.; Price, C. P.; Jayasankar, A.; Matzger, A. J.; Rodrı́guezHornedo, N. r.
General principles of pharmaceutical solid polymorphism: A
supramolecular perspective. Advanced Drug Delivery Reviews 2004, 56, (3), 241-274.
13.
Hilfiker, R., Polymorphism: in the pharmaceutical industry. John Wiley & Sons:
2006.
14.
Her, L.-M.; Deras, M.; Nail, S. L. Electrolyte-induced changes in glass transition
temperatures of freeze-concentrated solutes. Pharm Res-Dordr 1995, 12, (5), 768-772.
15.
Ediger, M. D.; Angell, C.; Nagel, S. R. Supercooled liquids and glasses. The
journal of physical chemistry 1996, 100, (31), 13200-13212.
16.
Angell, C.; MacFarlane, D.; Oguni, M. The Kauzmann paradox, metastable liquids,
and ideal glasses. Ann. NY Acad. Sci 1986, 484, 241-247.
17.
Baird, J. A.; Van Eerdenbrugh, B.; Taylor, L. S. A classification system to assess
the crystallization tendency of organic molecules from undercooled melts. Journal of
pharmaceutical sciences 2010, 99, (9), 3787-3806.

100
18.
Alba-Simionesco, C.; Fan, J.; Angell, C. Thermodynamic aspects of the glass
transition phenomenon. II. Molecular liquids with variable interactions. The Journal of
chemical physics 1999, 110, (11), 5262-5272.
19.
Patterson, J. E.; James, M. B.; Forster, A. H.; Lancaster, R. W.; Butler, J. M.; Rades,
T. The influence of thermal and mechanical preparative techniques on the amorphous state
of four poorly soluble compounds. Journal of pharmaceutical sciences 2005, 94, (9), 19982012.
20.
Yu, L.; Reutzel-Edens, S. M.; Mitchell, C. A. Crystallization and Polymorphism
of Conformationally Flexible Molecules: Problems, Patterns, and Strategies. Organic
Process Research & Development 2000, 4, (5), 396-402.
21.
Yu, L. Amorphous pharmaceutical solids: preparation, characterization and
stabilization. Advanced drug delivery reviews 2001, 48, (1), 27-42.
22.
Savolainen, M.; Heinz, A.; Strachan, C.; Gordon, K. C.; Yliruusi, J.; Rades, T.;
Sandler, N. Screening for differences in the amorphous state of indomethacin using
multivariate visualization. Eur J Pharm Sci 2007, 30, (2), 113-123.
23.
Shamblin, S. L.; Tang, X.; Chang, L.; Hancock, B. C.; Pikal, M. J. Characterization
of the time scales of molecular motion in pharmaceutically important glasses. The Journal
of Physical Chemistry B 1999, 103, (20), 4113-4121.
24.
Ward, S.; Perkins, M.; Zhang, J.; Roberts, C. J.; Madden, C. E.; Luk, S. Y.; Patel,
N.; Ebbens, S. J. Identifying and mapping surface amorphous domains. Pharm Res-Dordr
2005, 22, (7), 1195-1202.
25.
Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and
computational approaches to estimate solubility and permeability in drug discovery and
development settings. Advanced drug delivery reviews 2012, 64, 4-17.
26.
Pudipeddi, M.; Serajuddin, A. Trends in solubility of polymorphs. Journal of
pharmaceutical sciences 2005, 94, (5), 929-939.
27.
Caira, M. R.; Robbertse, Y.; Bergh, J. J.; Song, M.; De Villiers, M. M. Structural
characterization, physicochemical properties, and thermal stability of three crystal forms
of nifedipine. Journal of pharmaceutical sciences 2003, 92, (12), 2519-2533.
28.
Law, D.; Schmitt, E. A.; Marsh, K. C.; Everitt, E. A.; Wang, W.; Fort, J. J.; Krill,
S. L.; Qiu, Y. Ritonavir–PEG 8000 amorphous solid dispersions: in vitro and in vivo
evaluations. Journal of pharmaceutical sciences 2004, 93, (3), 563-570.
29.
KiMURA, K.; Hirayama, F.; Arima, H.; UEKAMA, K. Effects of Aging on
Crystallization, Dissolution and Absorption Characteristics of Amorphous Tolbutamide-2Hydroxypropyl-. BETA.-cyclodextrin Complex. Chemical and pharmaceutical bulletin
2000, 48, (5), 646-650.
30.
Hoffman, J. D. Thermodynamic driving force in nucleation and growth processes.
The Journal of Chemical Physics 1958, 29, (5), 1192-1193.
31.
Hancock, B. C.; Parks, M. What is the true solubility advantage for amorphous
pharmaceuticals? Pharm Res-Dordr 2000, 17, (4), 397-404.
32.
Bhugra, C.; Pikal, M. J. Role of thermodynamic, molecular, and kinetic factors in
crystallization from the amorphous state. Journal of pharmaceutical sciences 2008, 97, (4),
1329-1349.

101
33.
Mullins, J. D.; Macek, T. J. SOME PHARMACEUTICAL PROPERTIES OF
NOVOBIOCIN. Journal of the American Pharmaceutical Association 1960, 49, (4), 245248.
34.
LENNERNÄS, H. Human jejunal effective permeability and its correlation with
preclinical drug absorption models. Journal of pharmacy and pharmacology 1997, 49, (7),
627-638.
35.
Wu, X.; Whitfield, L. R.; Stewart, B. H. Atorvastatin transport in the Caco-2 cell
model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
Pharm Res-Dordr 2000, 17, (2), 209-215.
36.
Corsini, A.; Bellosta, S.; Baetta, R.; Fumagalli, R.; Paoletti, R.; Bernini, F. New
insights into the pharmacodynamic and pharmacokinetic properties of statins.
Pharmacology & therapeutics 1999, 84, (3), 413-428.
37.
Kim, J.-S.; Kim, M.-S.; Park, H. J.; Jin, S.-J.; Lee, S.; Hwang, S.-J.
Physicochemical properties and oral bioavailability of amorphous atorvastatin hemicalcium using spray-drying and SAS process. International journal of pharmaceutics 2008,
359, (1), 211-219.
38.
Gutzow, I.; Avramov, I.; Kästner, K. Glass formation and crystallization. Journal
of Non-Crystalline Solids 1990, 123, (1), 97-113.
39.
Yoshioka, M.; Hancock, B. C.; Zografi, G. Crystallization of indomethacin from
the amorphous state below and above its glass transition temperature. Journal of
pharmaceutical sciences 1994, 83, (12), 1700-1705.
40.
ABE, Y.; ARAHORI, T.; NARUSE, A. Crystallization of Ca (PO3) 2 glass below
the glass transition temperature. Journal of the American Ceramic Society 1976, 59, (11‐
12), 487-490.
41.
Gordon, M.; Taylor, J. S. Ideal copolymers and the second‐order transitions of
synthetic rubbers. i. non‐crystalline copolymers. Journal of Applied Chemistry 1952, 2, (9),
493-500.
42.
Simha, R.; Boyer, R. On a general relation involving the glass temperature and
coefficients of expansion of polymers. The Journal of Chemical Physics 1962, 37, (5),
1003-1007.
43.
Yoshioka, M.; Hancock, B. C.; Zografi, G. Inhibition of indomethacin
crystallization in poly (vinylpyrrolidone) coprecipitates. Journal of pharmaceutical
sciences 1995, 84, (8), 983-986.
44.
Barandiaran, J.; Colmenero, J. Continuous cooling approximation for the
formation of a glass. Journal of Non-Crystalline Solids 1981, 46, (3), 277-287.
45.
Cabral, A.; Cardoso, A.; Zanotto, E. Glass-forming ability versus stability of
silicate glasses. I. Experimental test. Journal of Non-Crystalline Solids 2003, 320, (1), 18.
46.
Trasi, N. S.; Taylor, L. S. Effect of polymers on nucleation and crystal growth of
amorphous acetaminophen. Crystengcomm 2012, 14, (16), 5188-5197.
47.
Leuner, C.; Dressman, J. Improving drug solubility for oral delivery using solid
dispersions. Eur J Pharm Biopharm 2000, 50, (1), 47-60.
48.
Kearney, A. S.; Gabriel, D. L.; Mehta, S. C.; Radebaugh, G. W. Effect of
polyvinylpyrrolidone on the crystallinity and dissolution rate of solid dispersions of the
antiinflammatory CI-987. International journal of pharmaceutics 1994, 104, (2), 169-174.

102
49.
El-Zein, H.; Riad, L.; El-Bary, A. A. Enhancement of carbamazepine dissolution:
in vitro and in vivo evaluation. International journal of pharmaceutics 1998, 168, (2), 209220.
50.
Khougaz, K.; Clas, S. D. Crystallization inhibition in solid dispersions of MK‐
0591 and poly (vinylpyrrolidone) polymers. Journal of pharmaceutical sciences 2000, 89,
(10), 1325-1334.
51.
Gupta, P.; Thilagavathi, R.; Chakraborti, A. K.; Bansal, A. K. Role of molecular
interaction in stability of celecoxib-PVP amorphous systems. Mol Pharmaceut 2005, 2, (5),
384-391.
52.
Miyazaki, T.; Yoshioka, S.; Aso, Y.; Kojima, S. Ability of polyvinylpyrrolidone
and polyacrylic acid to inhibit the crystallization of amorphous acetaminophen. Journal of
pharmaceutical sciences 2004, 93, (11), 2710-2717.
53.
Van den Mooter, G.; Wuyts, M.; Blaton, N.; Busson, R.; Grobet, P.; Augustijns, P.;
Kinget, R. Physical stabilisation of amorphous ketoconazole in solid dispersions with
polyvinylpyrrolidone K25. Eur J Pharm Sci 2001, 12, (3), 261-269.
54.
Konno, H.; Taylor, L. S. Influence of different polymers on the crystallization
tendency of molecularly dispersed amorphous felodipine. J Pharm Sci-Us 2006, 95, (12),
2692-2705.
55.
Zografi, G. States of water associated with solids. Drug Development and
Industrial Pharmacy 1988, 14, (14), 1905-1926.
56.
Andronis, V.; Yoshioka, M.; Zografi, G. Effects of sorbed water on the
crystallization of indomethacin from the amorphous state. Journal of pharmaceutical
sciences 1997, 86, (3), 346-351.
57.
Levine, H.; Slade, L. Water as a plasticizer: physico-chemical aspects of lowmoisture polymeric systems. Water science reviews 1988, 3, 79-185.
58.
Konno, H.; Taylor, L. S. Ability of different polymers to inhibit the crystallization
of amorphous felodipine in the presence of moisture. Pharm Res-Dordr 2008, 25, (4), 969978.
59.
Rodrıguez-Hornedo, N.; Kelly, R. C.; Sinclair, B.; Miller, J., Crystallization:
general principles and significance on product development. Taylor & Francis: 2006.
60.
De Yoreo, J. J.; Vekilov, P. G. Principles of crystal nucleation and growth. Reviews
in mineralogy and geochemistry 2003, 54, (1), 57-93.
61.
Lindfors, L.; Forssén, S.; Westergren, J.; Olsson, U. Nucleation and crystal growth
in supersaturated solutions of a model drug. J Colloid Interf Sci 2008, 325, (2), 404-413.
62.
Davis, K.; Dove, P.; De Yoreo, J. Resolving the controversial role of Mg2 in calcite
biomineral formation. Science 2000, 290, 1134-1137C.
63.
Frank, F. The influence of dislocations on crystal growth. Discuss. Faraday Soc.
1949, 5, 48-54.
64.
Dove, P. M.; De Yoreo, J. J.; Davis, K. J. Inhibition of CaCO3 crystallization by
small molecules: the magnesium example. Solid-fluid interfaces to nanostructural
engineering 2004, 55-82.
65.
Kubota, N. Effect of impurities on the growth kinetics of crystals. Crystal Research
and Technology 2001, 36, (8‐10), 749-769.
66.
Chernov, A. The spiral growth of crystals. Physics-Uspekhi 1961, 4, (1), 116-148.

103
67.
Alonzo, D. E.; Zhang, G. G. Z.; Zhou, D. L.; Gao, Y.; Taylor, L. S. Understanding
the Behavior of Amorphous Pharmaceutical Systems during Dissolution. Pharm ResDordr 2010, 27, (4), 608-618.
68.
Brouwers, J.; Brewster, M. E.; Augustijns, P. Supersaturating drug delivery
systems: The answer to solubility‐limited oral bioavailability? Journal of pharmaceutical
sciences 2009, 98, (8), 2549-2572.
69.
Raghavan, S.; Trividic, A.; Davis, A.; Hadgraft, J.
Crystallization of
hydrocortisone acetate: influence of polymers. International journal of pharmaceutics
2001, 212, (2), 213-221.
70.
Alonzo, D. E.; Raina, S.; Zhou, D.; Gao, Y.; Zhang, G. G.; Taylor, L. S.
Characterizing the impact of hydroxypropylmethyl cellulose on the growth and nucleation
kinetics of felodipine from supersaturated solutions. Cryst Growth Des 2012, 12, (3), 15381547.
71.
Matsumoto, T.; Zografi, G. Physical properties of solid molecular dispersions of
indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinylacetate) in
relation to indomethacin crystallization. Pharm Res-Dordr 1999, 16, (11), 1722-1728.
72.
Shamblin, S. L.; Zografi, G. The effects of absorbed water on the properties of
amorphous mixtures containing sucrose. Pharm Res-Dordr 1999, 16, (7), 1119-1124.
73.
Qian, F.; Huang, J.; Hussain, M. A. Drug–polymer solubility and miscibility:
Stability consideration and practical challenges in amorphous solid dispersion
development. J Pharm Sci-Us 2010, 99, (7), 2941-2947.
74.
Marsac, P. J.; Shamblin, S. L.; Taylor, L. S. Theoretical and practical approaches
for prediction of drug–polymer miscibility and solubility. Pharm Res-Dordr 2006, 23, (10),
2417-2426.
75.
Deneau, E.; Steele, G. An in-line study of oiling out and crystallization. Organic
process research & development 2005, 9, (6), 943-950.
76.
Rumondor, A. C.; Ivanisevic, I.; Bates, S.; Alonzo, D. E.; Taylor, L. S. Evaluation
of drug-polymer miscibility in amorphous solid dispersion systems. Pharm Res-Dordr
2009, 26, (11), 2523-2534.
77.
Utracki, L. Glass transition temperature in polymer blends. Advances in Polymer
Technology 1985, 5, (1), 33-39.
78.
Sakaguchi, T.; Taniguchi, N.; Urakawa, O.; Adachi, K. Calorimetric study of
dynamical heterogeneity in blends of polyisoprene and poly (vinylethylene).
Macromolecules 2005, 38, (2), 422-428.
79.
Van Eerdenbrugh, B.; Lo, M.; Kjoller, K.; Marcott, C.; Taylor, L. S. Nanoscale
mid‐infrared imaging of phase separation in a drug–polymer blend. Journal of
pharmaceutical sciences 2012, 101, (6), 2066-2073.
80.
Marsac, P. J.; Rumondor, A. C.; Nivens, D. E.; Kestur, U. S.; Stanciu, L.; Taylor,
L. S. Effect of temperature and moisture on the miscibility of amorphous dispersions of
felodipine and poly (vinyl pyrrolidone). Journal of pharmaceutical sciences 2010, 99, (1),
169-185.
81.
Pouchlý, J.; Patterson, D. Polymers in mixed solvents. Macromolecules 1976, 9,
(4), 574-579.
82.
Robard, A.; Patterson, D.; Delmas, G. The" Δη Effect" and Polystyrene-Poly (vinyl
methyl ether) Compatibility in Solution. Macromolecules 1977, 10, (3), 706-708.

104
83.
Corrigan, O. I. Mechanisms of Dissolution of Fast Release Solid Dispersions. Drug
Development and Industrial Pharmacy 1985, 11, (2-3), 697-724.
84.
Corrigan, O. I. Retardation of polymeric carrier dissolution by dispersed drugs:
Factors influencing the dissolution of solid dispersions containing polyethlene glycols.
Drug Development and Industrial Pharmacy 1986, 12, (11-13), 1777-1793.
85.
Dubois, J. L.; Ford, J. L. Similarities in the release rates of different drugs from
polyethylene glycol 6000 solid dispersions. Journal of pharmacy and pharmacology 1985,
37, (7), 494-495.
86.
Sjökvist, E.; Nyström, C. Physicochemical aspects of drug release. VI. Drug
dissolution rate from solid particulate dispersions and the importance of carrier and drug
particle properties. International journal of pharmaceutics 1988, 47, (1), 51-66.
87.
Higuchi, W. I. Diffusional models useful in biopharmaceutics. Drug release rate
processes. J Pharm Sci-Us 1967, 56, (3), 315-324.
88.
Higuchi, W.; Mir, N.; Desai, S. Dissolution rates of polyphase mixtures. J Pharm
Sci-Us 1965, 54, (10), 1405-1410.
89.
Saers, E. S.; Craig, D. Q. An investigation into the mechanisms of dissolution of
alkyl p-aminobenzoates from polyethylene glycol solid dispersions. International journal
of pharmaceutics 1992, 83, (1), 211-219.
90.
Konno, H.; Handa, T.; Alonzo, D. E.; Taylor, L. S. Effect of polymer type on the
dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm
Biopharm 2008, 70, (2), 493-499.
91.
Usui, F.; Maeda, K.; Kusai, A.; Nishimura, K.; Yamamoto, K. Inhibitory effects
of water-soluble polymers on precipitation of RS-8359. International Journal of
Pharmaceutics 1997, 154, (1), 59-66.
92.
Acartürk, F.; Kişlal, Ö.; Celebi, N. The effect of some natural polymers on the
solubility and dissolution characteristics of nifedipine. International journal of
pharmaceutics 1992, 85, (1), 1-6.
93.
Loftsson, T.; Fri, H.; Gu, T. K. The effect of water-soluble polymers on aqueous
solubility of drugs. International journal of pharmaceutics 1996, 127, (2), 293-296.
94.
Alonzo, D. E.; Gao, Y.; Zhou, D.; Mo, H.; Zhang, G. G. Z.; Taylor, L. S.
Dissolution and precipitation behavior of amorphous solid dispersions. J Pharm Sci-Us
2011, 100, (8), 3316-3331.

105

CHAPTER 2. DISSOLUTION PERFORMANCE OF HIGH DRUG LOADING
CELECOXIB AMORPHOUS SOLID DISPERSIONS FORMULATED WITH
POLYMER COMBINATIONS

2.1

Abstract

The aims of this study were twofold. First, to evaluate the effectiveness of selected
polymers in inhibiting solution crystallization of celecoxib. Second, to compare the release
rate and crystallization tendency of celecoxib amorphous solid dispersions (ASDs)
formulated with a single polymer, or binary polymer combinations. The effectiveness of
polymers, polyvinylpyrrolidone (PVP), hydroxypropylmethyl cellulose (HPMC) or HPMC
acetate succinate (HPMCAS), in maintaining supersaturation of celecoxib solutions was
evaluated by performing nucleation induction time measurements. Crystallization kinetics
of ASD suspensions were monitored using Raman spectroscopy. Dissolution experiments
were carried out under non-sink conditions. Pure amorphous celecoxib was found to
crystallize rapidly through both matrix and solution pathways. Matrix and solution
crystallization was inhibited when celecoxib was molecularly mixed with a polymer,
resulting in release of the drug to form supersaturated solutions. Cellulosic polymers were
more effective than PVP in maintaining supersaturation. Combining a cellulosic polymer
and PVP enabled improved drug release and stability to crystallization. Inclusion of an
effective solution crystallization inhibitor as a minor component in ternary dispersions
resulted in prolonged supersaturation following dissolution.

Reprinted (adapted) from (Xie, T.; Taylor, LS. Dissolution Performance of High Drug Loading
Celecoxib Amorphous Solid Dispersions Formulated with Polymer Combinations. Pharm Res).
Copyright (2016) Springer.
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This study shows the feasibility of formulation strategies for ASDs where a major polymer
component is used to achieve one key property e.g. release, while a minor polymer
component is added to prevent crystallization.

2.2

Introduction

It has been suggested that up to 80% of new molecular entities have sub-optimum aqueous
solubility1 which can lead to solubility-limited bioavailability. The low aqueous solubility
of many new compounds can be attributed in part to the nature of contemporary drug
discovery methodologies. Formulations containing amorphous drug are promising for the
oral delivery of poorly water-soluble drugs since the amorphous form of a compound has
higher free energy as compared to the crystalline counterparts, which may give rise to
higher apparent solubility and dissolution rates2. This in turn may lead to improved drug
absorption and increased bioavailability relative to the crystalline counterpart. Despite the
potential benefit, the application of formulation containing pure amorphous drug remains
limited primarily because of their higher instability: the thermodynamic driving force
always favors a transformation towards a lower energy crystalline state3.
Polymers are often employed to form amorphous solid dispersions (ASDs) with a drug to
improve the physical stability during processing and storage4. Polymers are thought to
inhibit crystallization through a number of mechanisms including reducing the drug
molecular mobility, by increasing the glass transition temperature (Tg) of the system 5,
and/or forming hydrogen bonds with the drug6, 7.
While it is obviously critical to stabilize the amorphous drug in the solid state, it is of equal
importance to prevent crystallization during dissolution of the ASD. Nevertheless, some of
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the fundamental processes underlying the concentration-time profiles attained during
dissolution are poorly understood, in particular due to the tendency to run dissolution
studies under sink conditions, which are unlikely to be found in vivo for many poorly water
soluble compounds. A number of factors need to be considered when evaluating the
dissolution behavior of ASDs including the amount of ASD introduced to the medium, the
drug loading, the relative dissolution rates of the individual components, the equilibrium
solubility of drug, the degree of supersaturation achieved, and the crystallization kinetics
of the drug. Alonzo et. al. demonstrated two pathways through which crystallization could
occur during the dissolution process 8. Nucleation and crystal growth could commence at
the surface of the amorphous solid matrix upon contact with dissolution medium due to a
reduction in Tg by the absorbed water. In this case, only a small extent of supersaturation
can be generated. Alternatively, if the dissolution rate of drug is fast relative to matrix
crystallization, drug may crystallize from the supersaturated solution, resulting in
desupersaturation at some point following dissolution. The more supersaturated the
solution is, the more prone it will be to crystallize. While it has been demonstrated that
polymers, when pre-dissolved in buffer, may inhibit either or both routes of crystallization
for pure amorphous compounds 8, little is known regarding the role of polymer during
dissolution of ASDs.
The aims of the current study were to evaluate the crystallization propensity of the pure
amorphous form of the poorly soluble anti-inflammatory agent, celecoxib (CEX), and to
compare the impact of various polymers, alone and in combination, on the route and
kinetics of crystallization and their impact on the dissolution rate of CEX from ASDs. It
was also of interest to determine the feasibility of using polymer combinations to improve
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the performance of ASDs with high drug loadings, hence the dispersions studied herein
had a 50% drug loading.

2.3

Materials

CEX was purchased from Attix Pharmaceuticals (Toronto, Ontario, Canada).
Polyvinylpyrrolidone (PVP) (Grade K12: Mw 2000–3000 g mol-1) was provided by BASF
(Ludwigshafen, Germany) and polyvinylpyrrolidone (PVP) (Grade K29/32: Mw 58,000 g
mol-1 ) was

purchased from

ISP

Technologies,

INC

(Wayne, NJ, USA).

Hydroxypropylmethylcellulose acetate succinate (HPMCAS, Type AS-MF), and
hydroxypropyl methylcellulose (HPMC, Grade 606) were supplied by Shin-Etsu Chemical
Co. (Tokyo, Japan). The molecular structures are shown in Figure 2-1.

2.4
2.4.1

Methods

Preparation of Bulk Amorphous Materials

CEX and the polymer(s) were dissolved in a 50:50 v/v solution of ethanol and
dichloromethane. Solvent removal was achieved by rotary evaporation. The ASDs (Table
2-1) were subsequently dried in a vacuum oven overnight to remove any residual solvent.
Pure amorphous CEX was prepared by melting crystalline CEX at approximately 180°C
on aluminum foil using a hot plate, followed by quench cooling. Based on analysis using
high performance liquid chromatography, no degradation was observed using this
procedure. Both ASDs and pure amorphous CEX were ground using a mortar and pestle
and sieved to obtain particle size fraction of 106-250µm. The solids were then stored in a
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desiccator containing phosphorous pentoxide at room temperature. The amorphous nature
of the ASDs and the pure CEX were verified by powder X-ray diffraction prior to use.

2.4.2

Phase transformation of slurred ASDs

ASD (200 mg) was slurred in 2 mL pH 6.8 100 mM sodium phosphate buffer (SPB) in a
scintillation vial equilibrated at 37°C and stirred at a constant rate. The kinetics of phase
transformation was monitored using a RamanRxn-785 Raman Spectrometer (Kaiser
Optical Systems, Inc., Ann Arbor, MI, USA) with a laser wavelength of 785 nm. Spectra
were collected every 15 minutes for 7 hours. Data were analyzed with OPUS software
(Version 7.2, Bruker Optics Inc, Billerica, Massachusetts, USA).

2.4.3

Inhibitory effectiveness of polymers on solution crystallization

275 µL of a 4 mg/mL methanol solution of CEX was pipetted into 50 mL pH 6.8 100 mM
SPB with and without 5 µg/mL pre-dissolved polymer. The solution was equilibrated at
37°C and stirred at 300rpm (+shaped magnetic stirrer, 0.75 inch diameter). Solution
concentrations were measured as a function of time using a SI photonics UV-Vis
spectrometer coupled with a fiber optic probe (SI Photonics Inc, Tuscon, Arizona, USA).
Wavelength scans (200-450nm) were performed at 1min interval for 8 hours. The
absorption peak at 249 nm was used to monitor solution concentration. Light scattering
was detected by monitoring the extinction at 350 nm at which the drug has no absorbance.
All measurements were performed in triplicate.
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2.4.4 Dissolution study of ASDs
8.8 mg crystalline or amorphous CEX or 17.6 mg of ASD was added to 400 mL pH 6.8
100 mM SPB, equilibrated at 37°C and stirred at 300 rpm with a stir bar (+shaped, 0.75
inch diameter). Solution concentration evolution as a function of time was measured using
the SI photonics system. Wavelength scans (200-450nm) were performed at 1min time
intervals for 16 hours. The absorption peak at 249 nm was used to monitor solution
concentration. Calibration solutions of CEX were prepared in methanol. All measurements
were performed in triplicate.

2.4.5

Effect of Polymer on the Equilibrium Solubility of CEX

The equilibrium solubility of CEX was determined by adding an excess amount of
crystalline CEX to 20 mL pH 6.8 100mM SPB with the absence/presence of 22µg/ml predissolved polymer in scintillation vials. The vials were equilibrated at 37°C for 48h in an
agitating water bath (Dubnoff metallic shaking incubator; PGC Scientific, Palm Desert,
CA, USA). Samples were then subject to ultracentrifugation to separate excess crystalline
CEX particles from the supernatant. Ultracentrifugation was performed at 35000 rpm for
30 minutes in an Optima L-100XP ultracentrifuge equipped with Swinging-Bucket Rotor
SW 41 Ti (Beckman Coulter, Inc., Brea, CA, USA). HPLC analysis were carried out with
an Agilent HPLC 1260 Infinity system (Agilent Technologies, Santa Clara, California,
USA). The chromatographic separation was performed by an XTerra Shield RP18 Column
(125Å, 3.5 µm, 3.9 mm X 100 mm) (Waters Cooperation, Milford, MA, USA). Water
(20%) and acetonitrile (80%) mixture was used as mobile phase and the flow rate was
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0.25mL/min. The ultraviolet detection wavelength was 250nm. All measurements were
performed in triplicate at room temperature.

2.4.6 Polarized Light Microscopy
The crystallization behavior of the pure amorphous CEX was observed using a Nikon
Eclipse E600 Pol microscope with 10x objective (Nikon Company, Tokyo, Japan). The
pulverized samples (106-250um) were placed on a microscope slide containing a
depression. 3-4 drops of pH 6.8 100 mM SPB with or without a pre-dissolved polymer
were then added to the particles. Images were processed by NIS-Elements software
package (Version 2.3; Nikon Company, Tokyo, Japan).

2.5
2.5.1

Results

Nucleation Induction Time

The effectiveness of the polymers in inhibiting crystallization from supersaturated solution
was assessed by performing nucleation induction time measurements. The experimental
nucleation induction time, tind, can be defined as the sum of the time for critical nucleus
formation (true nucleation time, tn), and growth to detectable size, tg.9
tind  tn  t g

(1)

The initial solution concentration generated was 22 µg/mL, which was approximately the
calculated “amorphous solubility” of CEX

10 11

, and therefore the maximum theoretical

concentration of free drug that can be achieved by dissolving an ASD. The onset of
crystallization was determined as a sudden increase of light scattering at 350 nm
concomitant with a rapid decrease in absorbance at 249nm 12. As shown in Figure 2-2, in
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the absence of any polymer, the drug concentration decreased rapidly and crystallization
commenced within 5 minutes. The solution became increasingly turbid with the
development of macroscopic crystals. Nucleation induction times extended to
approximately 1hr in the presence of PVP-K12 and 2hrs with PVP-K29/32. It was
noteworthy that the rate of desupersaturation following nucleation induction was slower in
the presence of PVP-K29/32 than in the presence of PVP-K12 and slower in the presence
of both of these polymers relative to in the absence of a polymer. In the case of HPMCAS
and HPMC, however, no substantial nucleation/crystal growth occurred and the initial level
of supersaturation was maintained for more than 8 hours. Furthermore, when combinations
of HPMCAS with PVP-K12 or PVP-K29 were evaluated, no significant desupersaturation
occurred, indicating that the effectiveness of HPMCAS in maintaining supersaturation was
not impaired by the presence of PVP.

2.5.2

Crystallization Kinetics of Slurred ASDs

The tendency of pulverized amorphous CEX and ASDs formulated with a 50% drug
loading to crystallize when added to aqueous media (SPB at 37°C) was evaluated using
Raman spectroscopy and results for the various systems summarized in Figure 2-4. The
crystalline and amorphous CEX reference spectra show distinct differences in peak
position, intensity and width, which can be used to monitor the phase transformation from
the amorphous to the crystalline form. For example, the crystalline form spectrum has a
peak at 1614 cm-1 with a small shoulder at 1596 cm-1, whereas the reference amorphous
CEX spectrum shows a peak at 1611 cm-1 with a much more pronounced shoulder at
approximately 1598 cm-1 (Figure 2-3).
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By monitoring the decrease in intensity of the 1598 cm-1 shoulder as a function of time, it
can be seen that the CEX:PVP-K12 ASD crystallized within 4 hours, as shown in Figure
4. When a small amount of the PVP was replaced with HPMCAS, to form a ternary
dispersion (consisting of 50% CEX, 40% PVP-K12 and 10% HPMCAS), the dispersion
remained amorphous for the duration of the experiment (7 hours). Increasing the molecular
weight grade of PVP used to form the dispersion, improved resistance to crystallization;
the shoulder at 1598 cm-1 (indicative of the amorphous form) persisted for 7 hours when
CEX:PVP-K29/32 ASDs were slurried. Both the CEX: HPMCAS ASD and the CEX:
PVP-K29/32: HPMCAS ternary ASD remained amorphous over this time frame.
Pure amorphous CEX crystallized rapidly during slurrying, whereby crystallization was
complete within an hour. Furthermore, it was found that the polymer needed to be present
in the dispersion to be an effective crystallization inhibitor; adding the polymer in predissolved form (22µg/ml) to the buffer did not substantially retard the crystallization
kinetics of the pure amorphous CEX (data not shown).

2.5.3

Dissolution Behavior of CEX ASDs

Figure 2-5 shows the dissolution profiles of ASDs of CEX formulated with different
polymers and polymer combinations at a drug loading of 50% (w/w). The maximum
apparent solution concentration of CEX achieved by dissolving the ASDs was between 2122µg/ml in all cases except for the dispersions that contained HPMC, which equals 100%
release of the CEX in the ASDs; the amount of ASD added was selected so that theoretical
concentration of CEX was equivalent to the reported amorphous solubility 10, 11. Thus the
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dissolution conditions are at-sink with respect to amorphous solubility and non-sink with
respect to crystalline solubility.
While the maximum concentration achieved was the same for these dispersions,
considerable differences in the time to achieve the maximum concentration and the
longevity of the achieved supersaturation can be noted between the different formulations.
Binary dispersions with either PVP-K12 or PVP-K29/32 showed faster dissolution rates
than the corresponding dispersions with HPMCAS or HPMC (Figure 2-5). However, PVPK12 was the least effective polymer at maintaining the generated supersaturation, with
desupersaturation being observed about 2hrs after all the CEX had dissolved. Interestingly,
the peak CEX concentration achieved by dissolving the PVP-K29/32 ASD was maintained
for approximately twice as long as that of the PVP-K12 ASD, although the initial
dissolution rates for the two systems were very similar. Dispersions with HPMCAS
dissolved more slowly, but did not desupersaturate over the experimental timeframe.
Dispersions with HPMC exhibited the slowest dissolution rate, the maximum
concentration achieved was only 16µg/ml and was still increasing by the end of the
experiment.
Replacing 20% of the PVP-K12 with HPMCAS led to two major changes in the dissolution
behavior of the dispersion (Figure 2-6). First, the dissolution rate was much slower, being
more similar in profile to that of the binary dispersion containing HPMCAS. Second, no
desupersaturation was observed and thus the ternary ASD has improved stability against
crystallization relative to the binary dispersion with PVP-K12. A similar profile was
observed for a ternary dispersion with PVP-K29/32 and HPMCAS. Replacing 20% of the
PVP-K12 or PVP-K29/32 with HPMC also resulted slower dissolution rates relative to the
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PVP only dispersion, albeit to different extents depending on the grade of PVP. Again, no
desupersaturation was observed in either case. Interestingly, the dissolution rate of the
ternary dispersion containing PVP-K12 with HPMC was much slower than for PVP-K29;
this difference between the PVP grades was not observed with the other ternary dispersions.
Additionally, it was found that pre-dissolved cellulosic polymers present in the dissolution
medium slightly reduced the dissolution rate of the CEX: PVP-K12 ASD, resulting in a
longer time period to achieve complete release, but were able to prevent desupersaturation
(Figure 2-7). In contrast to the dispersions, the solution concentration time profile achieved
by dissolving amorphous CEX was similar to that obtained by dissolving crystalline CEX,
despite a faster initial release rate. Dissolution of amorphous CEX into buffer containing
5µg/ml pre-dissolved HPMCAS or HPMC resulted in only a slightly higher final
concentration, as shown in Figure 2-8.

2.5.4 Polarized Light Microscopy
Figure 2-9 shows that when neat amorphous CEX was exposed to phosphate buffer, the
material appears to undergo rapid crystallization from the amorphous particles. In addition,
some crystallization from the solution phase was also observed. When a cellulosic polymer
was present in the buffer, solution crystallization was not observed whereas matrix
crystallization was still evident, albeit proceeding at a much slower rate (Figure 2-10 and
Figure 2-11).
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2.5.5

Equilibrium Solubility of CEX

The measured equilibrium solubility of crystalline CEX was 1.5µg/mL. Polymers, when
present at a concentration of 22µg/ml in SPB, did not substantially impact the crystalline
solubility of CEX, as demonstrated by the results summarized in Table 2-2.

2.6

Discussion

For ASD formulations, it is essential to prevent crystallization (either nucleation and/or
growth) both in the solid formulation during storage, as well as during the dissolution
process, either from the dissolving amorphous matrix, or from the supersaturated solution
generated by dissolution under non-sink conditions. However, the polymer that is the best
crystallization inhibitor in the solid formulation, may not be effective in preventing
crystallization from aqueous solution and vice versa. For example, it was observed that
polyacrylic acid was very effective at inhibiting the crystal growth of acetaminophen from
supercooled liquids13, and hence retarded crystallization from amorphous solid dispersions,
but was ineffective in preventing either nucleation or crystal growth from aqueous
solutions14. Other systems show similar types of behavior6,

15-17

. Therefore, it may be

appropriate to use combinations of polymers 18 to ensure adequate stability during storage
and optimum performance during dissolution. Although ternary dispersions have been used
to improve dissolution rates,

19 20

, as well as to improve physical stability in the solid

dispersion21, there is relatively little work evaluating the impact of binary polymer
combinations on crystallization kinetics during ASD dissolution.
Crystallization during dissolution of amorphous materials can occur through surface/bulk
crystallization of the solid matrix upon contact with the dissolution medium or from the
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supersaturated solution generated upon dissolution

8, 22

. The former process impacts the

achievable extent of supersaturation, because any crystals formed will act as seeds,
growing rapidly and depleting the supersaturation. If no crystallization from the matrix
occurs, solution crystallization will govern the longevity of the supersaturated solution
formed by dissolution of amorphous material; once nucleation from the solution phase
commences, desupersaturation will be observed shortly thereafter due to growth of the
nuclei. Ideally, matrix crystallization should be inhibited during the dissolution process, in
order to achieve a higher level of supersaturation 8.
The microscope images and the Raman spectra revealed that pure amorphous CEX
crystallized rapidly and primarily via the matrix route upon contact with buffer. Absorption
of water will decrease the glass transition temperature, leading to increased molecular
mobility and hence rapid crystallization. Polymers, when pre-dissolved in buffer, were not
able to substantially impede the onset of crystallization, although their presence did extend
the time needed to complete crystallization during the slurry experiment. Correspondingly,
little supersaturation was generated during the dissolution of pure amorphous CEX in
buffer or buffer containing a pre-dissolved polymer (Figure 2-8). This indicates either that
complete matrix crystallization is rapid, or that the seed crystals formed grow rapidly under
these conditions, depleting the supersaturation produced by dissolution of any residual
amorphous material. Furthermore, polymers dissolved in solution are clearly unable to
inhibit the formation of crystals in the amorphous matrix. These observations confirm the
need to prevent matrix crystallization in order generate supersaturated solutions.
When formulated as an ASD, even at drug loadings as high as 50%, CEX stability to
crystallization upon exposure to buffer is considerably improved, although some
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differences are seen depending on the polymer used to form the ASD. The Raman data
indicate that the CEX: PVP-K12 ASD is more prone to crystallization in the slurry
experiments as compared to other ASDs which didn’t crystallize over the timeframe of the
experiment. Raman spectroscopy alone does not enable us to identify the pathway through
which crystallization occurred. However, since all binary and ternary ASDs gave complete
release of the drug during the dissolution experiments, achieving the 21-22µg/ml targeted
CEX concentration and yielding supersaturated solutions, it is apparent that matrix
crystallization was completely inhibited. Therefore, any difference in dissolution
performance for the different ASDs can be attributed to the impact of a specific polymer
or polymer combination on crystallization from the solution phase.
The overall desupersaturation profile observed following complete release of the drug will
depend on the impact of the polymer on both nucleation and growth kinetics from the
solution phase. Since growth cannot occur until nuclei have formed, the impact of polymers
on crystal nucleation is of paramount importance. Nucleation kinetics are often inferred
from measurement of the induction time, which is defined as the time required for stable
nuclei to form and grow to a detectable size (equation 1). If it is assumed that steady-state
nucleation is achieved quickly and that tn>> tg, then the induction time for the formation of
a critical nucleus9 can be expressed as:
tind  J 1

(2)

Where J is the nucleation rate, which is given by classical nucleation theory (CNT) as:
16𝜋𝛾 3 𝑣 2
𝐽 = 𝐴𝑒𝑥𝑝 [− 3 3
](3)
3𝑘 𝑇 (ln 𝑆)2
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Where γ is the interfacial tension, v is the molecular volume of the crystallizing solute, k is
the Boltzmann constant, T is the temperature, and S is supersaturation23. S can be
expressed24 in terms of chemical potential differences as:
𝜇 − 𝜇∗
𝑙𝑛𝑆 =
(4)
𝑅𝑇
where µ is the solute chemical potential, and µ* is the chemical potential of a solute in a
saturated solution, and R is the gas constant. In dilute solutions, S can be determined from
the ratio, c/c*, where c is the solute concentration in the supersaturated solution and c is
the crystal solubility. From equation 3 it is apparent that the main factors influencing the
nucleation rate (and hence induction time) are temperature (a constant in our studies),
supersaturation and interfacial tension. In the presence of the polymers, experimental
induction times are extended indicating that the nucleation rate is decreased, with
differences being observed between the polymers. PVP-K12 is the least effective polymer
(Figure 2-2) with desupersaturation commencing after 60 min whereas in the presence of
HPMCAS or HPMC, no discernable nucleation or crystal growth can be observed for 8 hrs.
These differences between polymer effectiveness cannot be explained based on changes in
supersaturation (the supersaturation is the same for all solutions containing polymers based
on consideration of solution concentration values and equilibrium solubilities; see Table 1)
or interfacial tension. Adsorption of a polymer to the nucleus would lead to a decrease in
interfacial tension, leading to an expected increase in nucleation rate based on equation 3,
rather than the decrease observed in this study. Although CNT is the main framework for
understanding nucleation phenomena, it is apparent that this theory does not readily allow
for obvious mechanistic insights into how polymers extend induction times. Computer
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simulations have suggested that nucleation occurs via a two-step process, whereby the first
step is the formation of a dense liquid cluster, followed by structural rearrangement of this
cluster to an ordered state25. Additives are proposed to interfere with the rearrangement
process depending on their relative affinity for the solute cluster and the solvent, as well as
some geometric considerations. The greater effectiveness of the cellulose derivatives as
nucleation inhibitors in comparison to either PVP grade may therefore relate to a greater
ability to interact with a dense liquid cluster of celecoxib, relative to the more hydrophilic
PVP which will also have a competing interaction with the solvent phase. This is in
accordance with previous studies where more hydrophilic polymers were found to have a
smaller impact on nucleation induction times of relatively lipophilic drugs relative to more
amphiphilic polymers (including many cellulose derivatives) which extended the longevity
of supersaturated solutions to a greater extent10, 26.
The induction time values are quite predictive of the dissolution performance, whereby the
dispersions formulated with PVP-K12 also undergo desupersaturation at the earliest time
point following dissolution. Interestingly, the higher tendency of the PVP-K12 dispersions
to undergo crystallization from solution can be mitigated by adding a small amount of an
effective crystallization inhibitor, either HPMCAS or HPMC, to the dispersion. Thus the
cellulose polymers dissolve sufficiently rapidly from the ternary dispersion to be effective
solution nucleation inhibitors and are able to inhibit CEX nucleation in the presence of
PVP. This strategy might be useful in vivo to improve the performance of a dispersion, by
combining a polymer that rapid releases the drug, but is a poor solution crystallization
inhibitor, with a small quantity of a polymer that is a good inhibitor. The induction time
experiments (Figure 2) confirm that the effectiveness of HPMCAS or HPMC in inhibiting
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solution nucleation was not impaired by the presence of PVP. These observations open up
a strategy of utilizing more than one polymer in an ASD formulation in order to improve
performance and also show that only very low polymer concentrations are required to
inhibit solution nucleation (only 5 μg/mL of polymer was used for the induction time
experiments shown in Figure 2). In the current study, high drug loading ASDs formulated
with PVP and HPMC or HPMCAS show enhanced stability against crystallization.
Furthermore, the ternary CEX: PVP-K29/32: HPMC dispersions have enhanced release
relative to the binary CEX: HPMC dispersions, from which the drug is released very slowly.
However, it is important to note that relative to the binary CEX: PVP-K12 dispersion,
somewhat surprisingly, release is delayed when a small quantity of either HPMCAS or
HPMC is added to matrix. This reduced release rate clearly may not be desirable. However,
based on the evidence shown in Figure 7, it is apparent that the additional polymer added
to improve stability against crystallization need not be present in the dispersion itself. Here
it can be seen that trace amounts (5 μg/mL) of both HPMC and HPMCAS effectively
inhibit crystallization from the CEX: PVP-K12 dispersions when pre-dissolved in buffer.
Thus, they could be potentially added to the formulation as a separate component from the
ASD matrix. Given the wide array of available polymers, as well as the current interest in
increasing drug loading, using very hydrophilic polymers to ensure rapid drug release,
combined with a small amount of an effective crystallization inhibitory polymer, is an
approach that should be investigated further based on the promising results shown in this
study.
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2.7

Conclusions

High drug loading amorphous solid dispersions of celecoxib formulated with different
polymers led to supersaturated solutions, but showed dramatically different release profiles
and solution crystallization behavior. Using a combination of polymers, where an effective
crystallization inhibition polymer was present as a minor component, led to the formation
of supersaturated solutions upon solid dispersion dissolution that had improved stability
against crystallization. These findings open up new formulation approaches for amorphous
solid dispersions, whereby one polymer is included to inhibit crystallization during
dissolution, whereas a second polymer is used to achieve another key property such as
rapid release, or enhanced storage stability.
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Table 2-1. Summary of the various ASDs prepared with different weight ratios
Drug-Polymer(s) System

w:w

CEX: PVP-K12

5:5

CEX: PVP-K29/32

5:5

CEX: HPMC

5:5

CEX: HPMCAS

5:5

CEX: PVP-K12: HPMC

5:4:1

CEX: PVP-K12: HPMCAS

5:4:1

CEX: PVP-K29/32: HPMC

5:4:1

CEX: PVP-K29/32: HPMCAS

5:4:1

Table 2-2 Crystalline CEX solubility in the absence/presence of pre-dissolved polymers

CEX solubility
(µg/mL)

No polymer

PVP-K12

PVP-K29/32

1.5±0.1

2.14±0.05

2.11±0.08

HPMCAS

HPMC

1.89±0.02 2.05±0.03

124

(a)

(b)

(c)

(d)

Figure 2-1. Chemical structures of CEX (a), PVP (b), HPMCAS(c), and HPMC (d)

Figure 2-2. Induction time measurements of CEX in the presence and absence of different
polymers.
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Figure 2-3. Raman spectra of pure crystalline (top) and amorphous (bottom) CEX over the
wavenumber range 1700-1000 cm-1
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(b)

(a)

(c)

(d)

(e)

Figure 2-4 Normalized intensities (y-axis) of CEX peaks in ASDs slurried in buffer for
different time periods: (a) CEX: PVP-K12 5:5 (b) CEX: PVP-K12: HPMCAS 5:4:1, (c)
CEX: PVP-K29/32 5:5, (d) CEX: HPMCAS 5:5, (e) CEX-PVP-K29/32: HPMCAS 5:4:1.
All ratios are on a weight basis. The wavenumber range shown 1640-1540 cm-1(x-axis).
From top to bottom: unexposed ASD, and after 0.5hr, 2.5hrs, 4hrs, and 7hrs exposure to
buffer, respectively.
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Figure 2-5 Dissolution profiles of binary ASDs

Figure 2-6 Dissolution profiles of binary and ternary ASDs
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Figure 2-7 Dissolution profiles of CEX: PVP-K12 ASDs in pure SPB with and without a
pre-dissolved polymer

Figure 2-8 Dissolution profiles of crystalline and amorphous CEX in SPB with and without
a pre-dissolved polymer

129

(a)

(b)

(c)

Figure 2-9 Polarized light microscope images of neat amorphous CEX exposed to pure
SPB. (a) Unexposed, (b) 2mins, (c) 10mins.

(a)

(b)

(c)

Figure 2-10 Polarized light microscope images of neat amorphous CEX exposed to SPB
with 5µg/mL pre-dissolved HPMC. (a) Unexposed, (b) 20mins, and (c) 60mins.

(a)

(b)

(c)

Figure 2-11 Polarized light microscope images of neat amorphous CEX exposed to SPB
with 5µg/mL pre-dissolved HPMCAS. (a) unexposed, (b) 5mins, and (c) 60mins.
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CHAPTER 3. EFFECT OF TEMPERATURE AND MOISTRUE ON THE SOLID
STATE STABILITY OF BINARY AND TERNARY AMORPHOUS SOLID
DISPERSIONS OF CELECOXIB

3.1

Abstract

The effectiveness of different polymers, alone or in combination, in inhibting
crystallization of amorphous solid dispersions of CEX was evaluated. It was found that
PVP and PVP-VA formed stronger hydrogen bonding with CEX than cellulose based
polymers. This, combined with their better effectiveness in raising the glass transition
temperatures (Tgs) of the dispersions, provided better physical stabilization of amorphous
CEX against crystallization in the absence of moisture. PVP was found to be miscible with
both CEX and HPMCAS. The presence of HPMCAS would not result in demixing of CEX
with PVP, in spite of a stronger hydrogen bonding between PVP and HPMCAS than that
between PVP and CEX. Consequently, the physical stability is minimally impaired by the
presence of HPMCAS when the major polymer present in the ternary dispersion is PVP.
The results of crystal growth rate measurements was predictive of the relative stability of
bulk ASDs. In the presence of moisture, the physical stability of CEX ASDs are strongly
affected by both the hygrocopicity and the strength of intermolecular interactions. PVP
ASDs was more susceptible than PVP/VA ASDs to moisture induced amorphousamorphous phase separation, followed by crystallization HPMC ASDs are less stable than
HPMCAS ASDs owing to higher amount of water uptake.
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3.2

Introduction

Drugs formulated as the amorphous form can provide advantages over their crystalline
counterparts by offering increased kinetic solubility and a faster dissolution rate,
contributing to improved absorption in vivo. However, such improvements in delivery are
inevitably accompanied with an increased risk of product instability, due to the intrinsic
tendency of an amorphous compound to crystallize during storage.
A polymer is often mixed with the amorphous drug at the molecular level to inhibit solid
state crystallization. The stabilizing effect of polymers is multifaceted. Polymers are
thought to reduce the molecular mobility of the amorphous drug at the storage temperature
by increasing the glass transition temperature (Tg) of the system 1, typically referred to as
an anti-plasticization effect. However, other studies have revealed that crystallization
inhibition by a polymer cannot always be rationalized based on Tg changes 2, 3. Nifedipine
was found to crystallize more readily than felodipine both from the pure amorphous form
and amorphous solid dispersions (ASDs) with polyvinylpyrrolidone (PVP) in spite of a
similar Tg and molecular mobility. The greater ease of nifedipine to crystallize was
attributed to a lower nucleation activation energy and a larger enthalpic crystallization
driving force4. Polymers may also contribute to the physical stabilization of amorphous
drug by forming specific inter-species interactions with the drug, such as hydrogen
bonding5 or ionic interactions6, 7. The strength of such interactions, as inferred using midinfrared spectroscopy, appears to be in-line with the relative effectiveness of polymers as
crystallization inhibitors for naringenin and quercetin8. Furthermore, the nature of the drugpolymer interactions formed in the amorphous systems were found to be much more critical
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for rapidly crystallizing systems, whereby less discrimination is seen for more slowly
crystallizing compounds, at least over shorter timeframes9.
Crystalline solids adsorb water by a surface adsorption mechanism10. Amorphous solids
are more hygroscopic than their crystalline counterparts due to their disordered structure
and higher free volume. In addition to surface adsorption, water may penetrate into the
bulk of amorphous materials. The moisture absorbed can be detrimental to the stability of
amorphous solid dispersions (ASDs) for several reasons. As an effective plasticizer with a
Tg as low as -137°C11, water can effectively reduce the Tg of the ASD and thereby increase
the molecular mobility at the storage temperature12 It has been shown that 1% water lowers
the Tg of indomethacin by 10 °C13. Water can also irreversibly disrupt the drug-polymer
interactions by competitively forming hydrogen bonds with a hydrophilic polymer14. Both
factors

15

may induce amorphous-amorphous phase separation

16

in the ASDs with

subsequent crystallization that preferentially occur in the drug-rich domains17.
If crystallization during storage can be avoided, then dissolution of the solid dispersion can
potentially yield a supersaturated solution of the drug with a substantially elevated solution
concentration relative to that obtained from the crystalline material. While it is obviously
vital to ensure that the drug remains amorphous during the product shelf life, it is of equal
significance to inhibit crystallization during dissolution over pharmaceutically relevant
timeframes. Unfortunately, choosing the optimum pharmaceutically acceptable inhibitor
for each of these crystallization pathways is largely empirical. Furthermore, the polymer
that is the best solid state inhibitor

18

may be ineffective as a solution crystallization

inhibitor 19 and vice versa. For example, it was observed that polyacrylic acid (PAA) was
very effective at inhibiting the crystal growth of acetaminophen from supercooled liquids5,
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20

, and hence prevented crystallization from amorphous solid dispersions, but was

ineffective at preventing either nucleation or crystal growth from aqueous solutions 21.
Similarly, PVP reduces both the crystal nucleation and growth rates from amorphous
felodipine18, 22, and in the absence of water, dispersions prepared with this polymer are
stable to crystallization23. However, PVP does not inhibit crystallization from
supersaturated felodipine solutions and the dissolution performance of felodipine-PVP
dispersions is relatively poor 19.
Therefore, an important advance in ASD formulation could be to incorporate combinations
of polymers, chosen to maximize crystallization inhibition in both the solid and solution
phases 24-26. Before this strategy can be implemented, however, it is necessary to determine
factors such as miscibility of the ternary systems. If the polymers are miscible, it should be
relatively straightforward to determine if a one phase amorphous system is produced when
the drug is added. However, if the polymers are immiscible/partially immiscible, it will be
important to determine how the drug is distributed between the two polymer phases. It is
expected that the drug will preferentially mix with the polymer chosen as the solid state
stabilizer, since the formation of inter-species interactions will promote miscibility, but to
the best of our knowledge, these issues have not been probed to date. By studying the
miscibility in a ternary system, we will also be able to evaluate if the polymer pair
miscibility influences the miscibility of the drug with either polymer.
It has been well documented that the solid state stability of ASDs are improved when the
polymer loading is increased. Therefore, for the strategy to be successful, it is also
necessary to determine the optimum level of solution stabilizing polymer, since it is clear
that an additional polymer cannot be added at the expense of drug loading.

136
Herein, we evaluated the solid state stability of celecoxib (CEX), a poorly soluble antiinflammatory agent, when formulated in ASDs with different polymer combinations and
exposed to high stress storage conditions of elevated temperature and/or relative humidity.
Previously, we reported that the dissolution performance of high drug loading ASDs of
CEX formulated with polyvinylpyrrolidone (PVP) were improved when 20% of the PVP
was replaced by a strong solution crystallization inhibiting polymer: either hydroxypropyl
methyl cellulose (HPMC) or HPMC acetate succinate (HPMCAS)27. It was therefore also
of interest to evaluate the solid state stability of ternary ASDs relative to the corresponding
binary ASDs.

3.3

Materials

CEX was purchased from Attix Pharmaceuticals (Toronto, Ontario, Canada).
Polyvinylpyrrolidone (PVP) (K29/32: Mw 58,000 g mol-1) was purchased from ISP
Technologies, INC (Wayne, NJ, USA). PVP (K12: MW 2000-3000g mol-1) and
vinylpyrrolidone-vinyl acetate copolymer (PVP/VA) (Kollidon VA64, Mw 45,000-47,000g
mol-1)

were

provided

by

BASF

Corporation

(Ludwigshafen,

Germany).

Hydroxypropylmethylcellulose acetate succinate (HPMCAS, Type AS-MF: Mw 17,000g
mol-1) and hydroxypropyl methylcellulose (HPMC, Type 606: Mw 35,600g mol -1) were
supplied by Shin-Etsu Chemical Co. (Tokyo, Japan). The molecular structures are shown
in Figure 3-1.
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3.4
3.4.1

Methods

Preparation of Bulk Amorphous Materials

CEX and the polymer(s) at different dry weight ratios were dissolved in a mixture of
ethanol and dichloromethane. Solvent removal was achieved by rotary evaporation. The
ASDs of the drug or polymer blends were subsequently dried in a vacuum oven overnight
to remove any residual solvent. They were then ground using a mortar and pestle and
sieved to obtain a particle size fraction of 106-250µm. They were then stored in a desiccator
containing phosphorous pentoxide at room temperature prior to use.

3.4.2

Infrared (IR) Spectroscopy

Solutions of drug and polymer mixtures at different dry weight ratios or single component
polymers were dissolved in a mixture of ethanol and dichloromethane. The solutions were
then dipped onto thallium bromoiodide (KRS-5) optical crystals and rotated on a KW-4A
spin coater (Chemat Technology, Inc, Northridge, CA, USA). IR spectra of the resulting
thin films were obtained on a Bruker Vertex 70 (Bruker, Billerica, MA, USA). 64 scans
were collected with a 4 cm-1 resolution for each sample over the wavenumber range from
4000cm-1 to 500 cm-1. Dry air was purged into the sampling and optical compartment to
prevent spectral interference from water vapor. Pure amorphous CEX was prepared by
melting the drug on an aluminum foil at approximately 180°C and quenched to room
temperature on a flat metal surface and gently ground by a mortar and pestle. No diffraction
peaks was observed in the powder x-ray diffraction pattern. Pure crystalline CEX was used
as is. The pure amorphous or crystalline CEX was placed in an attenuated total reflectance
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(ATR) attachment and the IR spectra was obtained using the same Bruker instrument. The
Opus 7.2 software (Bruker, Billerica, MA, USA) was used to analyze the spectra.

3.4.3

Thermal Analysis

Thermal analysis was carried out using a TA Q2000 DSC with a cooling refrigerator system
(TA Instruments, New Castle, DE, USA). Indium and tin was used for calibration of
temperature and indium was used for calibration of enthalpy. Dry nitrogen was purged at a
rate of 50mL min-1. 3-5mg of the samples were weighed into an aluminum T zero sample
pan and sealed using a hermetic T zero lid with a pinhole. The glass transition temperature
was determined by heating the sample at approximately 20°C min-1 to approximately 30°C
above Tg, followed by cooling and reheating at 20°C min-1. The onset temperature of the
second heating scan was reported.

3.4.4 Dynamic Vapor Sorption
Moisture sorption isotherms of the ASDs and pure polymers were measured by a
Symmetrical Gravimetric Analyzer (SGA-100) (VTI Corporation, Hialeah, FL, USA).
Samples were dried at 45°C with dry nitrogen purged into the sorption analyzer prior to
exposure to increasing RH. The equilibrium criterion for the drying step was less than 0.01%
w/w change within 2 min with a maximum drying time of 60min. The sample was then
exposed to RH from 5 to 95% with 10% step increase at 25°C. The maximum time for
equilibration in each step was 180 min.
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3.4.5

Crystal Growth Rate Measurements

Physical mixtures were prepared by mixing the crystalline drug and the polymer(s) in a
cryogenic mill (6750 freezer mill, Spex Sampleprep, Metuchen, New Jersey, USA). The
mixture were then melted between two cover slips on a hot plate and quench cooled to
room temperature on a flat metal surface. The coverslips were then stored in an oven at
80°C until small nuclei were formed and became visible. The increase in diameter of the
crystal nuclei with time on a hot stage set at the temperature of interest were measured
using a polarizing microscope as described previously18.

3.4.6

Storage Conditions and Powder X-ray Diffraction

ASDs of CEX were stored in 20ml open scintillation vials in a dessicator, and then subject
to different environmental conditions for long term stability studies: 80°C/0%RH
(Drierite®), room temperature (22-25°C) /94%RH (saturated solution of potassium nitrate),
and 40°C/75%RH (saturated solution of sodium chloride). Powder X-ray diffraction
(PXRD) pattern were taken periodically to evaluate the crystallization kinetics using a
Rigaku SmartLab diffractometer (Rigaku Cooperation, The Woodlands, TX, USA). The
patterns were collected in step scan mode with a scan range from 5° to 35° and a scan speed
of 4°/min. The tube voltage and current were 44kV and 40mA, respectively. A silicon
standard was used to calibrate the instrument.

3.5
3.5.1

Results

Fourier Transform Infrared Spectroscopy

Figure 3-2 shows the IR spectra of crystalline and amorphous forms of the pure drug,
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focusing on the high wavenumber region. Crystalline CEX show a doublet at 3225cm-1 and
3322cm-1, which arise from N-H stretching vibrations associated with the asymmetric and
symmetric motions respectively of the NH2 of the sulfonamide group (Figure 1). These
peaks shifted to 3268cm-1 and 3351cm-1 for amorphous CEX. These values are very close
to those reported by Chawla et al28. It has been established that a lower peak frequency of
the N-H group is typically associated with a shorter hydrogen bond distance29. Therefore,
the hydrogen bonding in the pure amorphous form of CEX appears weaker than in the
crystalline form.
In amorphous mixtures of CEX and PVP, a peak at 3196cm-1 emerged and increased in
intensity at the expense of the 3268cm-1 peak as the polymer loading increased (Figure 3-3).
Correspondingly, the C=O peak of PVP at 1682cm-1 developed a shoulder at approximately
1661cm-1 (the drug has no absorbance at this wavenumber), increasing in dominance as the
drug to polymer ratio increased. The spectra suggest that an increasing fraction of the drug
NH2 groups was involved in hydrogen bonding with the C=O of PVP as the polymer
loading increased. For CEX-HPMCAS ASDs, the NH peak of CEX at 3268cm-1 gradually
shifted towards 3237cm-1 as the polymer loading increased, whereas the HPMCAS’s ester
carbonyl peak15 shifted from 1743cm-1 to 1734cm-1 (Figure 3-4). Therefore, compared to
the dispersion with PVP and based on the relative extent of the peak shifts in the presence
of the polymer, the hydrogen bonding between CEX and HPMCAS was found to be much
weaker.
For the PVP: HPMCAS films, the peak at 1682cm-1 showed a shoulder at 1643cm-1, and
can be assigned to the C=O of PVP hydrogen bonded to the OH group of HPMCAS (Figure
3-5). This shoulder was lower in wavenumber than that observed in CEX: PVP films,
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indicating that the hydrogen bonding between the two polymers was stronger than that
between the drug and PVP. Furthermore, the fact that the peak at 1682cm-1 persists and was
dominant in the binary polymer blend spectra indicates that not all PVP monomers were
involved in hydrogen bonding with HPMCAS even when HPMCAS was present at very
high weight fraction.
For ternary mixtures where HPMCAS was present as a minor fraction, the spectra (Figure
3-6) were similar to those obtained from a binary mixture of CEX and PVP, and no shoulder
at 1643cm-1 (characteristic of PVP-HPMCAS interactions) can be observed. It is unclear
whether hydrogen bonding between CEX and HPMCAS exists in the ternary systems and
whether it will form at the cost of reduced hydrogen bonding between CEX and PVP, which
might potentially substantially impair the solid state stability of the ternary ASDs relative
to the corresponding CEX: PVP binary ASDs.
To further evaluate this, the HPMCAS loading was increased up to 40%, and it can be
deduced that the hydrogen bonding between CEX and PVP persist in this dispersion
(Figure 3-7). The shoulder at 1643cm-1, indicative of hydrogen bonding between PVP and
HPMCAS, eventually emerged when the HPMCAS loading was increased to 60% (Figure
3-8). Furthermore, distinct spectral differences between the ternary mixture at a ratio of
1:3:6 and the binary mixture of PVP: HPMCAS 3:7 were observed in the 1630cm-1 to
1670cm-1 region. This suggests that hydrogen bonding between CEX and PVP persists in
the ternary mixture even when a high weight fraction of HPMCAS is present in the ternary
mixture.
PVP/VA is a copolymer of vinylpyrrolidone and vinylacetate, and hence it has two types
of C=O group, pyrrolidone and acetate with characteristic peaks at 1684cm-1 and 1737cm-
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1

, respectively. Similar to the case of CEX: PVP films, the C=O peak at 1684cm -1 showed

a shoulder at 1662cm-1 when PVP/VA was mixed with CEX. Correspondingly, the NH peak
of CEX shifted from 3268cm-1 to approximately 3198cm-1. This indicates that the hydrogen
bonding strength between the C=O group of the vinylpyrrolidone monomer of PVP/VA and
the NH2 group of CEX was comparable to that observed in CEX: PVP dispersions.
Interestingly, at high drug loadings (70% and 90%), the C=O of the vinylacetate group of
PVP/VA showed a shoulder at lower wavenumber, indicating a potential weak hydrogen
bonding interaction with CEX. When the spectra of CEX: PVP/VA and CEX: PVP-K29/32
films were compared at the same drug loading (70%), based on the NH2 stretching region,
it appears that a larger fraction of drug molecules was involved in hydrogen bonding in the
case of CEX: PVP-K29/32 than in CEX: PVP/VA. This can be presumably attributed to
the dilution effect due to the presence of the vinylacetate monomer in PVP/VA which is a
weaker hydrogen bond acceptor than the vinylpyrrolidone carbonyl. The difference in the
carbonyl stretching region indicates that most of PVP/VA pyrrolidone monomers have
engaged in hydrogen bonding with CEX, in contrast to the PVP system, where there was a
larger fraction of PVP with free C=O remaining at the same 70% drug loading.
To investigate the potential impact of environmental moisture on the miscibility and
stability of mixtures during storage, spin coated films were exposed to high relative
humidity (94%RH). Moisture was then removed by purging dry air into the chamber of the
IR spectrometer prior spectral acquisition. For CEX: PVP-K29/32 films (Figure 3-11-13),
the peak at 3196cm-1 decreased in intensity whereas the peak at 3268 cm-1 increased in
intensity. Correspondingly, there was a slight but discernable decrease in C=O shoulder at
1661cm-1. This suggests that water irreversibly disrupts the hydrogen bonding of PVP with
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CEX and induced amorphous-amorphous phase separation to some extent. This
phenomenon appears more pronounced in films with higher polymer loading due to a
higher amount of water uptake by the hygroscopic polymer. Subsequently, the amorphous
CEX partially crystallized as indicated by the appearance of peak at about 3236 cm -1 in
CEX: PVP 7:3 within 18 days of storage. Crystallization was also evident by visual
inspection in the form of white opaque spots appearing on the initially transparent film.
The faster crystallization at higher drug loading is expected since at high drug loadings
there was a higher fraction of CEX that is not hydrogen bonded with PVP to begin with,
despite a smaller extent of moisture induced amorphous-amorphous phase separation.
Similarly, for felodipine and PVP system that undergoes moisture induced drug-polymer
demixing14, it was found that at higher drug loading, crystallization was faster even though
the amount of water uptake by the ASD was reduced30.
In contrast, CEX: HPMCAS and CEX: PVP/VA spin coated films (Figure 3-14 and Figure
3-15) were more resistant to amorphous-amorphous phase separation and/or crystallization
as they showed no notable changes in the spectra following exposure to moisture over
18days. After storage for more than a month, crystallization mainly occurred on the edges
of the IR substrates for both CEX: HPMCAS and CEX: PVP/VA spin coated films at high
drug loadings (7:3 and 9:1).
The changes in spectra of the ternary films (Figure 3-16) were similar to those observed
for the binary CEX: PVP films owing to the fact that PVP was present in a larger fraction
than HPMCAS. In addition, PVP may phase separate from HPMCAS due to moisture
sorption, as indicated in Figure 3-17, since the small shoulder at 1643cm-1 is lost following
exposure to moisture and drying.
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3.5.2

Isothermal Moisture Sorption

To understand the impact of moisture on the solid state stability of ASDs, it is necessary to
quantify the amount of water absorbed by each pure component as a function of relative
humidity. As shown in Figure 3-18, pure amorphous CEX was very hydrophobic with only
2 wt. % water absorbed at 95%RH. Particles were retrieved after the experiment and
observed under the polarized microscope (images not shown). Partial crystallization
occurred in this case despite relatively low moisture sorption by the pure drug. The pure
polymers differ substantially in hygroscopicity, with the order from highest to lowest
moisture sorption being PVP>PVP/VA>HPMC>HPMCAS. Moreover, the amount of
water absorbed by PVP was minimally affected by the molecular weight grade.
The binary ASD at 50% drug loading absorbs much less moisture than the corresponding
pure polymer. This is expected considering the hydrophobicity of the drug30. The ASDs
shows the same rank order of hygroscopicity as the corresponding pure polymer in terms
of moisture sorption profiles with the exception of CEX: PVP/VA ASD whose moisture
sorption isotherm was similar to that of the CEX: HPMC ASD. Furthermore, it was found
that the binary ASDs showed a dramatic increase when the relative humidity was increased
to above 85% with the exception of the CEX: HPMCAS ASD. This effect was the more
pronounced in ASDs with PVP than with PVP/VA or HPMC. When the calculated
moisture sorption profiles based on the water uptake and the weight fraction of each
component were plotted against the experimental profiles (Figure 3-20), it is clear that
water uptake is largely suppressed in CEX:PVP/VA but dramatically increased in
CEX:PVP system at 95%RH. This agrees with the IR results that CEX: PVP undergoes
moisture induced partial demixing whereas CEX: PVP/VA does not. In a phase separated
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system, the moisture sorption of the binary system is expected to be additive whereas a
negative deviation from the calculated values is expected for a miscible system.
The moisture sorption profiles of the ternary ASDs where PVP was in excess (Figure 3-21)
exhibited a similar pattern to the corresponding binary CEX: PVP ASDs. However, it is
also apparent that replacing PVP with a less hygroscopic cellulosic polymer did result in a
slight reductions in water uptake.

3.5.3

Thermal Analysis

Despite some practical limitations31, DSC analysis remains the most frequently used
method to probe the mixing state of a drug with a polymer32. To this end, Tg as a function
of composition was measured and results are shown in Figure 3-22. The drug alone has a
Tg of approximately 55°C, which is substantially lower than the Tg values observed for
the polymers. For binary ASDs of the drug with different polymers, a single T g value was
obtained for each composition, suggesting that only a single amorphous phase was present.
In other words, the drug appears to be miscible with these polymers. PVP-K12 and PVP/VA
have lower Tg values than HPMCAS and HPMC, but apparently they were much more
effective in raising the Tg values of the ASDs.
Similarly, Sakurai et al 24 reported that the Tg values of solid dispersions of a BCS class II
drug prepared with PVP or PVP/VA were close to the predicted values using Gordon Taylor
equation, whereas a negative deviation was observed in the dispersions with HPMC.
Consequently, the ternary solid dispersions prepared with both HPMC and PVP/VA or PVP
provided better resistance to crystallization than the dispersions with HPMC alone at 40°C
/75%RH, presumably due to reduced molecular mobility.
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Polymer-polymer blends are frequently largely immiscible due to the low entropy of
mixing for two large molecules33. Consequently, miscibility between polymers can only be
anticipated when they can form specific interactions and hence have a favorable enthalpic
contribution to the free energy of mixing34. For binary polymer blends of PVP and
HPMCAS, a single Tg value was obtained for each composition (Figure 3-23), indicating
that only a single amorphous phase was present. This agrees with the IR results that PVP
can form strong hydrogen bonds with HPMCAS (Figure 3-5).
With three components, the phase behavior in the solid state immediately becomes very
complex. Understanding the miscibility of the ternary system is of crucial importance,
since it is desirable that the solid state stabilizing polymer is in the same amorphous phase
as the drug. Nevertheless, it is also expected that the final concentration of the solution
stabilizing polymer (HPMCAS or HPMC) will be low27, and therefore it should at least not
interfere with the miscibility of the drug and the solid state stabilizing polymer (PVP). The
IR results suggest that CEX has a higher affinity with PVP than HPMCAS, which is not
impaired by the competition from HPMCAS for hydrogen bonding with PVP. Hence, a
miscible ternary system is expected. This is further supported by the single Tg values
obtained for CEX: PVP: HPMCAS ASDs at 8:1.6:0.4 and 5:4:1 ratios (Figure 3-24).
Moreover, the ternary ASD’s Tg values were close to, but slightly lower than that of the
CEX: PVP binary ASDs due to the fact that PVP was present as the major component in
the ternary ASDs.
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3.5.4

Crystal Growth Rate

To quantitatively evaluate the impact of the polymers, crystal growth rate measurements in
the presence and absence of the polymers were determined. As shown in Figure 3-25, CEX
has the highest growth rate in the absence of any polymer. Crystal growth was much faster
in the presence of HPMCAS than in the presence of PVP at an equivalent weight percent
of polymer. Increasing the molecular weight of PVP only slightly reduced the growth rate.
The crystal growth rate of CEX in the presence of PVP/VA was slightly faster than that in
the presence of PVP. This may be because more vinylpyrrolidone carbonyl groups are
present in PVP than in PVP/VA at the same polymer loading, though the hydrogen bonding
strength of the PVP/VA’s vinyl pyrrolidone group with CEX was comparable to that
between PVP and CEX. Replacing a minor proportion of PVP with HPMCAS led to a small
increase in crystal growth rate, although the growth rate remained substantially lower than
the for the CEX:HPMCAS dispersion.

3.5.5 Solid State Stability during Storage
Figure 3-26 shows PXRD patterns of the binary and ternary ASDs which were stored at
80°C/0%RH. At 80% drug loading, the crystallization kinetics of the ternary ASD where
HPMCAS was present in minor fraction was comparable to that of the binary CEX:
PVP/VA ASDs, both of which crystallized slightly faster than that of the binary CEX: PVPK29/32 ASD. In contrast, CEX: HPMCAS ASD crystallized the fastest. These trends are
in good agreement the crystal growth rate measurements from the melt quenched films,
implying that the solid state properties of the ternary ASD could be largely predicted by
the corresponding binary ASD closest to the ternary composition. Similarly, CEX: HPMC
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ASD was found to crystallize much faster than the corresponding ternary ASD containing
both PVP and HPMC. The poor solid state stabilizing capability of cellulose derivatives
can be attributed to weak hydrogen bonding with CEX (HPMC does not have carbonyl
group to form hydrogen bonding with CEX at all) and/or their lower effectiveness in
increasing the Tg of ASDs.
For ASDs with 60% drug loading stored at RT (~20°C)/94%RH, CEX: PVP/VA was the
most stable binary ASD remaining amorphous for up to 150 days and crystallized thereafter.
CEX: HPMCAS was stable for up to 115 days and crystallized thereafter. The binary ASDs
with HPMC or PVP and the ternary ASDs where PVP was the major polymer was relatively
unstable, with some diffraction peaks observed within a month. Similarly, at an 80% drug
loading under the same storage condition, the ranking order of solid state stability was
CEX:PVP/VA>CEX:HPMCAS>CEX:PVP-K29/32:HPMCAS>CEX:PVP-K29/32 (data
not shown).
For pure amorphous CEX, the PXRD pattern after 3 days of storage closely resembled that
of the pure crystalline form. This suggests that although the addition of hygroscopic
polymers increased the water uptake of the system, the tendency of the drug in ASD matrix
to crystallize is reduced relative to pure amorphous form at high storage relative humidity35.
At 40°C/75%RH where both the temperature and humidity were elevated relative to the
ambient conditions, CEX: PVP/VA 8:2 ASD remained amorphous for up to 4 months.
CEX:HPMCAS dispersion was stable for up to 45days and crystallization was detected
thereafter. Interestingly, at the same drug loading, CEX: PVP-K29/32 and the
corresponding ternary ASD outperform CEX: HPMCAS at this storage condition. While
the ASD with PVP absorbs more water at all relative humidities than ASD with HPMCAS,
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these difference are less pronounced at or below 75%RH. Hence, the drug-polymer
interaction strength may become the dominant factor determining the stability of ASDs.
From the results above, it is clear that PVP/VA was very effective in stabilizing the
amorphous CEX at both elevated temperature and humidity. We also found that PVP/VA
was a good solution crystallization inhibitor for CEX from nucleation inhibition
measurements (unpublished data). Therefore, it appears that instead of using 2 different
polymers, the same goal might be reached by using a single polymer: PVP/VA, with
multiple functional groups on this single polymer. However, the dissolution rate of CEX:
PVP/VA ASD was much slower than the CEX: PVP: HPMCAS ternary ASDs27 with a
smaller extent of supersaturation was generated under the same experimental setting
(unpublished data). This maybe undesirable for drugs such as CEX which is mainly used
for pain management36. Similarly, Six et al25 found that itraconazole was miscible with
PVP/VA and the dispersion was stable against crystallization. But the dissolution rate was
slow, with only 45% drug release after 3h. In contrast, Eudragit E100 was miscible with
itraconazole only up to 13% w/w drug loading and failed to provide adequate physical
stabilization. However, the release of the drug was relatively fast. The ternary ASD of
itraconazole exhibited both fast dissolution and improved physical stability relative to the
corresponding binary ASDs

3.6

Discussion

Crystallization from the amorphous state is complicated. Quantitative prediction based on
a single variable maybe inappropriate in many cases. Instead, a qualitative appreciation of
different factors may be useful, as reviewed by Bhugra et al37. There are two types of
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mobility associated with amorphous material. The α mobility is considered as global
mobility associated with the glass transition temperature, and is often assessed by
measuring the structural relaxation time38. Above Tg, the viscosity is relatively low, and
hence the slow diffusion of molecules over a large length scale is less restricted. Therefore,
the difference between the storage temperature and the glass transition temperature is often
used as a crude approximation of the stability of amorphous materials. At temperature
below Tg, the material become highly viscous and hence the translational (or diffusive)
and rotational motions (α mobility) are substantially suppressed. In such case, higher
frequency local motions (β mobility) may become critical in determining crystallization
rate38. Yoshioka et al39,
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found that the dry amorphous indomethacin (Tg=50°C)

crystallized completely within 3 weeks at 30°C and the rate greatly increased when the
temperature was increased, presumably due to the increase in molecular mobility. In
contrast, when indomethacin was dispersed with a low level of PVP (5%) and stored at up
to 50 °C, an induction period of more than 20 days was required for crystallization to
initiate. Hancock and Zografi41 found that the temperature dependence of molecular
motions below Tg differed considerably than that above Tg, and was rapidly changing. The
authors suggested that amorphous materials should be stored at least 50°C below the glass
transition temperature so as to minimize the risk of crystallization over shelf life. In this
study, we found that PVP and PVP/VA are more effective in raising Tg of ASDs than
cellulosic derivatives, which contribute to the difference in the crystallization kinetics. This
is perhaps, at least intuitively, consistent with the existence of strong hydrogen bonding
between CEX and PVP or PVP/VA which may restrict the diffusive motion and hence selfassociation of the drug molecules in the dispersions. Similarly, Miyazaki et al5 found that
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PAA provided better physical stabilization for amorphous acetaminophen than PVP by
forming a stronger hydrogen bonding interaction with the drug and a larger decrease in
molecular mobility as indicated by the longer enthalpy relaxation time, despite a similar
Tg value. The hydrogen bonding between CEX and HPMCAS is very weak, and the
increase in Tg is minimal at high drug loading. However, a dramatic decrease in crystal
growth rate and much slower crystallization kinetics of ASDs relative to pure amorphous
CEX were observed even at very low polymer loading. HPMC does not have a carbonyl to
form hydrogen bonding with CEX and the difference in Tg between CEX: HPMC and CEX:
HPMCAS is small. Yet the crystallization kinetics of CEX: HPMC ASD is comparable to
that of CEX: HPMCAS ASD. Therefore, the improved stability of CEX when molecularly
mixed with a cellulosic derivative cannot be solely attributed to these two factors. Bhugra
suggested37 that polymeric additives impact drug diffusion by at least three mechanisms:
(1) polymers may act as a diluent to reduce the chemical potential of the drug. In this case,
a proportional decrease in crystallization rate is envisaged. (2) Through drug-polymer
interactions to restrict the local mobility42. (3) Impede the drug transport to the growing
crystals by accumulating on the amorphous-crystal interface. This mechanism may be
critical at high drug loadings22 and help explain our results.
Crystallization is a sequential process involving both nucleation and growth. The
temperature range where nucleation is favored is expected to be lower than where crystal
growth is favored43, 44. Significant crystallization occurs where the nucleation zone and
growth zone overlap20, 37. It has been reported in several studies18, 20 that slower crystal
growth rate is often associated with stronger hydrogen bonding. While it is anticipated that
a reduced crystal growth rate could translate to a slower overall crystallization kinetics of
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bulk ASDs, no direct evidence of such correlation, to the best of our knowledge, has been
reported. For acetaminophen20, the most effective polymer in reducing the nucleation rate,
HPMCAS, was found to be the worst growth inhibitor. Conversely, one of the best crystal
growth inhibitor, PAA, significantly increased the nucleation rate. This demonstrates that
polymers may stabilize amorphous drugs by selectively inhibiting nucleation or growth or
both. In that study, the authors also highlighted a good correlation between hydrogen
bonding strength with crystal growth but a lack of correlation between this factor and
nucleation rate. In the current study, the temperature dependence of the nucleation rate is
not investigated. Yet, a good correlation between the growth rate and crystallization
kinetics of the bulk ASDs has been established, at least qualitatively. This indicates either
that polymers effective in inhibiting crystal growth of CEX are also effective in inhibiting
nucleation or that inhibiting nucleation is less important than inhibiting crystal growth in
retarding overall crystallization.
In a study by Curatolo et al45, 41 small and polymeric molecules were tested for their
effectiveness in initiation and maintaining supersaturation for each of 9 structurally diverse
low solubility drugs, HPMCAS was found to be the most effective precipitation inhibitor.
Consequently, spray dried dispersions (SDDs) prepared with HPMCAS were consistently
superior to SDDs formulated with other polymers in both achieving and maintaining
supersaturation during in vitro dissolution studies. Warren et al46 tested the precipitation
inhibition behavior of 53 polymeric materials for supersaturated solution of danazol, the
majority of superior precipitation inhibitor were cellulose based. While the mechanisms of
superiority of cellulosic polymers as solution state inhibitor are not clearly understood,
these studies nevertheless indicate the necessity of incorporating them into ASD
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formulations to ensure adequate dissolution performance for many poorly water soluble
drugs26. The utility of PVP as a good hydrogen bond donor to stabilize ASDs has been
reported in numerous studies (add ref). Wegiel et al47 found that due to a stronger hydrogen
bonding interaction, a relatively small amount of PVP is required to successfully produce
amorphous solid dispersion of resveratrol as compared to HPMC, HPMCAS,
carboxymethyl cellulose acetate butyrate (CMCAB), and PAA. At the same drug loading,
PVP dispersions were more stable than dispersions formulated with those polymers in the
absence of moisture. In that study, it was also revealed that inter-species ionic interactions
between Eudragit® E100 provided even better physical stabilization. Nevertheless, such
type of interaction is less frequently observed in the literatures and is relatively hard to be
predicted a priori. From the discussion above, it is speculated that using the PVP and
HPMCAS polymer blend may potentially have a broad applicability as a strategy for ASD
formulation, and the need for further investigation is clearly warranted. It is anticipated
that such polymer pair could be used to produce high drug loading ASDs of drugs with low
Tg and difficult to be rendered amorphous with satisfactory solid state stability as well as
dissolution performance. Last but not least, PVP is found to be miscible with HPMCAS at
all proportions, and the addition of HPMCAS will not impair the miscibility of PVP with
CEX even at high HPMCAS loading. This observation maybe of practical significance in
scenarios where the composition of ASDs needs to be balanced for optimum outcome.
To understand the impact of water on the solid state stability of ASDs, the
hydrophobicity/hydrophilicity of the individual component, the strength of drug-polymer
interaction and water uptake by ASDs need to be taken into account. As compared to CEX:
PVP-K29/32, CEX: PVP/VA absorbs much less water and hence is more resistant to
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amorphous-amorphous phase separation and plasticization induced crystallization during
storage at high relative humidity. Similarly, Rumondor et al15 found that for both felodipine
and quinidine, the strength of hydrogen bonding the drugs with PVP/VA was comparable
to that with PVP, but the PVP/VA containing mixture experienced smaller extent of
moisture induced phase separation than PVP containing mixture, attributed to a reduced
amount of water uptake. In contrast, moisture induced drug-polymer demixing was absent
in both indomethacin:PVP48 and indomethacin:PVP/VA systems. Such difference was
attributed to a stronger hydrogen bonding between indomethacin’s COOH and C=O of
PVP than that between OH of felodipine or NH of quinidine and C=O of PVP. Interestingly,
while HPMCAS dispersion of CEX absorbs less water than PVP/VA dispersion, CEX:
PVP/VA still outperforms CEX: HPMCAS at 94%RH, most likely due to the stronger drugpolymer interaction strength as evidenced by both the IR spectra and Tg values. By the
same argument, CEX: PVP/VA was more stable than CEX: HPMC despite a similar
moisture sorption profile. Finally, while replacing a small amount of more hygroscopic
PVP with a less hygroscopic cellulose derivative did resulted in reduced water uptake in
ternary ASDs relative to the corresponding binary ASD with PVP, this reduction was not
large enough to result in a discernable difference in the solid state stability.

3.7

Conclusion

Polymers that can form stronger hydrogen bonding and more effective in reducing
molecular mobility of CEX are found to be more effective in inhibiting crystallization in
the absence of moisture. The measured crystal growth rate can be used to predict the
relative crystallization kinetics of bulk ASDs formulated with different polymers. This
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might potentially reduce the time and cost associated with long term physical stability
studies. This study also demonstrated proof of concept for the approach of using miscible
binary polymers to maximize crystallization inhibition in both the solid and solution phases
and provided greater confidence in the use of solid dispersion strategies. When subject to
high relative humidity, ASDs of CEX with stronger drug-polymer interaction and lower
hygroscopicity will be less susceptible to moisture induced phase separation and
crystallization.
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Figure 3-1. Chemical structures of CEX (A), PVP (B), PVP/VA (C), HPMCAS (D), and
HPMC (E).

Figure 3-2 FT-IR spectra of pure amorphous CEX (red) and pure crystalline CEX (blue)
showing the wavenumber range from 3100cm-1 to 3500cm-1.
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Figure 3-3 FT-IR spectra of CEX:PVP-K29/32 spin coated films (From top to bottom: pure
PVP (blue), drug:polymer ratios of 1:9 (red), 3:7 (pink), 5:5 (cyan), 7:3 (brown), 9:1 (green),
and pure amorphous CEX (orange), respectively) showing the wavenumber range from
3100cm-1 to 3500cm-1 and from 1550cm-1 to 1750cm-1. The arrows show the emergence of
peaks indicating hydrogen bonding between the celecoxib NH2 group and the PVP
carbonyl group.

Figure 3-4 FT-IR spectra of CEX:HPMCAS spin coated films (From top to bottom: pure
HPMCAS (blue), 1:9 (red), 3:7 (pink), 5:5 (cyan), 7:3 (brown), 9:1 (green), and pure
amorphous CEX (orange), respectively) showing the wavenumber range from 3100cm-1 to
3500cm-1 and from 1550cm-1 to 1850cm-1
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Figure 3-5 FT-IR spectra of PVP: HPMCAS spin coated films showing the wavenumber
range from 1600cm-1 to 1800cm-1

Figure 3-6 FT-IR spectra of CEX: PVP-K29/32: HPMCAS spin coated films (From top to
bottom: 1:8:1 (red), 3:6:1 (pink), 5:4:1 (cyan), 70:25:5 (brown), 90:8:2 (green),
respectively) showing the wavenumber range from 3100cm-1 to 3600cm-1 and from
1550cm-1 to 1800cm-1
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Figure 3-7 FT-IR spectra of CEX: PVP-K29/32: HPMCAS spin coated films: 3:4:3 (red),
35:30:35 (blue), and 4:2:4 (green) showing the wavenumber range from 3100cm-1 to
3500cm-1 and from 1550cm-1 to 1800cm-1.

Figure 3-8 FT-IR spectra of CEX: PVP-K29/32: HPMCAS 1:3:6 (blue) and PVP:
HPMCAS 3:7 (red) spin coated films showing the wavenumber range from 3100cm-1 to
3500cm-1 and from 1550cm-1 to 1800cm-1.

Figure 3-9 FT-IR spectra of CEX: PVP/VA spin coated films (From top to bottom: pure
PVP/VA (blue), 1:9 (red), 3:7 (magenta), 5:5 (cyan), 7:3 (brown), 9:1 (green), and pure
amorphous CEX (orange), respectively) showing the wavenumber range from 3100cm-1 to
3500cm-1 and from 1550cm-1 to 1800cm-1.
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Figure 3-10 FT-IR spectra of CEX: PVP/VA 7:3 (purple) and CEX: PVP-K29/32 7:3 (green)
spin coated films showing the wavenumber range from 3100cm-1 to 3500cm-1 and from
1550cm-1 to 1800cm-1.

Figure 3-11 FT-IR spectra of pure PVP(blue), CEX: PVP 3:7 unexposed (red), 1day(green),
18days(purple), and amorphous CEX(orange) spin coated films showing the wavenumber
range from 3100cm-1 to 3500cm-1 and from 1550cm-1 to 1800cm-1.
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Figure 3-12 FT-IR spectra of PVP(blue), CEX: PVP 5:5 unexposed (red), 1day(green),
18days(purple), and amorphous CEX(orange) spin coated films showing the wavenumber
range from 3100cm-1 to 3500cm-1 and from 1550cm-1 to 1800cm-1.

Figure 3-13 FT-IR spectra of PVP(blue), CEX: PVP 7:3 unexposed (red), 1day(green),
4days (black), 18days(purple), amorphous CEX(orange), and crystalline CEX (pink) spin
coated films showing the wavenumber range from 3150cm-1 to 3350cm-1 and from
1550cm-1 to 1800cm-1.
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(a)

(b)

(c)

Figure 3-14 FT-IR spectra of CEX: PVP/VA 3:7(a) 5:5 (b) and 7:3 (c) spin coated films
before (red) and after 18days (purple) of storage at 94%RH/RT showing the wavenumber
range from 3100cm-1 to 3500cm-1

(a)

(b)

(c)

Figure 3-15 FT-IR spectra of CEX: HPMCAS 3:7(a) 5:5 (b) and 7:3 (c) spin coated films
before (red) and after 18days (purple) and 2 months (green) of storage at 94%RH/RT
showing the wavenumber range from 3100cm-1 to 3500cm-1

Figure 3-16 CEX: PVP-K29/32: HPMCAS 5:4:1 before (red) and after 1days (green) and
18days (purple) of storage at 94%RH/RT showing the wavenumber range from 3100cm -1
to 3500cm-1 and from 1550cm-1 to 1800cm-1
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Figure 3-17 PVP: HPMCAS 1:1 spincoated films before (red) and after 1 day storage
(purple) at 94%RH/RT showing the wavenumber range from 1550cm-1 to 1800cm-1

Figure 3-18 Moisture sorption isotherms of pure amorphous CEX and polymers
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Figure 3-19 Moisture sorption isotherms of binary ASDs of CEX with different polymers

Figure 3-20 Experimental and calculated moisture sorption isotherms of binary ASDs of
CEX with PVP-K29/32 or PVP/VA
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Figure 3-21 Moisture sorption isotherms of the ternary ASDs

Figure 3-22 Tg values of ASDs of CEX with a single polymer
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Figure 3-23 Tg values of PVP and HPMCAS blends

Figure 3-24 Tg values of CEX: PVP (8:2 and 5:5), CEX: HPMCAS (8:2 and 5:5) and
CEX:PVP:HPMCAS (8:1.6:0.4 and 5:4:1) ASDs
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Figure 3-25. Crystal growth rate of CEX in the absence and presence of polymers.

Figure 3-26. PXRD of ASDs stored at 80°C/0%RH.
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Figure 3-27 PXRD of ASDs stored at RT/94%RH

Figure 3-28 PXRD of pure crystalline CEX, and pure amorphous CEX before and after
storage at RT/94%RH
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.
Figure 3-29 PXRD of ASDs stored at 40°C /75%RH
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CHAPTER 4. IMPROVED RELEASE OF CELECOXIB FROM HIGH DRUG
LOADING AMORPHOUS SOLID DISPERSIONS FORMULATED WITH
POLYACRYLIC ACID AND CELLULOSE DERIVATIVES

4.1

Abstract

Amorphous solid dispersions (ASDs) have been extensively exploited as a strategy for
improving the dissolution performance of poorly water-soluble drugs. However, factors
underpinning the observed dissolution profiles are not clearly understood and the choice of
polymeric carriers is largely empirical. In the current study, the dissolution performance of
a high drug loading ASD containing the poorly water soluble, anti-inflammatory agent,
celecoxib, was optimized by using binary polymers combinations. Polyacrylic acid (PAA),
a highly water soluble polymer, was used to substantially increase the dissolution rate of
the drug, while hydroxypropyl methyl cellulose (HPMC) or HPMC acetate succinate
(HPMCAS), were added to stabilize the solid amorphous matrix against crystallization
upon hydration, as well as to maintain supersaturation. Quantitative measurements of the
impact of the polymers on the solution nucleation and growth rates of celecoxib revealed
that, while the cellulose derivatives are effective nucleation inhibitors, it is more difficult
to completely prevent crystal growth in solutions containing seed crystals, in particular at
high supersaturations. Therefore, it is critical to prevent the formation of crystals in the
dissolving matrix during dissolution. By using certain ratios of HPMC and PAA, both rapid
release as well as crystallization inhibition could be achieved, even at high drug loadings.

Reprinted (adapted) with permission from (Xie, T.; Taylor, LS. Improved Release of Celecoxib
from High Drug Loading Amorphous Solid Dispersions Formulated with Polyacrylic Acid and
Cellulose Derivatives. Mol Pharmaceutics). Copyright (2016) American Chemical Society.
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Utilizing combinations of polymers may therefore be useful to tailor release profiles, while
providing optimized crystallization inhibition.

4.2

Introduction

Pharmaceutical pipelines are currently populated with a high percentage of drug candidates
which are very lipophilic, and/or have high melting points, leading to extremely low
aqueous solubility1, 2. Strategies to improve the dissolution rate and apparent solution
concentration can be divided into two main approaches3. The first encompasses dosage
forms containing solubilizing additives whereby the equilibrium crystalline solubility of
the drug is increased by processes such as binding with surfactant micelles or complexation
with cyclodextrins. Dissolution rate is typically enhanced, however, the free fraction of the
drug, which is in equilibrium with the solubilized fraction, remains limited4. The second
approach involves drug delivery systems such as amorphous solid dispersions (ASDs) that
generate supersaturated solutions. A supersaturated solution has a higher free drug
concentration than that generated from dissolution of the crystalline form in the same
medium. High energy state ASDs are thus formulated with the goal of generating and
maintaining a higher free drug concentration than can be achieved with the crystal,
whereby the higher concentration persists for biologically relevant timeframes. This is
advantageous since the passive drug flux across the gastrointestinal wall is expected to be
proportional to the free drug concentration5, 6, and hence the degree of supersaturation. The
dissolution rate of the drug when molecularly dispersed a highly soluble polymer is also
typically enhance by factors such as improved particle hydrophilicity and wettability7-10.
However, amorphous solids and supersaturated solutions are thermodynamically
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metastable. Crystallization from amorphous formulations is complex and may occur either
directly from the solid matrix upon contact with the dissolution medium, or from a
supersaturated solution generated during dissolution under non-sink conditions

11

.

Polymers play an essential role in modifying crystallization kinetics both from the matrix12
and solution phase13, enabling supersaturated solutions to be generated and maintained
when the optimum polymer is employed in the formulation11, 14, 15. In order to understand
the mechanisms of release from ASDs and to optimize polymer selection it is therefore
essential to evaluate the polymer impact on different crystallization pathways, as well as
to determine the relative impact of the polymer on crystal nucleation and growth.
Not only does the polymer play a pivotal role as a crystallization inhibitor for both the
matrix and solution phases, but the release rate of the drug from the ASDs will depend on
both the type and the amount of the polymer in the formulation. In their seminal work on
sulfathiazole-PVP amorphous solid dispersions, Higuchi and coworkers showed that as the
drug loading increased, the rate of drug release was dramatically reduced, even though
there was no crystallization of the drug16. Corrigan reviewed mechanisms of release from
solid dispersions and identified different controlling factors that depend on the
drug:polymer ratio and the difference in solubility between the drug and polymer8. In his
review, it was noted that, at low drug loadings, the drug dissolves simultaneously with the
polymer. In contrast, at high drug loadings, the polymer may dissolve faster than the drug
leaving behind a drug-rich layer and hence the dissolution behavior becomes drug
controlled.
Corrigan 8 proposed a model suggesting that the dissolution rate of component B, GB, in
the ASD will be regulated by that of component A, GA, as follows:

177
𝐺𝐵 =

𝑁𝐵
𝑁𝐴

𝐺𝐴

(1)

where N is the proportion of each component. Equation 1 will hold if:
𝑁𝐴
𝑁𝐵

𝐷 𝐶

> 𝐷𝐴𝐶𝑆𝐴

(2)

𝐵 𝑆𝐵

where D is the diffusion coefficient and Cs is the solubility of each component. This forms
the theoretical basis for drug controlled release from amorphous solid dispersions at
moderate to high drug loading and polymer controlled release at low drug loadings 15, 17.
The drug:polymer ratio in the ASD is an important practical consideration for all but the
most potent compounds. Low drug:polymer ratios, while typically leading to enhanced
release rates, result in large or even multiple dosage units, which is undesirable from a
patient compliance perspective. Therefore, in order to use ASDs more broadly as an
enabling strategy for poorly water soluble compounds, there is a need to increase drug
loading, while maintaining the amorphous form of the drug, the supersaturated solution,
and achieving an adequate rate of drug release, in particular for therapeutic indications
where a rapid onset of action is required, for example pain management.
Celecoxib (CEX), a cyclooxygenase-2 inhibitor, is a poorly water soluble compound that
is mainly used to treat pain arising from osteo and rheumatoid arthritis18. It has been widely
used to explore the properties of amorphous solid dispersions and is known to crystallize
rapidly from aqueous solutions when either no polymer is present19, or if the polymeric
excipient employed is a poor crystallization inhibitor20.

A number of studies have

evaluated the release rate of celecoxib from amorphous solid dispersions at high drug
loading. It has been noted previously that celecoxib release rate slows considerably with
an increase in drug loading20. Albers et al succeeded in circumventing this issue, achieving
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rapid celecoxib release from an ASD prepared by hot melt extrusion and formulated with
a polymethacrylate carrier, at a 50% drug loading. However, the resultant supersaturated
solution was very short lived, crystallizing in less than ten minutes21 indicating that this
polymer is a poor solution crystallization inhibitor. In a clinical study6, Morgen et al. found
that amorphous nanoparticles of CEX formulated with ethylcellulose and casein were much
more rapidly absorbed than a 50:50 w/w spray dried dispersion of CEX and HPMCAS,
leading to a much shorter time to achieve the maximum drug concentration (Tmax) and a
slightly higher area under the curve (AUC) for the nanoparticles as compared to the spray
dried dispersion. They suggested that the nanoparticle formulation might be useful
therapeutically due to the fast onset of action.
Herein we explore an alternative approach to achieve rapid celecoxib release, and
sustained supersaturation levels upon dissolution of high drug loading solid dispersions
under non-sink dissolution conditions. The specific goal of this research was to combine a
polymer with rapid release properties with polymers selected for their crystallization
inhibitory properties, in order to attain an improved release rate at high drug loading,
together with a sustained supersaturation level. To achieve this, CEX dispersions were
prepared with polyacrylic acid (PAA) and either hydroxypropyl methylcellulose (HPMC)
or HPMC acetate succinate (HPMCAS) and the dissolution rate and extent of
supersaturation was evaluated under non-sink conditions. PAA is a highly water soluble,
weakly acidic polymer that is often used in pharmaceutical applications for drug delivery22
and was selected to facilitate rapid drug release. However, PAA has been noted to be a
poor inhibitor of solution crystallization.23, 24 HPMCAS and HPMC are both used in ASDs
formulations25,

26

and ASDs of CEX with HPMCAS have been shown previously to
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improve bioavailability relative to the conventional dosage form containing crystalline
drug6. Furthermore, HPMC and HPMCAS have been found to be good crystallization
inhibitors for numerous compounds27,

28

. The impact of the polymers on celecoxib

crystallization in an aqueous environment was evaluated in order to better understand
factors impacting the extent of drug release and the longevity of the supersaturated
solutions generated upon dissolution. Nucleation induction times and growth rates were
measured in the presence and absence of the polymers in order to compare their efficiency
as crystallization inhibitors. Polarized light microscopy was used to evaluate crystallization
behavior, while non-sink dissolution testing was used to evaluate the rate, extent and
longevity of supersaturation following dissolution of the various ASDs.

4.3

Materials

CEX was purchased from Attix Pharmaceuticals (Toronto, Ontario, Canada). PAA was
purchased from Sigma-Aldrich Corporation (St. Louis, Mo, USA). HPMCAS, Type ASMF and HPMC, 606 grade were supplied by Shin-Etsu Chemical Co. (Tokyo, Japan). The
molecular structures are shown in Figure 4-1

4.4
4.4.1

Methods

Preparation of Bulk Amorphous Materials

CEX and the polymer(s) with different dry weight ratios were dissolved in a mixture of
ethanol and dichloromethane (50:50 v/v). Solvent removal was achieved by rotary
evaporation. The ASDs were subsequently dried in a vacuum oven overnight to remove
any residual solvent. The ASDs were then ground using a mortar and pestle and sieved to
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obtain a particle size fraction of 106-250µm. (Note that for CEX: HPMCAS 1:9 ASD, cryomilling was applied to achieve particle size reduction). They were then stored in a
desiccator containing phosphorous pentoxide at room temperature. A Rigaku SmartLab
diffractometer (Rigaku Cooperation, The Woodlands, TX, USA) was used to confirm that
the samples were amorphous prior to use. PXRD patterns were collected in step scan mode
(0.02°/step) with a scan range from 5° to 35° and a scan speed of 4°/min. The tube voltage
and current used to collect the pattern were 44kV and 40mA, respectively.

4.4.2

Nucleation Induction Time Measurements

275 µL of a 4 mg/mL or 2mg/mL methanol solution of CEX was pipetted into 50 mL pH
6.8 100 mM sodium phosphate buffer (SPB) with and without pre-dissolved polymer to
create an initial CEX concentrations of 22µg/mL or 11µg/mL. The solution was
equilibrated at 37°C and stirred at 300rpm (+shaped magnetic stirrer, 0.75 inch diameter).
Solution concentrations were measured as a function of time using an SI photonics UV-Vis
spectrometer coupled with a fiber optic probe. Wavelength scans (200-450nm) were
performed at 1min intervals for 8hrs in the absence of polymers and 16hrs in the presence
of polymers. The absorption peak at 249 nm was used to monitor solution concentration of
CEX. Light scattering was detected by monitoring the extinction at 350 nm; the drug had
no absorbance at this wavelength. All measurements were performed in triplicate.

4.4.3

Seeded Desupersaturation Experiments

7mg of CEX crystals were suspended in 50 mL pH 6.8 100 mM SPB. The SPB was
equilibrated at 37°C and stirred at 300rpm (+shaped magnetic stirrer, 0.75 inch diameter)
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in the absence or presence of pre-dissolved HPMCAS. 275 µL of a 4 mg/mL, or 2mg/mL
methanol solution of CEX was pipetted into the suspension to create different initial CEX
concentrations. The solution concentration as a function of time was monitored by the SI
photonics UV-Vis system as described above.

4.4.4

Dissolution Studies of ASDs

When assessing the dissolution behavior of amorphous solid dispersions with the goal of
gaining insight into the release mechanisms, it is critical to select the appropriate volume
of medium. Conventionally, dissolution testing is carried out using sink conditions3, which
are unlikely to be achievable in vivo for poorly water-soluble drugs and does not typically
allow appropriate evaluation of the crystallization behavior since the solution will not
become supersaturated. Therefore, non-sink conditions are preferred when evaluating
amorphous formulations mechanistically since these enable the degree of supersaturation
to be evaluated. For this study, the dissolution conditions were chosen to correspond to “at
sink” conditions with respect to the reported “amorphous solubility” of celecoxib. In other
words, if the formulation remains amorphous during the dissolution experiment, complete
drug release is expected, while if some crystallization of the drug occurs in the ASD matrix,
this fraction of the drug will not be able to dissolve because the solution will be
supersaturated with respect to the crystalline solubility.
An amount of ASD that contained 8.8mg CEX (see Table 4-1 for details of the total mass
of ASD added) was added to 400 mL pH 6.8 100 mM SPB, equilibrated at 37°C and stirred
at 300 rpm with a stir bar (+shaped, 0.75 inch diameter). These dissolution conditions
should lead to the complete dissolution of amorphous CEX based on the reported
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“amorphous solubility” value of approximately 22 μg/mL20, 29. Solution concentration
evolution as a function of time was measured using the SI Photonics UV system.
Wavelength scans (200-450nm) were performed at 1min time intervals for 16 hours. The
absorption peak at 249 nm was used to monitor solution concentration of CEX. Calibration
solutions of CEX were prepared in methanol. All measurements were performed in
triplicate.

4.4.5

Effect of Polymer on the Equilibrium Solubility of CEX

The equilibrium solubility of CEX was determined by adding an excess amount of
crystalline CEX to 20 mL pH 6.8 100mM SPB with the absence/presence of 22µg/ml predissolved polymer in scintillation vials. The vials were equilibrated at 37°C for 48h in an
agitating water bath (Dubnoff metallic shaking incubator; PGC Scientific, Palm Desert,
CA, USA). Samples were then subject to ultracentrifugation to separate excess crystalline
CEX particles from the supernatant. Ultracentrifugation was performed at 35000 rpm for
30 minutes in an Optima L-100XP ultracentrifuge equipped with Swinging-Bucket Rotor
SW 41 Ti (Beckman Coulter, Inc., Brea, CA, USA). High performance liquid
chromatography (HPLC) analyses were carried out with an Agilent HPLC 1260 Infinity
system (Agilent Technologies, Santa Clara, California, USA). The chromatographic
separation was performed by an XTerra Shield RP18 Column (125Å, 3.5 µm, 3.9 mm X
100 mm) (Waters Cooperation, Milford, MA, USA). Water (20%) and acetonitrile (80%)
mixture was used as mobile phase and the flow rate was 0.25mL/min. The ultraviolet
detection wavelength was 250nm. All measurements were performed in triplicate at room
temperature.
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4.4.6 Polarized Light Microscopy
The ASDs (106-250µm) were placed on a glass slide with a depression. A few drops of pH
6.8 100 mM SPB were then added to the particles. The crystallization behavior of ASDs
was observed using a Nikon Eclipse E600 Pol microscope with 10x objective (Nikon
Company, Tokyo, Japan). Images were processed by NIS-Elements software package
(Version 2.3; Nikon Company, Tokyo, Japan).

4.4.7

Thermal Analysis

Thermal analysis was carried out using a TA Q2000 DSC with a cooling refrigerator system
(TA Instruments, New Castle, DE, USA). Nitrogen was purged at a rate of 50mL min-1.
Approximately 5mg of the samples were weighed into an aluminum Tzero sample pan and
sealed using a hermetic Tzero lid with a pinhole. The glass transition temperature was
determined by heating the sample at approximately 20°C min-1 to approximately 30 °C
above the glass transition temperature (Tg), followed by cooling and reheating. The Tg
onset in the second heating scan was reported.

4.4.8

Fourier Transform Infrared Spectroscopy

Polymer(s) was dissolved in a mixture of ethanol and dichloromethane. The resultant
solution was then spin coated onto a thallium bromide (KRS-5) optical crystal. FT-IR
spectra were obtained on a Bruker Vertex 70 spectrometer (Bruker, Billerica, MA, USA)
in transmission mode and the spectra were subsequently converted into units of absorbance.
64 scans were collected with a 4 cm-1 resolution for each sample over the wavenumber
range from 4000cm-1 to 500 cm-1. Dry air was purged into the sampling and optical

184
compartment to prevent spectral interference from water vapor. Opus 7.2 software (Bruker,
Billerica, MA, USA) was used to analyze the spectra.

4.5
4.5.1

Results and Discussion

Equilibrium Solubility of CEX

The measured equilibrium solubility of crystalline CEX was 1.5µg/mL in the absence of
any polymers, and this value is in good agreement with the value reported by Abu-Diak et
al20. Polymers, when present at a concentration of 22µg/mL in SPB, did not substantially
impact the crystalline solubility of CEX, as shown in Table 4-2. Based on the solubility
values of crystalline CEX in the presence and absence of the polymers, it is apparent that
the polymers do not solubilize the drug, and therefore will not substantially impact the
supersaturation and hence the driving force for nucleation.

4.5.2

Impact of Polymers on Nucleation Induction Times

The effectiveness of the polymers in inhibiting crystallization from supersaturated solution
was assessed by performing nucleation induction time measurements. It is well known that
the nucleation rate is highly dependent on the degree of supersaturation in the system, S,
which is typically defined by30:
𝑐

𝑆 = 𝑐∗

(3)

Where c is the concentration of the crystallizing solute in the solution and c* is the
concentration of a saturated solution. To assess the ability of the various polymers to
maintain supersaturation, a level of supersaturation close to the experimentally measured
and calculated “amorphous solubility” of CEX19, 20, 29, 31, 22 μg/mL, was generated. This
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concentration is considerably higher than the measured crystalline solubility (shown in
Table 4-2) and hence a large driving force for nucleation is present. It has been shown
previously that the “amorphous solubility” represents the highest free drug concentration
that can be achieved, and hence this is the maximum possible supersaturation4,

31, 32

.

Therefore, the effectiveness of the polymers at the maximum theoretical driving force for
nucleation is being assessed.
The experimental nucleation induction time, tind, can be defined as the sum of the time for
critical nucleus formation (true nucleation time, tn), and the time for growth to detectable
size, tg.

tind  tn  t g

(4)

The onset of crystallization is readily determined from the UV spectroscopic measurements
from the abrupt increase in scattered light at a non-absorbing wavelength of 350 nm
concomitant with rapid decrease in absorbance at 249nm, where CEX shows an absorption
peak33.
As shown in Figure 4-2, in the absence of any polymer, nucleation was rapid and the drug
concentration decreased rapidly whereby crystallization commenced within 5 minutes at
an initial CEX concentration of 22 µg/mL (For clarity, data points after 3hrs are not shown).
This concentration represents a very high initial supersaturation and the rapid
desupersaturation is consistent with previous reports that CEX is a rapid crystallizer from
aqueous solutions20, 34. The induction time increased to approximately 20 minutes when
the initial CEX concentration was reduced to 11 µg/mL, in agreement with classical
nucleation theory which predicts a decrease in the nucleation rate (and hence an increase
in induction time) with decreasing supersaturation35.
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The nucleation induction time and the rate of desupersaturation did not change in the
presence of pre-dissolved PAA (Figure 4-3), indicating that this polymer is an ineffective
crystallization inhibitor. In contrast, the initial supersaturation was effectively maintained
for the duration of the experiment, 16 h, when small quantities of either HPMCAS or
HPMC were dissolved in solution. When HPMCAS was used in combination with PAA,
no significant desupersaturation occurred, indicating that the effectiveness of HPMCAS in
maintaining supersaturation was not impaired by the presence of PAA. This result lends
support to our proposed strategy of combining two polymers in an amorphous formulation,
since the crystallization inhibitory properties of a given polymer are not diminished by the
presence of a second polymer, at least for the system studied herein.
The remarkable increase in the induction time in the presence of HPMCAS or HPMC
cannot be explained by changes to the supersaturation due to increasing the solubility of
the crystalline drug, since the polymers have very little impact on the crystal solubility and
must be due to subtle molecular level interactions that are difficult to probe experimentally,
as with all direct investigations of the nucleation process. Nevertheless, the superiority of
HPMCAS or HPMC relative to PAA is perhaps not particularly surprising. Previously, it
has been suggested that for a polymer to be an effective crystallization inhibitor, it needs
to have a suitable level of hydrophobicity; too hydrophilic and it will preferentially interact
with the water, and too hydrophobic and it will preferentially interact with itself, rather
than interacting with the nucleating drug phase29, 36. Warren et al27 tested the precipitation
inhibition behavior of 53 polymeric materials for supersaturated solution of danazol, and
the majority of superior precipitation inhibitor were amphiphilic cellulose derivatives. On
the other hand, PAA is very hydrophilic, and is expected to have a much stronger
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interaction with water than with CEX in solution. Therefore, the nucleation of CEX in
solution was unaffected by the presence of PAA. Previous studies have also noted that
PAA is an ineffective inhibitor of nucleation29.

4.5.3

Characterization of Binary Dispersions Containing PAA or HPMCAS

The dissolution rate of CEX: HPMCAS ASDs was highly dependent on the drug loading,
as shown in Figure 4-4. At low drug loadings (10% drug), the initial release rate was rapid
and complete release of the drug to reach the reported amorphous solubility was achieved
in 4 hours whereby the supersaturation was retained for the duration of the experiment (16
h). It is of interest to note that the solution concentration achieved from the HPMCAS
dispersion is similar to that reported in another study with CEX: PVP dispersions20. In that
particular study, the authors also made note of the fact that the dispersion dissolved to reach
a maximum concentration equivalent to the “amorphous solubility”, even though excess
drug was present. The sustained supersaturation achieved by dissolution of the HPMCAS
dispersions confirms the excellent crystallization inhibitory properties of HPMCAS
towards supersaturated solutions of CEX. Furthermore, the achievement of complete drug
release indicates that HPMCAS inhibits matrix crystallization, enabling the drug to
dissolve to the amorphous solubility. As the drug loading was increased, the release rate
became much slower. For 50% drug loading, the solution concentration increased slowly
and complete release was achieved only after 16 h. In a study by Curatolo et al28, 41 small
and polymeric molecules were tested for their effectiveness in initiation and maintaining
supersaturation for each of 9 structurally diverse low solubility drugs, HPMCAS was found
to be the most effective precipitation inhibitor. Consequently, spray dried dispersions
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(SDDs) prepared with HPMCAS were consistently superior to SDDs formulated with other
polymers in both achieving and maintaining supersaturation during in vitro dissolution
studies.
In contrast, a high drug loading CEX: PAA 5:5 dispersion exhibited an extremely fast
dissolution rate, reaching a maximum CEX concentration of 11μg/mL within 3 minutes.
However, the release was incomplete and the supersaturation generated by the ASD
dissolution was rapidly depleted by crystallization and the CEX concentration approached
the crystalline solubility within 60 minutes. A similar profile was obtained when the drug
loading was reduced to 30% or 10% (data not shown). The substantial increase in initial
drug release rate can presumably be attributed to the greater hydrophilicity and complete
ionization of the carrier PAA (the pKa of PAA is 4.28)37, which result in a high polymer
solubility and hence fast dissolution. The pH of the medium after dissolution was measured
and was found to be unchanged. CEX is weakly acidic with a pKa of 11.1 and hence
remained as the unionized form during dissolution. The rapid desupersaturation of the
supersaturated CEX solutions generated by dissolution of the CEX:PAA dispersions is in
excellent agreement with the nucleation-induction time results shown in Figure 2, and is
consistent with the poor nucleation inhibition properties of PAA. The incomplete release
from the PAA dispersions suggests either that matrix crystallization has occurred prior to
complete dissolution, or that there is very rapid solution crystallization of the dissolved
drug that efficiently depletes the supersaturation while the matrix may still dissolve
simultaneously.
Polarized light microscopy was used as a complementary method to study the phase
behavior of the CEX:PAA and CEX: HPMCAS ASDs. From Figure 4-5, it is apparent that
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the CEX: PAA 5:5 ASD was amorphous following preparation with no evidence of
birefringence under polarized light. The amorphous nature of the material following
preparation was also verified by powder x-ray diffraction. Therefore, the incomplete
release observed during dissolution is not due to some initial fraction of crystalline material.
After adding a few drops of SPB, rapid dissolution from the solid matrix was observed,
concomitant with the emergence of needle-shaped crystals. However, this process
proceeded so rapidly that it was not possible to unambiguously differentiate matrix
crystallization from solution crystallization based on these images alone. In contrast,
crystallization was not observed in the case of CEX: HPMCAS 3:7 ASD, which dissolved
much more slowly (Figure 4-6)
These results suggest that preparing a high drug loading dispersion with PAA, whereby
drug release is fast, but supersaturation is not sustained due to the rapid drug crystallization,
that also includes a polymer with good crystallization inhibition properties, could lead to
improved overall dissolution performance. To test this idea, HPMCAS was pre-dissolved
in the buffer and the dissolution behavior of the CEX: PAA 5:5 ASD was evaluated, and
the results are shown in Figure 4-7.
For this system, the release rate was very fast, although the release was again not complete
and the maximum concentration achieved was ~10 μg/mL. Different from the CEX:PAA
dispersion described above (Figure 3), the supersaturation that was generated was
maintained for 16 h, because there is now an effective crystallization inhibitor (i.e.
HPMCAS) in solution. It therefore appears that the incomplete release is due to the
crystallization of CEX in the matrix. In other words, there is a competition between matrix
crystallization (which HPMCAS in the solution phase is unable to influence) and release

190
of CEX into solution (whereby HPMCAS is able to inhibit crystallization of dissolved
CEX). Thus, once the matrix has crystallized, no further CEX release can occur because
the solution is supersaturated with respect to the crystal solubility. The undissolved solids
were retrieved soon after the peak concentration was reached. The polarized light
microscopic images verified that those solids were needle-shaped crystals, consistent with
the stable crystalline form of CEX38 (Figure 4-8). Decreasing the drug loading to 10% did
not substantially improve the extent of drug release, indicating that PAA is a very poor
inhibitor of matrix crystallization, irrespective of the drug loading.

4.5.4

Impact of HPMCAS on Crystal Growth Rate

It is interesting that the supersaturation that was generated by the rapid, albeit partial release
of CEX was maintained for 16 h and was not reduced by the presence of the crystals
produced by matrix crystallization. Typically, the presence of crystal seeds would be
expected to lead to rapid desupersaturation as the crystals grow at the expense of the
solution concentration, until the equilibrium crystal solubility is reached39. The lack of
desupersaturation suggests that that HPMCAS is able to inhibit crystal growth, at least at
the supersaturation achieved by dissolution of the ASD. Crystal growth inhibition can be
evaluated by adding crystal seeds to a solution of known supersaturation. If this is done in
the presence and absence of a polymer, then the effectiveness of a polymer can be
assessed36, 39, 40.
Figure 4-9 shows results from independent seeded crystallization experiments in the
presence and absence of HPMCAS at two supersaturations. In the absence of polymer,
desupersaturation is rapid, and immediate, without the short lag time seen for the induction

191
time experiments. It is clear that HPMCAS is indeed an effective inhibitor of CEX crystal
growth at both high and lower supersaturations. At an initial concentration of 11 μg/mL,
very little desupersaturation was seen for the duration of the experiment. This explains why
any crystals formed during the dissolution of the PAA ASDs did not lead to
desupersaturation when HPMCAS was present; at the supersaturation generated,
HPMCAS is able to effectively block crystal growth. HPMCAS is a less effective inhibitor
of growth at a higher supersaturation, in agreement with theoretical models41 and previous
studies40, although the rate of desupersaturation at the highest supersaturation tested (22
μg/mL CEX) is still fairly slow for the two polymer concentrations studied. By measuring
the slopes of the desuperaturation profiles, the relative crystal growth rates can be
quantified as36:
𝑅0 ⁄𝑅𝑝 

(5)

Where R0 is the mass growth rate in the absence of the polymer and Rp is the mass growth
rate in the presence of the polymer. The slope of the linear region in the seeded
desupersaturation curves in the absence of HPMCAS over the initial 5 minutes was used
as R0. For simplicity, the slope of the seeded desupersaturation curves over the entire 16h
in the presence of HPMCAS was used to approximate Rp. From this analysis, we found the
relative growth rates were approximately 130 CEX 11µg/mL, HPMCAS 11µg/mL), 70
(CEX 22 µg/mL, HPMCAS 5µg/mL) and 158 (CEX 22µg/mL, 22 µg/mL) based on the
data shown in Figure 4-9.
It has also been suggested that the relative growth rate data can be used in combination
with induction time data to estimate the relative impact of the polymer on the nucleation
rate by application of the following equation39, 42:
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(6)

Where J0 and Jp are the nucleation rates in the absence and presence of a polymer,
respectively, and tu,0 and tu,p are the induction time in the absence and presence of a polymer,
respectively. For induction time measurements at 22 µg/mL initial CEX concentration with
5 µg/mL predissolved HMCAS, we failed to observe a sharp change in the slope of
desupersaturation profile over the experimental timeframe. Therefore, 960 minutes was
used as the value for tu,p. In this case, using an R0/Rp ratio of 70, the calculated relative
impact of the polymer on the nucleation rate was ~4000.
From this analysis, it can be surmised that, although the presence of 5µg/mL HPMCAS
resulted in substantial inhibition of both nucleation and crystal growth of CEX in SPB, the
relative impact of HPMCAS on nucleation was still far more pronounced than its impact
on crystal growth, despite the fact that the nucleation induction time in the presence of
HPMCAS was underestimated.

4.5.5

Characterization of Ternary CEX:PAA:HPMCAS Dispersions

The next logical step was to add HPMCAS to the CEX: PAA ASD, with the aim of
inhibiting the matrix crystallization of CEX that occurs when the drug is formulated with
PAA, while still maintaining a rapid release rate. Shown in Figure 4-10 are the dissolution
profiles of CEX: PAA: HPMCAS ternary ASDs which vary with respect to drug loading
as well as the amount of each polymer. At 4:5:1 and 5:4:1 ratios, where HPMCAS was a
minor component, it can be seen that there was an initial burst release of CEX leading to a
solution with a concentration between 12-14 μg/mL, whereby the concentration was
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sustained for 16 h. While this is a slight improvement over the systems shown in Figure
4-7, where HPMCAS was present only in the dissolution medium, it is apparent that some
matrix crystallization was still occurring since complete release was not achieved at either
ratio. In an attempt to reduce the matrix crystallization, ASDs where a larger fraction of
PAA was replaced by HPMCAS were investigated. This approach appeared to be
reasonably successful in inhibiting matrix crystallization for a 5:3:2 CEX:PAA:HPMCAS
dispersion, since the highest drug concentration reached was approximately 19µg/mL and
was still increasing by the end of 16h. This is close to the nominal concentration that would
be achieved by complete release (22μg/mL). However, the improved matrix stability was
achieved at the cost of the release rate, whereby a much smaller extent of initial burst
release was observed (rapid release to 6 μg/mL within 5 min), which was followed by a
sustained period of much slower release. The origin of this apparent biphasic drug release
will be discussed in more detail subsequently, but immediately raises the suspicion of
(partial) phase separation between PAA and HPMCAS. Further replacement of PAA by
HPMCAS (5:2:3) resulted in even smaller extent of burst release, again followed by a
period of sustained slow release. A compromise between drug loading and release rate
could be seen at a CEX drug loading of 30% (3:6:1), where full and rapid release was
achieved, and the supersaturation was maintained over the experimental time frame. The
release profile was similar for the 1:8:1 CEX: PAA: HPMCAS ASD.
Polarized light microscopy studies were interesting. When the CEX: PAA: HPMCAS 3:6:1
ASD was exposed to buffer (Figure 4-11), rapid initial dissolution was observed and the
solid matrix collapsed with the generation of fine particles. In agreement with the
dissolution results, where complete release was observed, no crystals could be detected for

194
this system based on the absence of birefringence under cross polarized light. At 2:1:1 ratio
(Figure 4-12), the initial dissolution of the ASD was still very fast. It was followed by
generation of more particles of various sizes which then dissolved slowly. Again, no
crystallization was observed in this case.

4.5.6

Characterization of Dispersions Containing CEX, PAA and HPMC

While the ternary dispersions of CEX with PAA and HPMCAS showed improvement in
terms of both release rate and crystallization inhibition over the respective binary
dispersions, it was not possible to achieve both rapid and complete release at a drug loading
of 50%. In addition, the biphasic dissolution profiles observed, while interesting, suggest
that a formulation strategy combining PAA and HPMCAS would lead to very complex
systems. HPMC is also a very effective nucleation inhibitor for CEX (Figure 4-3), hence
binary and ternary dispersions were evaluated with this polymer.
Similar to the binary CEX: HPMCAS ASDs, the dissolution rate of binary CEX: HPMC
ASDs decreased with an increase in drug loading, as shown in Figure 4-13, and were even
slower than the corresponding HPMCAS ASDs, whereby release was incomplete at the
end of 16 h from the higher drug loading dispersions. The ternary ASDs showed a much
faster release rate, benefiting from the presence of the fast releasing PAA. At a 30% drug
loading, the ternary ASD containing 60% PAA and 10% HPMC dissolved much more
rapidly than the corresponding binary HPMC ASD, and essentially complete CEX release
was achieved by 2hrs, with the supersaturation being sustained for an additional 14 h. At a
50% drug loading, the ternary ASD containing 10% HPMC exhibited fast dissolution and
yielded about 85% release. Again the supersaturation generated was substantially
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maintained. This dispersion achieved a greater extent of release than the corresponding
ternary dispersion with PAA and HPMCAS, with only a slightly slower release rate.
The 2:1:1 CEX: PAA: HPMC ASD did not exhibit the biphasic dissolution behavior seen
with the high drug loading CEX: PAA: HPMCAS ASDs (which showed a burst release
followed by much slower dissolution at the 5:2:3 or 5:3:2 ratios, Figure 4-10). Dissolution
experiments of CEX: PAA: HPMC ASDs at 5:2:3 and 5:3:2 ratios were not carried out
because their profiles were expected to be similar to that at 2:1:1 ratio. Figure 4-14 shows
that a different pattern of dissolution was observed for the CEX: PAA: HPMC ASD (3:6:1
ratio) ASD when viewed under the microscope. In this case, the initial particles remained
intact, gradually decreasing in size as dissolution proceeded, with the particles eroding
from the particle edges. They showed no evidence of disintegration into smaller particles
as seen for the ternary systems formulated with HPMCAS.
The different pattern of dissolution, whereby the particles undergo a slower erosion process
rather than an initial burst release as seen for some of the CEX:PAA:HPMCAS systems
appears to be beneficial to the initiation and maintenance of supersaturation. To prevent
matrix crystallization and/or subsequent desupersaturation, it is important that the
inhibitory polymer remains in close contact with the drug during hydration, and is released
simultaneously. Since the HPMC-containing dispersions appear to undergo erosion, then
drug and HPMC should remain in contact during hydration and release should occur
concurrently.
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4.5.7 Miscibility Characterization
Despite some practical limitations, DSC analysis remains the most common technique to
determine the mixing state of a drug with a polymer43. The measured Tg of each pure
component and the ASDs at 1:1 ratio are listed in Table 4-3. Each binary ASDs at a 1:1
ratio had a Tg value in between that of the two pure components, which indicates that the
drug has some miscibility with each polymer.
IR spectroscopy can be used to interrogate the miscibility in polymer blends44 and was used
to better understand the PAA-HPMCAS and PAA-HPMC systems. Unfortunately, it was
not possible to use DSC analysis for this purpose due to the similarity in the glass transition
temperature values for the polymers used as shown in Table 4-3. The IR spectra
(wavenumber range from 1600cm-1 to 1800 cm-1) of spin coated films of pure PAA,
HPMCAS, HPMC or binary mixtures of PAA and the cellulose polymers are shown in
Figure 4-15 and Figure 4-16. Pure PAA has a peak at 1710cm-1, which may be assigned to
C=O stretching of dimerized carboxylic acid22, 45. Pure HPMCAS has a C=O stretching
peak at 1743cm-1. The spectra of PAA and HPMCAS mixtures show both of these peaks
with little change in the wavenumber. In other words, the spectra of the mixtures are
additive, suggesting a lack of specific intermolecular interactions between PAA and
HPMCAS.
Hence the IR data suggest that PAA and HPMCAS are immiscible. This is not necessarily
very surprising. Because of the low entropy of mixing for two large molecules46, polymers
are typically only miscible when they can form specific interactions and hence have a
favorable enthalpic contribution to the free energy of mixing47. PAA forms carboxylic acid
dimers22 in the pure polymer, which would only be disrupted if a more favorable
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intermolecular interaction can be formed. It thus appears that HPMCAS lacks the ability
to form favorable intermolecular interactions with PAA and that these two polymer
consequently do not mix. Examples of poor miscibility with other components have been
reported for both polymers. For example, PAA has been reported to be immiscible with the
small molecule, felodipine, due to the lack of favorable drug-polymer interactions48.
HPMCAS has been reported to be only partially miscible with one cellulose derivative,
carboxymethyl cellulose acetate butyrate, but miscible with another cellulose derivative,
HPMC, illustrating the challenges with predicting polymer miscibility a priori49.
Furthermore, when CEX (which has no signal in the carbonyl region) was mixed with the
polymer blend polymer, the polymer carbonyl peaks still showed very little change in
wavenumber relative to in the pure polymer spectra (Figure 4-15), suggesting that adding
CEX does not result in improved miscibility of the two polymers.
If PAA and HPMCAS do not mix in the ternary dispersion, but CEX exhibits some degree
of miscibility with each polymer, as suggested by the DSC data shown above, a situation
can be envisaged where CEX exists in two domains; dispersed in a PAA-rich domain, and
dispersed in a HPMCAS-rich domain. Such phase separation would explain the observed
biphasic dissolution profiles and sequence of events seen from the microscope images.
Thus, during the dissolution of the ternary ASDs, a fraction of CEX is rapidly released into
solution due to the very fast dissolution of the PAA-rich domains, whereas the release from
the HPMCAS-rich domains is much slower, as seen for the binary CEX-HPMCAS
dispersions. This would also provide an explanation about why it is was hard to inhibit
matrix crystallization by adding HPMCAS; presumably the inhibitory polymer needs to be
in reasonably close contact with the drug to inhibit crystallization, and this may not occur
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for all drug molecules if substantial phase separation occurs because the polymers are not
miscible.
In blends of HPMC and PAA, a shoulder at 1735cm-1 emerged and increased at the expense
of the peak at 1710cm-1 as the ratio of PAA:HPMC decreased (Figure 4-16). Pure HPMC
does not have any absorption peaks in this spectral region. This observation indicates that
the presence of HPMC may disrupt the PAA carboxylic acid dimers. This might occur
through either the formation of hydrogen bonding between the OH group of HPMC and
the C=O group of PAA or due to hydrogen bond interactions between the OH group of
PAA with acceptor groups on HPMC. The change in the hydrogen bonding of PAA in the
presence of HPMC suggests that these two polymers exhibit some degree of miscibility. In
the ternary blend of CEX:PAA:HPMC, that same spectroscopic pattern is seen in the
carbonyl region, indicating that the addition of CEX does not lead to demixing of PAA and
HPMC. Again, this observation is consistent with the dissolution results obtained for
ternary dispersions formulated with combinations of HPMC and PAA where it was
observed that the release rate was intermediate to that of the binary dispersions with each
polymer, while the extent of release was improved due to the matrix crystallization
inhibitory properties of HPMC.

4.6

Conclusions

HPMCAS and HPMC were effective inhibitors of CEX solution nucleation. These
polymers were also very effective at inhibiting crystallization from the matrix of an ASD
during the hydration stage of dissolution. However, the drug release rates from ASDs
formulated with either polymer at moderate to high drug loadings (30-50% drug) were slow,
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and could only be improved at the expense of drug loading. Conversely, PAA was a poor
inhibitor of solution crystallization but led to extremely fast drug release (albeit incomplete
due to crystallization), even at high drug loadings. The expected advantages of combining
a fast release polymer, PAA, with a good matrix and solution crystallization inhibitor,
HPMC or HPMCAS were realized at a drug loading of 30% and partially realized at higher
drug loadings. Combining two polymers to optimize both drug release and supersaturation
thus appears to be a viable formulation strategy, although attention needs to be paid to the
miscibility of the ternary systems.
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Table 4-1 List of the ASDs evaluated and their total mass used for dissolution studies
Drug:Polymer Weight Ratio. The value in parentheses

System

indicates the total mass of ASD used in dissolution study to
give a theoretical CEX concentration of 22 μg/mL
CEX: PAA

5:5 (17.6mg), 3:7 (29.3mg), 1:9 (88mg)

CEX: HPMCAS

6:4 (14.7mg), 5:5 (17.6mg),
3:7 (29.3mg)and 1:9 (88mg)

CEX: HPMC

5:5 (17.6mg) and 3:7 (29.3mg)

CEX: PAA: HPMCAS

5:2:3 (17.6mg) , 5:3:2 (17.6mg), 5:4:1 (17.6mg),
4:5:1 (22mg), 3:6:1 (29.3mg), and 1:8:1 (88mg)

CEX: PAA: HPMC

2:1:1 (17.6mg), 5:4:1 (17.6mg), and 3:6:1 (29.3mg)

Table 4-2 Crystalline CEX solubility in the absence and presence of pre-dissolved polymers

CEX solubility (µg/mL)

No Polymer

PAA

HPMCAS

HPMC

1.5±0.1

1.72±0.06

1.89±0.02

2.05±0.03

Table 4-3 Tg of the pure drug, pure polymers, and the ASDs

Material

Tg

CEX

56±1

HPMCAS

117±1

HPMC

140±5

PAA

128±1

CEX: HPMCAS 1:1

67±1

CEX: HPMC 1:1

71±6

CEX: PAA 1:1

83±2
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(A)

(C)

(B)

(D)

Figure 4-1 Chemical structures of CEX (A), PAA (B), HPMCAS (C), and HPMC (D).

Figure 4-2 Induction time measurements of CEX in the absence of polymers
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Figure 4-3 Induction time measurements of CEX in the presence of different polymers

Figure 4-4 Dissolution Profiles of CEX: PAA and CEX: HPMCAS ASDs. The total mass
of dispersion added to the medium to achieve a theoretical CEX concentration of 22μg/mL
is indicated.
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(a)

(d)

(b)

(e)

(c)

(f)

Figure 4-5 CEX:PAA 5:5 ASD in air (a) and after 20sec(b), 1min(c), 3mins(d), 5mins(e),
and 10mins(f) following addition of SPB. The arrows indicated obvious needle-shaped
crystals.

(a)

(b)

(c)

Figure 4-6 CEX:HPMCAS 3:7 ASD after 5mins (a), 15mins (b), and 30mins (c) following
addition of SPB.
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Figure 4-7 Dissolution profiles of CEX: PAA ASDs in the presence of pre-dissolved
HPMCAS. The total mass of dispersion added to the medium to achieve a theoretical CEX
concentration of 22μg/mL is indicated.

Figure 4-8 Solids retrieved soon after the peak concentration was reached during
dissolution of a 5:5 CEX: PAA ASD in SPB with pre-dissolved HPMCAS
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Figure 4-9 Seeded Desupersaturation of CEX in the presence and absence of pre-dissolved
HPMCAS

Figure 4-10 Dissolution Profiles of CEX: PAA: HPMCAS ternary ASDs. The total mass
of dispersion added to the medium to achieve a theoretical CEX concentration of 22μg/mL
is indicated.
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(a)

(b)

(c)

(d)

(e)

(f)

Figure 4-11 CEX: PAA: HPMCAS 3:6:1 ASD: Unexposed (a), 20sec (b), 1min (c), 2mins
(d), 5mins (e), and 10mins (f).

(a)

(b)

(c)

Figure 4-12 CEX: PAA: HPMCAS 2:1:1 ASD: Unexposed (a), 5min (b), and 30min (c)
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Figure 4-13 Dissolution profiles of CEX: HPMC and CEX: PAA: HPMC ASDs. The total
mass of dispersion added to the medium to achieve a theoretical CEX concentration of
22μg/mL is indicated.

(a)

(b)

(c)

(d)

Figure 4-14 CEX: PAA: HPMC 3:6:1 ASD: Unexposed (a), 1min (b), 3mins(c), and
20mins (d)
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Figure 4-15 Infrared spectra of spin coated polymeric films showing wavenumber range
from 1600cm-1 to 1800cm-1: pure PAA (yellow), pure HPMCAS (red), PAA: HPMCAS
7:3 (pink), 5:5 (blue), 3:7 (green) and CEX: PAA: HPMCAS 2:1:1 (black)

Figure 4-16 Infrared spectra of spin coated polymeric films showing wavenumber range
from 1600cm-1 to 1800cm-1: pure PAA (yellow), pure HPMC (red), PAA: HPMC 7:3
(pink), 5:5 (blue), 3:7 (green) and CEX: PAA: HPMC 2:1:1 (black).
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